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CHAPTER 1 
Overview of Automated Oligosaccharide Synthesis and the Synthesis of β-Mannosidic 
Linkages 
Shu-Lun Tang and Nicola L. B. Pohl* 
 
1. Strategies for automated synthesis of oligosaccharides 
The automated synthesis of oligosaccharides (Seeberger et al. 2008; Hsu et al. 2011) 
is considered challenging compared to the synthesis of the other two major categories of 
biomolecule, peptides and nucleotides, for three reasons. First, instead of using limited 
amounts of building blocks for building up oligopeptides (from 21 canonical amino acids) 
and oligonucleotides (from 8 major nucleotides), the number of building blocks for chemical 
oligosaccharide synthesis is tremendously large due to the complexity of the oligosaccharide 
structures. In order to provide specific stereoselectivity, regioselectivity, and branch points 
for both linear and branched oligosaccharides, the building blocks require different protecting 
group strategies for various target glycosidic linkage formations. Second, the amide bond and 
phosphodiester bond formation reactions have been developed into relatively robust and 
straightforward reactions; however, glycosylation usually requires anhydrous conditions for 
higher yield and often low temperatures for better stereoselectivity. These factors set a higher 
mechanical standard for the robotics platform for carrying out oligosaccharide synthesis. 
Furthermore, the building blocks for oligosaccharide synthesis usually require multiple 
synthetic steps (5-14 steps) to synthesize; therefore, the cost of each building block is 
significantly higher than peptides and nucleotides.  
 
  2 
Automated solid-phase synthesis of oligosaccharides 
Although the automated synthesis of oligosaccharides has proven more challenging 
compared to oligopeptides and oligonucleotides, Seeberger and co-workers have developed a 
similar strategy to the already well-established automated solid-phase synthesis of 
oligopeptides by using a modified automated peptide synthesizer along the lines proposed by 
Bruce Merrifield in his Nobel address (Merrifield and Steward 1965; Merrifield 1985). This 
method was called the automated solid-phase synthesis of oligosaccharides (Plante et al. 
2001). After repeating glycosylation and deprotection cycles, the oligosaccharide chain could 
be built on the polymeric solid support; the subsequent cleavage of the linker releases the 
oligosaccharide from the solid phase. Although this strategy has the advantage of solid-phase 
synthesis— namely easy purification by washing of the resin—unfortunately, for each 
glycosylation, 10 to 20 equivalents of precious building block has to be charged to the 
synthesizer and at least 9 to 19 equivalents of building block are wasted at each coupling 
cycle. Moreover, the reactions on the solid phase cannot be easily monitored while the 
program is running, and, once the saccharide has been cleaved from the resin, if further chain 
elongation is needed, the reloading of the saccharide on the resin can be problematic.  
 
One-pot oligosaccharide synthesis 
The one-pot oligosaccharide synthesis strategy was first introduced by Wong and coworkers 
in 1999 (Zhang et al. 1999; Hsu et al. 2011). This method relies on building blocks with 
different anomeric activation group reactivity provided by different protecting groups. The 
most reactive building block (donor) is activated and reacts with the second reactive building 
block. Then the anomeric activation group on the second reactive building block is 
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subsequently activated and reacts with the 3rd reactive building block. In order to apply this 
strategy to the synthesis of a wide variety of oligosaccharides, a library of building blocks 
with different anomeric reactivity has been built up and a computer program called Optimer 
was developed for selecting the building blocks. This one-pot strategy provides a 
straightforward way to synthesize complex oligosaccharides with no purification steps during 
the chain elongation. Although the choice of synthetic strategy is computer-assisted, the 
automation of the synthesis of oligosaccharides using this strategy has not been reported. 
 
Automated solution-phase synthesis of oligosaccharide 
In order to synthesize a wider range of oligosaccharides compared to the one-pot 
strategy and to overcome the drawback of the solid-phase methods, the Pohl group is 
developing an automated solution-phase synthesis protocol to synthesize oligosaccharides 
(Pohl 2008). By attaching a C8F17 fluorocarbon chain (F-tag) to the reducing end of 
saccharides, the reaction can be handled under homogeneous solution-phase conditions 
similar to ordinary bench-top reactions and the purification can be easily completed by a 
special robotics platform using fluorous solid phase extraction (FSPE). The F-tag modified 
saccharide can then be carried on through additional synthetic steps. Since the reaction is in 
solution-phase, only 1.5 to 3.5 equivalents of precious building block is used for each 
glycosylation. Compared to the 10 to 20 equivalents of building block required for typical 
solid-phase protocols, up to 18.5 equivalent of building block could be saved at each 
coupling cycle by the solution-phase strategy. In addition, just an easy thin layer 
chromatography (TLC) or mass spectrometry analysis can be used to monitor the reaction. 
Moreover, any F-tag containing saccharides can be reinjected to the synthesizer for further 
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reactions, including oligosaccharides already produced from the synthesizer. This advantage 
provides more flexibility compared to automated or manual solid-phase synthesis strategies.  
However, the complete scope and utility of this new platform still needs to be demonstrated 
even with the most synthetically challenging glycosidic linkages such as β-mannosides. 
 
2. The challenges of β-mannoside synthesis 
β-Mannoside can be found in a wide variety of natural products including 
mammalian, insect, plant, fungal, and bacterial saccharides. In order to study these important 
saccharides, the chemical synthesis of β-mannoside could provide substrates needed for 
additional biological studies; however, the β-mannosidic linkage is one of the most 
challenging glycosidic linkages to synthesize (El Ashry et al. 2005). The challenges of the 
formation of this 1,2-cis linkage are attributed to three major factors (Figure 1). After the 
activation of the mannosyl donor, leaving of the activation group leads to the formation of 
the oxocarbenium intermediate. However, steric hindrance from the axial C-2 substituent 
blocks the β face of the pyranose ring and prevents the formation of the β-mannoside. 
Second, the anomeric effects also favor the thermodynamically more stable α-mannoside 
over the less stable β-mannoside (El Ashry et al. 2005). Finally, the most reliable way to 
control the stereochemistry of the anomeric carbon during the glycosylation is to use 
neighboring-group participation by a group such as an ester. After the formation of the 
oxocarbenium intermediate, the neighboring ester carbonyl attacks the anomeric position and 
forms a stabilized five-member ring intermediate, which blocks the α face of the pyranose 
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ring and does not allow the glycosyl acceptor (nucleophile) to attack from the β face. As 
result, formation of the α-mannoside is predominant  (Figure 1). 
 
 
Figure 1. The three-fold challenge of forming β-mannosides. 
 
3. Current synthetic strategies toward β-mannoside synthesis 
 
Crich’s 4,6-O-benzylidene strategy 
In order to synthesize this challenging linkage, various methodologies have been 
developed. One of the most widely used methods is Crich’s 4,6-O-benzylidene strategy. The 
origin of the β-selectivity comes from the crucial 4,6-O-benzylidene group. After the 
mannosyl glycosyl donor is activated by an activator such as triflic anhydride, an equilibrium 
between the covalent α-anomeric triflate, the contact ion pair (CIP), and the solvent-
separated ion pair (SSIP) is formed (Figure 2). The torsional strain of the fused bicyclic 
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system makes the oxocarbenium intermediate less stable and drives the equilibrium toward 
the α-anomeric triflate that ultimately results in the formation of a β-mannoside via an SN2 
mechanism. Also, the electron-withdrawing effect of the benzylidene is maximized by the 
locked C6-O6 bond being antiperiplanar to the C5-O5 bond; therefore the oxocarbenium is 
destabilized and shifts the equilibrium to the α-triflate that provides the β-mannoside. 
However, this method needs low activation temperatures in most cases and the selective 
deprotection of the 4,6-O-benzylidene is sometimes tricky. These two factors make 
automation of this procedure more challenging (Crich 2010; Crich 2011). In addition, the 
approach does not allow flexibility in the protecting group design for further chain extension. 
Therefore, protecting group manipulations after glycosylation can add to the length and 
complexity of syntheses. 
 
 
Figure 2. Crich’s 4,6-O-benzylidene strategy. 
 
Kim’s carboxybenzyl strategy 
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This strategy is based on Crich’s 4,6-O-benzylidene and provides high β-selectivity 
and has been applied to a wide variety of oligosaccharide synthesis. Except for the 
sulfoxide/thiol donor, which Crich has reported for the glycosylation, Kim’s anomeric 
carboxybenzyl group (CB) is also used as the leaving group for 4,6-O-benzylidene protected 
donors (Kim et al. 2001; Kim et al. 2008). (Figure 3) The ease of the CB group 
formation/activation and its high β-selectivity made this method the choice for later 
automated solid-phase synthesis of a β-mannoside (Codee et al. 2008). Unfortunately, this 
method still suffers from problems in facile chain extension just like Crich’s original 
solution. 
 
 
Figure 3. Kim’s carboxybenzyl strategy 
 
Oxidation-reduction sequence  
Another method for β-mannan synthesis relies on an oxidation-reduction sequence 
and was first reported by Kotchetkov et al (Betaneli et al. 1980). This approach begins from a 
glucosyl donor with a C-2 participating group (Figure 4). After the glycosylation, the β-
glucoside is formed followed by a deacylation reaction to furnish a free equatorial hydroxyl 
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group at the C-2 position. The oxidation gives a C-2 ketone and the following hydride 
reduction reduces the ketone into an axial hydroxyl to finally yield the desired β-mannoside. 
Bundle and coworkers have utilized this method to construct a variety of fungal β-1,2-
mannan oligomers for immunology studies related to candidiasis. The advantage of this 
strategy for application to an automation platform is that there is no need for very low 
temperature glycosylations (Wu and Bundle 2005). However, conditions for carrying out 
oxidations and reductions on the automation platform would have to be developed. 
 
 
Figure 4. Oxidation-reduction sequence 
 
4. Automated solid-phase synthesis of β-mannosides 
Seeberger and coworkers have tried to use their modified solid-phase peptide 
synthesizer for the synthesis of a β-mannosidic linkage (Codee et al. 2008). The group 
utilized Crich’s 4,6-O-benzylidene strategy with Kim’s CB as the anomeric leaving group 
and also used the less bulky but expensive (triisopropylsiloxy)methyl (Tom) group to protect 
the 3-OH for better β-selectivity. After three cycles of glycosylation-deprotection, a 
trisaccharide with two β-mannosidic linkages was formed. It was worth noting that for each 
glycosylation step up to 9.0 to 10 equiv. of precious donors have been charged into the 
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synthesizer, which was both economically and ecologically problematic. In addition, only the 
simplest chain extension at the 3-position has been attempted. Application of the approach to 
β-mannosides linked at the 2-, 4-, or 6-positions would require complex protecting group 
manipulations. 
 
 
Figure 6. Automated solid-phase synthesis of β-mannan 
 
5. A new approach to the automated synthesis of β-mannans using a solution-phase 
strategy 
In order to provide a strategy which could produce the biologically important β-
mannans in a highly efficient and economical way, this dissertation will illustrate the 
development of the automated solution-phase synthesis of different β-mannans including the 
fungal β-1,2-mannans by using both oxidation-reduction and β-directing mannuronate 
strategies, and also reveals a new strategy for β-mannan synthesis by reduction of 
mannuronate esters to alcohols. The following chapter will show the power of this automated 
solution-phase method to create β-1,4-mannuronate and β-1,4-mannan oligomers up to 
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hexasaccharides. The subsequent chapter will demonstrate the application of this new β-
mannan synthesis strategy for the synthesis of the insect N-glycan terminal trimannosides for 
fluorous microarray and isothermal titration calorimetry (ITC) studies to investigate the 
binding affinity of the pea enation mosaic virus (PEMV) in the aphid digestion system for 
clues to the virus transmission pathway of the virus in these notorious pests. Finally, the 
automated solution-phase synthesis of β-1,6-mannan and β-1,3-mannan oligomers will 
present the scope of the automated solution-phase synthesis of β-mannans and its potential 
for synthesizing other oligosaccharides containing this challenging linkage.  
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CHAPTER 2 
Automated Solution-Phase Synthesis of β-1,2-Mannans 
Shu-Lun Tang and Nicola L. B. Pohl* 
 
Abstract 
β-1,2-Mannoside is considered one of the most challenging glycosidic linkages to 
chemically synthesize due to its thermodynamically and kinetically disfavored formation. 
This linkage can be found in the cell wall polysaccharides of Candida albicans and is a target 
structure for potential vaccines against these yeast infections. To develop the first automated 
synthetic approach to this important linkage, two approaches were tested in an automated 
solution-phase synthesis platform: an oxidation-reduction sequence and a β-directing 
mannuronate strategy. Both strategies effectively produced a β-1,2-mannan disaccharide by 
automation. However, further chain extension proved problematic with both methods. The β-
directing mannuronate strategy was the higher yielding method to synthesize the β-1,2-
mannan efficiently and could thereby be the ideal strategy for future automated solution-
phase synthesis of 1,2-linked and other β-mannan structures.  
 
Introduction 
The β-mannosidic linkage is a 1,2-cis-glycosidic linkage considered to be one of the 
most difficult linkages to synthesize because of the thermodynamically favored formation of 
α-mannoside and the kinetically disfavored formation of β-mannoside from the steric 
hindrance from the C-2 substituent (El Ashry et al. 2005). This particular linkage exists in 
many crucial natural products, including the β-1,2-mannans, which is the immunogenic part 
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of the cell wall phosphomannan of Candida albicans, an organism that mainly infects 
immunocompromised and long-term antibiotics treatment patients. The antifungal drugs for 
candidiasis often cause side effects and drug resistance in C. albicans. Given these problems, 
a vaccine against this pathogen would be ideal. To this end, Bundle and co-workers have 
synthesized bovine serum albumin (BSA) conjugated β-1,2-mannans and proven that as 
small as a disaccharide conjugate could be a potential vaccine for the candidiasis treatment 
(Nitz et al, 2000; Nitz and Bundle 2001; Wu and Bundle 2005). The group utilized an 
oxidation-reduction sequence strategy starting from the formation of a 2-O-acetyl-β-
glucoside followed by deacetylation, oxidation, and reduction to convert the C-2 equatorial 
hydroxyl to axial to become a β-mannoside ready for further chain extension. The advantage 
of this method is the availability of gram scale production of the β-1,2-mannans under 
moderate conditions and a short building block synthesis route (Nitz et al, 2000; Nitz and 
Bundle 2001; Wu and Bundle 2005). The big disadvantage to this approach, however, is the 
two additional steps required at each coupling step. This approach would also require an 
automation strategy that does not just include protocols for glycosylation and deprotection, 
but would require additional protocols for oxidation and reduction reactions compatible with 
the automation platform. 
For other β-mannoside synthesis strategies, in addition to Crich’s classic 4,6-O-
benzylidene methodology (Crich 2010; Crich 2011), van der Marel and coworkers have 
developed a new strategy to construct the β-mannosidic linkage while synthesizing a series 
of alginate β-mannuronic acid oligomers (van den Bos et al. 2006; Codee et al. 2009; 
Dinkelaar et al. 2009; Walvoort et al. 2009). (Figure 1) The C-5 carboxylate of the 
mannuronate provides high β-selectivity with a wide range of glycosyl acceptors.  The origin 
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of the unique selectivity is believed to be from the electron-withdrawing nature of the 
carboxylate. When the thiomannoside donor is activated by triflic anhydride, the equilibrium 
between the α-anomeric triflate, and 3H4 and 4H3 conformers of the oxocarbenium 
intermediate are formed. The electron-withdrawing C-5 carboxylate destabilized the 
oxocarbenium ion and shifts the equilibrium to the anomeric α-triflate, which leads to the β-
mannuronate through a SN2 mechanism. Because of the through-space stabilization of the 
cation by the pseudoaxial C-5 carboxylate and the lowest energy conformation of the ring 
substituents, the 3H4 conformer is favored over the 4H3 conformer and gives the β-
mannuronate. The spirit of this mannuronate strategy is analogous to Crich’s 4,6-O-
benzylidene strategy, however, without the fused benzylidene ring, the masking strategy of 
the overall oligosaccharide synthesis has more flexibility without the necessity of the 
selective benzylidene cleavage. Furthermore, the acid lability of the benzylidene can be a 
problem during further chain extension (Crich et al. 2004). We reasoned that this strategy to 
β-mannuronates could possibly provide a new, shorter or more flexible route to β-mannans if 
a global ester reduction method could be developed successfully. Herein, we report the first 
automated solution-phase synthesis of the challenging β-mannan linkage by an automated 
method to the oxidation-reduction sequence and also by a new β-mannan synthesis strategy 
that relies on a β-directing mannuronate followed by a global hydride reduction of the C-5 
esters. Comparison of these two methods showed the latter strategy to be a more efficient 
method for the automated synthesis of β-mannans. 
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Figure 1. β-Directing effect of a mannuronate building block 
 
Results and discussion 
Although the automated solid-phase synthesis of β-mannan up to two β-mannosidic 
linkages has been reported previously (Codee et al. 2008), a homogeneous automated 
solution-phase synthesis approach should be a more efficient and economical way to 
construct oligosaccharides due to the absence of the repeating rinsing cycles and the need for 
large excesses of glycosyl donors (Codee et al. 2008). The real time TLC or MS monitoring 
of the reaction and reinjection after bench-top purification also allows more flexibility 
compared to a traditional automated solid-phase protocol. In order to implement the 
oxidation-reduction sequence to the automated solution-phase synthesis protocols, the 
glucosyl donor 4 was synthesized. The p-chlorobenzylation of the known orthoester 1 (Tsai 
et al. 2012) gave the fully protected 2. The p-chlorobenzyl protected sugars are known for 
their crystalline characteristics that provide convenient purification and storage and, indeed, 
compound 2 did readily crystalize from dichloromethane (DCM). The orthoester was 
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hydrolyzed under acidic conditions to yield solid 3. Subsequent trichloroacetimidate 
formation gave the desired glycosyl donor 4 for the initial automated solution-phase 
synthesis run of β-1,2-mannan. (Figure 2) The automation started from the glycosylation of 
the fluorous allyl tag (F-tag) and the trichloroacetimidate donor 4 (2.0 equiv.) catalyzed by 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.1 equiv.) at 0 °C under Ar 
atmosphere. After 30 min a small aliquot of solution was transferred out of the synthesis 
platform for TLC reaction monitoring. After the reaction was finished, triethylamine was 
added to quench the reaction and the solvent was removed under reduced pressure generated 
by the vacuum pump unit. The deacetylation was carried out without further purification by 
adding sodium methoxide methanol solution to the reactor and the mixture was vortexed for 
1 h at 25 °C, and quenched by AcOH/MeOH after the TLC showed the completion of the 
reaction. The solvent was removed under reduced pressure and the mixture was loaded onto 
the fluorous solid phase extraction (FSPE) cartridge. The automated synthesis platform 
finished the elution, collected the product fractions, evaporated the solvent and transferred 
the product with a free 2-OH to the reactor vial for the oxidation. The Dess-Martin oxidation 
was chosen for the automated synthesis due to its mild conditions and more complete 
reaction compared to the previously reported Albright-Goldman oxidation (Nitz and Bundle 
2001). The Dess-Martin periodinane (DMP) in 1,2-dichloroethane (DCE) was added to the 
reactor and vortexed at 50 °C for 45 min. After TLC showed the completion of the reaction, 
the solvents was removed under reduced pressure and the fluorous-modified product was 
purified by FSPE. The reduction of the C-2 ketone to an axial alcohol was completed by L-
Selectride (Wu and Bundle 2005) followed by another FSPE. At this stage, the F-tag-
modified β-mannoside monomer was produced and ready for another glycosylation-
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deacetylation-oxidation-reduction cycle. After 2 cycles (8 steps), the desired β-1,2-mannan 
disaccharide 5 was successfully synthesized in 8% yield over 8 steps (73% per reaction step). 
The further chain extension was tested; however, the formation of trisaccharide A from the 
glycosylation of disaccharide 5 with the donor 4 could not be affected, likely due to the 
weakened acceptor nucleophilicity from the built-up electron-withdrawing effect from 
multiple p-chlorobenzyl groups when compared to the previously reported similar benzyl 
groups protected β-1,2-di-mannoside acceptor (Wu and Bundle 2005). The deprotection of 5 
was accomplished by hydrogenolysis of the p-chlorobenzyl ethers catalyzed by 20% 
Pd(OH)2/C and the fully deprotected β-1,2-mannan 6 was obtained in 87% yield. Although 
this result represents the first automated solution-phase synthesis of the β-mannan, the 
approach requires too many reactions and transfer steps in between each glycosylation for a 
high overall yield of the final product. Therefore, a second strategy using a mannuoronate 
donor with β-directing C-5 carboxylate was explored.   
 
 
 
! 17 
 
Figure 2. Synthesis of donor 4 and the automated solution–phase synthesis of !-1,2-mannan 
via oxidation-reduction sequence  
Reagents and conditions: (a) pClBnCl, NaH, DMF, 0 °C to rt, 20 h, 86%; (b) 2 N HCl, DCM, 
rt, 2 h, quant.; (c) Cl3CCN, DBU, DCM, 0 °C, 3 h, 88%; (d) TMSOTf, DCE, 0 °C 45 min; (e) 
NaOMe, MeOH, 25 °C, 2 h; (f) DMP, DCE, 50 °C, 45 min; (g) L-Selectride, THF, -20 °C, 
45 min; (h) NaOMe, MeOH, 50 °C, 2 h; (i) H2, Pd(OH)2/C, MeOH, 20 °C, 87% 
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Compared to the oxidation-reduction sequence strategy, the mannuronate should 
provide a shorter synthetic route without the inversion of the C-2 position.  The p-
methoxybenzyl (PMB) group was chosen as the masking group for the 2-OH because of its 
small size, which provides a less hindered β-face for the glycosyl acceptor. The synthesis of 
the mannuronate donor 12 started from the selective opening of the benzylidene acetal of the 
known compound 7 (Oshitari et al. 1997) with borane tetrahydrofuran complex (BH3⋅THF) 
and dibutylboron triflate (Jiang and Chan 1998) to afford 8 with a free 6-OH. The oxidation 
of the primary alcohol by 2,2,6,6-tetramethyl-1-piperidinyloxy free radical (TEMPO) and 
(diacetoxyiodo)benzene (BAIB) (van den Bos et al. 2006) generated the carboxylic acid 9. 
The esterification of the carboxylic acid with methyl iodide/K2CO3 gave the fully protected 
methyl mannuronate 10 (van den Bos et al. 2006). N-Bromosuccinimide (NBS) was utilized 
to remove the anomeric thiophenyl group (Liew and Wei 2002) to afford alcohol 11 with a 
free anomeric hydroxyl and the following trichloroacetimidate formation produced the 
desired donor 12 for the automated synthesis.  
The automated synthesis started from the attachment of the fluorous allyl tag 
(Mamidyala et al. 2006) and donor 12 (3.0 equiv.) with TMSOTf (0.1 equiv.) at -20 °C. After 
30 min, the solvent was removed under reduced pressure and ceric ammonium nitrate (CAN) 
solution in MeCN/H2O = 1/9 was added to the mixture and vortexed for 1 h. After the 
reaction showed completion based on TLC, the mixture was transferred to the SPE station for 
the FSPE purification. Another glycosylation-deprotection-FSPE cycle was performed and 
the crude product was transferred out of the synthesis platform and purified manually to 
afford the desired β-1,2-mannuronate dimer 13 in 38% over 4 steps (79% per step). The 
attempt for further chain extension was also tested using the standard conditions for 
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glycosylation with the donor 12. However due to the low reactivity of the acceptor, the 
reaction did not succeed instead, the only formed product was the hydrolyzed donor. 
Therefore, a trial for a mixed strategy was initiated that involved attachment of glucosyl 
donor C followed by a deacetylation-oxidation sequence. Interestingly, glycosylation with 
the glucose building block did take place in 68% yield. Therefore, the inherent reactivity of 
the growing mannose chain is not as large an issue as matching the correct donor.  
Unfortunately, the subsequent Dess-Martin oxidation reaction was not successful. Steric 
hindrance at the glucosyl C-2 position is a likely explanation for the difficulty of this 
reaction.  
To complete the synthesis of the disaccharide, di-mannuronate 13 was reinjected back 
into the synthesis platform vial and treated with a lithium triethylborohydride (LiTEBH) 1.0 
M solution in THF. Fortunately, the esters were reduced quantitatively to afford the desired 
β-1,2-mannan disaccharide 14. After hydrogenolysis of the benzyl groups with catalytic 10% 
Pd/C, the deprotected 6 was obtained in 89% yield. The β-directing mannuronate strategy 
only required one step to construct one β-mannosidic linkage. Compared to the 4 steps 
required for the glycosylation-deacetylation-oxidation-reduction sequence, the β-directing 
mannuronate strategy was more efficient and significantly improved the overall yield of the 
final β-1,2-mannan. Furthermore, these two strategies provided comparable yields to the 
automated solid-phase synthesis of β-mannan (Codee et al. 2008) using Crich’s 4,6-O-
benzylidene strategy with 70% to 80% fewer donor equivalents required for each 
glycosylation. Even in producing a disaccharide, 7.0 equivalents of glycosyl donor were 
saved with the new mannuronate-based strategy. 
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Figure 3. Synthesis of donor 12 and the automated solution–phase synthesis of β-1,2-mannan 
via mannuronate donor strategy 
Reagents and conditions: (a) BH3⋅THF, Bu2BOTf, 0 °C, 3 h, 86%; (b) TEMPO, BAIB, 
DCM/H2O, rt, 45 min, 76%; (c) MeI, K2CO3, DMF, rt, 6 h, 87%; (d) NBS, NaHCO3(s) 
acetone/H2O, rt, 1 h, 87%; (e) Cl3CCN, DBU, DCM, 0 °C, 3 h, 89%; (f) TMSOTf, DCM, -20 
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°C, 30 min; (g) CAN, MeCN/H2O, 25 °C, 4 h; (h) LiTEBH/THF, DCM, 0 °C, 30 min; (i) H2, 
Pd/C, MeOH, 20 °C, 89% (a: purified on bench-top) 
 
Conclusions 
Protocols for the successful synthesis of the challenging β-1,2-mannan linkage have 
now been developed on an automated solution-phase synthesis platform protocol via both an 
oxidation-reduction sequence and a new β-directing mannuronate strategy. The latter proved 
to be a more efficient way to construct β-mannans. Although further work is needed to 
extend this work to longer polymannan oligosaccharide fragments, the current method now 
allows the incorporation of the difficult 1,2-linked β-mannoside building block into 
automated solution-phase synthesis strategies. 
 
Experimental section 
 
General materials and methods 
Dichloromethane (DCM) and dichloroethane (DCE) for glycosylation were distilled 
from calcium hydride. Tetrahydrofuran (THF) was collected from PureSolv Micro solvent 
purification system (Innovative Technology, Inc., Amesbury, MA) before reactions. All other 
commercial solvents and reagents were reagent grade and used as received without further 
purification. The reactions were monitored by thin layer chromatography (TLC) with 250 µm 
Sorbent Technologies silica gel HL TLC plates. The hydrogenation reaction under 1000 psi 
hydrogen was operated in the Parr model 4766 general purpose vessel high pressure reactor 
(Parr Instrument Company, Moline, IL). The developed TLC plates were visualized by stain 
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with p-anisaldehyde solution followed by heating on a hot plate. Flash column 
chromatography was performed with Zeochem ZEOprep 60 silica gel, 40-63 µm particle 
size. The automated solution phase synthesis was performed in the Chemspeed ASW1000  
(Chemspeed, Augst, Switzerland) synthesis platform with hood, 16 reactor vials (13-mL 
capacity each) and heating/cooling unit (200 °C to -20 °C) machined to hold the SPE 
cartridges at the Iowa State University Machine Shop. 1H and 13C NMR spectra were 
obtained at 400 MHz and 100 MHz on a Bruker DRX-400 spectrometer and a Varian MR-
400 spectrometer. The C-H coupling constants were measured by the coupled 13C NMR 
spectra. Chemical shifts (δ) were reported in parts per million (ppm) relative to CDCl3 and 
CD3OD as internal references. Mass spectra were obtained on a Finnigan TSQ700 triple 
quadrupole mass spectrometer (Finnigan MAT, San Jose, CA) fitted with a Finnigan ESI 
interface.  
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General procedure for automated synthetic cycles to produce β-1,2-mannosides 
 
Reactor Block Reagent Rack SPE Cartridge Block
TLC well
SPE 
cartridges
Inert Reagent Rack
1
2
3
4
5
6
7
8
9
11 12
13
14
15
17
16
18
ASW1000
10
 
Figure 4. Basic layout of automated solution-phase oligosaccharide synthesizer (ASW1000) 
1: F-tagged acceptor (solution in DCM/DCE), 2: TEA, 3: DMF, 4: NaOMe/MeOH, 5: 
LiTEBH (1.0 M in THF), 6: Dess Martin periodinane/DCE, 7: water, 8: CAN/MeCN, 9: 
AcOH/MeOH, 10: L-Selectride (1.0 M in THF), 11: MeOH, 12: reservoir (toluene), 13: 
TMSOTf (0.55 M in DCM/DCE), 14: donor, 15: DCM/DCE, 16: THF, 17: 80 % MeOH, 18: 
FSPE cartridge. 
 
Part A: Oxidation-reduction sequence 
1. Sample Preparation 
Donor molecule (148 mg, 0.200 mmol) was dissolved in anhydrous DCE (1.6 mL) in 
the 13 mL-vial and placed at the inert reagent rack (Donor) under argon atmosphere. A 0.055 
M trimethylsilyltrifluoromethanesulfonate (TMSOTf) solution (5.0 mL) in anhydrous DCE 
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was prepared in an 8 mL-vial and placed as indicated on the inert reagent rack under argon. 
MeOH (100 mL) was placed in the stock solution bottle at the stock solution station as 
indicated. Toluene (1.0 L) was placed in the stock solution bottle and placed at the reservoir 
bottle rack with tubing as reservoir solution for rinsing. Anhydrous DCE (20 mL) was 
transferred to the 50 mL-vial and placed as indicated on the inert reagent rack under argon. 
Anhydrous tetrahydrofuran (THF, 10 mL) was transferred to the 50 mL-vial and placed as 
indicated on the inert reagent rack under argon.  80% methanol/water (100 mL) stock was 
prepared in the 100 mL-vial and placed as indicated on the inert reagent rack. F-tagged 
acceptor molecule (50 µmol) was dissolved with anhydrous DCE (0.8 mL) in a Wheaton 8 
mL-E-Z extraction vial (conically-bottomed) flushed with argon, capped with septa and 
placed at the reagent rack as indicated. Triethylamine (TEA, 5.0 mL) was transferred to an 8 
mL-vial capped with septa and placed at the reagent rack as indicated. N,N-
dimethylformamide (DMF, 8.0 mL) was transferred to an 8 mL-vial capped with septa and 
placed at the reagent rack as indicated. A 0.5 M sodium methoxide solution in methanol (5.0 
mL) was prepared in an 8 mL-vial capped with septa and placed at the reagent rack as 
indicated. A 0.2 M acetic acid solution in methanol (5.0 mL) was prepared in an 8 mL-vial 
capped with septa and placed at the reagent rack as indicated. Dess-Martin periodinane 
solution (0.21g in 5.0 mL DCE) was prepared in an 8 mL-vial flushed with argon, capped 
with septa and placed at the reagent rack as indicated. L-Selectride solution in THF (1.0 M, 
3.0 mL) was transferred to an 8 mL-vial capped with septa and placed at the reagent rack as 
indicated. Water (8.0 mL) was transferred to an 8 mL-vial capped with septa and placed at 
the reagent rack as indicated. A fluorous solid phase extraction (FSPE) cartridge (2.0 g, 10 
cc) was preconditioned with 80% methanol/water and placed on the machined FSPE block as 
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indicated. An empty Wheaton 8 mL-E-Z extraction vial was placed under the FSPE 
cartridge. 
 
2. Cleaning Cycle 
Prior to introduction of reagents, the ASW1000 reactor vials were cleaned, dried and 
purged with argon by running the cleaning cycle. During the cleaning cycle, each of the 16 
reactor vials (13 mL capacity each) was rinsed with toluene (8.0 mL) and methanol (8.0 mL) 
3 times each. After the solvents were completely removed, the reactor vials were dried under 
vacuum and purged with argon for 45 minutes. Reagent solutions were prepared by 
azeotropic removal of water from each building block with toluene; the resulting building 
blocks were then dried under high vacuum. After the cleaning cycles were done, the reagents 
were transferred into the reagent vials respectively, which were then placed on the inert 
condition reagent rack and general atmosphere reagent rack. 
 
3. Glycosylation 
The needle transferred the acceptor molecule (F-tag) solution (0.8 mL) to the reaction 
vial 1, followed by the transfer of the donor molecule solution (0.8 mL). The mixture was 
vortexed under ambient temperature at 800 rpm for 20 min. Then the reactor vials were 
cooled to 0 °C by the heat transfer oil with 800 rpm vortex rate. The TMSOTf solution (0.1 
mL) was transferred into the reactor vial 1 under 200 rpm vortex rate. After each individual 
transfer, the needle (inside and outside) was rinsed by toluene (2.0 ml) before operating the 
next task. The reaction mixture was vortexed at 800 rpm for 45 minutes at 0 °C under argon 
atmosphere. After the reaction time the needle withdrew 20 µL of the solution from the 
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reaction mixture and placed it into the first well of the microtiterplate for thin layer 
chromatography monitoring. TEA (0.05 mL) was added to the solution for quenching and the 
solvent was evaporated under reduced pressure.   
 
4. Deacetylation 
To the dried residue after the glycosylation, methanol (0.5 mL) was added to the 
reactor vial followed by NaOMe solution (0.4 mL). The reaction mixture was vortexed at 800 
rpm for 1 hour at room temperature. After the reaction time the needle withdrew 20 µL of the 
solution from the reaction mixture and placed it into the second well of the microtiterplate for 
thin layer chromatography monitoring. An acetic acid (0.75 mL) solution added to reactor 
vial for quenching followed by addition of toluene (1.0 mL) and solvent was evaporated 
under reduced pressure.  
  
5. Fluorous solid-phase extraction (FSPE) 
DMF (0.4 mL) was added to the reactor vials to dissolve the crude mixture and the 
vials were vortexed at 800 rpm for 3 minutes. The reaction mixture (1.2 mL) was carried to 
the FSPE cartridge at the FSPE block and dispensed at a speed of 1.0 mL/s via the 10 mL 
syringe. Then 80% methanol (2.0 mL) was used to rinse the empty reactor vial. The 80% 
methanol solution was removed from the reactor vial and delivered to the FSPE cartridge. 
The 80% methanol rinsing and transferring was repeated one more time. Additional 80% 
methanol solution (4.0 mL, repeated 2 times) was used to rinse the FSPE cartridge. During 
the 80% methanol rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to 
be disposed. MeOH (2.0 mL, repeated 3 times) was used to wash the FSPE cartridge for 
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eluting the desired compound. During the task, the FSPE cartridge was positioned as ‘SPE 
collect’ to be placed right above the 8 mL vial for collection of the sample. After the task, the 
position of the SPE rack was changed into ‘SPE direct’ for the needle to withdraw the 
collected sample from the conically-bottomed vial and deliver it to the clean reactor vial for 
the next reaction. Toluene (1.0 mL) was added to the solution and solvent was evaporated 
under reduced pressure. After the evaporation cycle, The MeOH wash step and the 
evaporation were repeated one more time. Once again toluene (1.0 mL) was added and 
removed under reduced pressure to remove residual water. 
 
6. Oxidation 
Dess-Martin periodinane in DCE (1.5 mL) was added to the sample and vortexed at 
800 rpm, 50 °C under argon atmosphere for 45 min. After the reaction time the needle 
withdrew 20 µL of the solution from the reaction mixture and placed it into the third well of 
the microtiterplate for thin layer chromatography monitoring. The solvent was removed 
under reduced pressure. 
 
7. Reduction 
L-Selectride 1.0 M in THF (1.0 mL) was added to the sample and vortexed at 800 
rpm, -20 °C under argon atmosphere for 45 min. After the reaction time the needle withdrew 
20 µL of the solution from the reaction mixture and placed it into the third well of the 
microtiterplate for thin layer chromatography monitoring. MeOH (0.5 mL) was added to 
quench the reaction. The solvent was removed under reduced pressure. 
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Part B: Mannuronate building block 
1. Sample Preparation 
Donor molecule (0.20 g, 0.30 mmol) was dissolved in anhydrous DCM (1.6 mL) in 
the 13 mL-vial and placed at the inert reagent rack (Donor) under argon atmosphere. A 0.055 
M trimethylsilyltrifluoromethanesulfonate (TMSOTf) solution (5.0 mL) in anhydrous DCM 
was prepared in an 8 mL-vial and placed as indicated on the inert reagent rack under argon. 
MeOH (100 mL) was placed in the stock solution bottle at the stock solution station as 
indicated. Toluene (1.0 L) was placed in the stock solution bottle and placed at the reservoir 
bottle rack with tubing as reservoir solution for rinsing. Anhydrous DCM (20 mL) was 
transferred to the 50 mL-vial and placed as indicated on the inert reagent rack under argon. 
Anhydrous tetrahydrofuran (THF, 10 mL) was transferred to the 50 mL-vial and placed as 
indicated on the inert reagent rack under argon.  80% methanol/water (100 mL) stock was 
prepared in the 100 mL-vial and placed as indicated on the inert reagent rack. F-tagged 
acceptor molecule (50 µmol) was dissolved with anhydrous DCM (0.8 mL) in a Wheaton 8 
mL-E-Z extraction vial (conically-bottomed) flushed with argon, capped with septa and 
placed at the reagent rack as indicated. Triethylamine (TEA, 5.0 mL) was transferred to an 8 
mL-vial capped with septa and placed at the reagent rack as indicated. N,N-
dimethylformamide (DMF, 8.0 mL) was transferred to an 8 mL-vial capped with septa and 
placed at the reagent rack as indicated. A 0.45 M CAN (ceric ammonium nitrate) solution in 
acetonitrile/water (9/1) (5 mL) was prepared in an 8 mL-vial capped with septa and placed at 
the reagent rack as indicated. LiTEBH solution in THF (1.0 M, 3.0 mL) was transferred to an 
8 mL-vial capped with septa and placed at the reagent rack as indicated. Water (8.0 mL) was 
transferred to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. A 
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fluorous solid phase extraction (FSPE) cartridge (2 g, 10 cc) was preconditioned with 80% 
methanol/water and placed on the machined FSPE block as indicated. An empty Wheaton 8 
mL-E-Z extraction vial was placed under the FSPE cartridge. 
 
2. Cleaning cycle (see part A) 
 
3. Glycosylation 
The needle transferred the acceptor molecule (F-tag) solution (0.8 mL) to the reaction 
vial 1, followed by the transfer of the donor molecule solution (0.8 mL). The mixture was 
vortexed under ambient temperature at 800 rpm for 20 min. Then the reactor vials were 
cooled to -20 °C during the 60 minutes wait time by the heat transfer oil with 800 rpm vortex 
rate. The TMSOTf solution (0.1 mL) was transferred into the reactor vial 1 under 200 rpm 
vortex rate. After each individual transfer, the needle (inside and outside) was rinsed by 
toluene (2 ml) before operating the next task. The reaction mixture was vortexed at 800 rpm 
for 30 minutes at 0 °C under argon atmosphere. After the reaction time the needle withdrew 
20 µL of the solution from the reaction mixture and placed it into the first well of the 
microtiterplate for thin layer chromatography monitoring. TEA (0.05 mL) was added to the 
solution for quenching and the solvent was evaporated under reduced pressure.   
 
4. PMB deprotection 
To the dried residue after the glycosylation, The CAN solution (1.0 mL) was added to 
the reactor vial. The reaction mixture was vortexed at 800 rpm for 1 h at room temperature. 
After the reaction time the needle withdrew 20 µL of the solution from the reaction mixture 
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and placed it into the second well of the microtiterplate for thin layer chromatography 
monitoring.  
 
5. Fluorous solid-phase extraction (FSPE) 
The reaction mixture (1.2 mL) was carried to the FSPE cartridge at the FSPE block 
and dispensed at a speed of 1 mL/s via the 10 mL syringe. Then 80% methanol (2.0 mL) was 
used to rinse the empty reactor vial. The 80% methanol solution was removed from the 
reactor vial and delivered to the FSPE cartridge. The 80% methanol rinsing and transferring 
was repeated one more time. Additional 80% methanol solution (4.0 mL, repeated 2 times) 
was used to rinse the FSPE cartridge. During the 80% methanol rinse, the cartridge was 
positioned at ‘SPE waste’ for the eluted mixture to be disposed. MeOH (2.0 mL, repeated 3 
times) was used to wash the FSPE cartridge for eluting the desired compound. During the 
task, the FSPE cartridge was positioned as ‘SPE collect’ to be placed right above the 8 mL 
vial for collection of the sample. After the task, the position of the SPE rack was changed 
into ‘SPE direct’ for the needle to withdraw the collected sample from the conically-
bottomed vial and deliver it to the clean reactor vial for the next reaction. Toluene (1.0 mL) 
was added to the solution and solvent was evaporated under reduced pressure. After the 
evaporation cycle, The MeOH wash step and the evaporation were repeated one more time. 
Once again toluene (1.0 mL) was added and removed under reduced pressure to remove 
residual water. 
 
7. LiTEBH Reduction 
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Anhydrous THF (1.0 mL) was added to the sample and vortexed at 800 rpm, 0 °C 
under argon atmosphere for 30 min. The LiTEBH (0.3 mL, 1.0 M in THF) was added to the 
reaction solution and the mixture was vortexed for 30 min at 800 rpm, 0 °C under argon 
atmosphere. After the reaction time the needle withdrew 20 µL of the solution from the 
reaction mixture and placed it into the fourth well of the microtiterplate for thin layer 
chromatography monitoring. MeOH (0.5 mL) was added to quench the reaction and the 
mixture was transferred out of the ASW. 
 
Synthetic procedures 
OpClBnO
pClBnO
OO
pClBnO
OHO
HO
OO
HO
OMe 21 OMe  
3, 4, 6-tri-O-p-chlorobenzyl-α-D-glucopyranose 1,2-(methyl orthoacetate) (2) 
α-D-glucopyranose 1,2-(methyl orthoacetate) (1) (1.42 g, 6.00 mmol) was dissolved in 
anhydrous DMF (20 mL) and 60% sodium hydride in mineral oil (1.20 g, 30.0 Significant 
figures: check throughout mmol) and p-chlorobenzyl chloride (3.86 g, 24.0 mmol) were 
added slowly at 0 °C under argon atmosphere. The reaction was allowed to warm to ambient 
temperature and stirred for 20 h. The reaction mixture was quenched with water (20 mL) at 0 
°C. The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were 
washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography on silica gel 
using EtOAc/petroleum ether/triethylamine (3/7/0.1) as eluent. The product was obtained as 
a yellow syrup (3.15 g, 5.16 mmol, 86%). 
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Rf: 0.27 (EtOAc/petroleum ether: 3/7) 
1H NMR (CDCl3, 400MHz): δ 7.20-7.30 (m, 10H, Harom), 7.08 (d, 2H, J = 8.4 Hz, Harom) 
5.75 (d, 2H, J = 5.2 Hz, H-1), 4.69 (d, 1H, J = 12 Hz), 4.51-4.56 (m, 3H), 4.44 (d, 1H, J = 
12.4 Hz), 4.37-4.39 (dd, 1H, J = 5.2, 4 Hz, H-2), 4.36, (d, 1H, J = 11.6 Hz), 3.78-3.80 (dd, 
1H, J = 4.4, 4.0 Hz, H-3), 3.73-3.77 (m, 1H, J = 9.6, 3.2, 2.8 Hz, H-5), 3.62-3.65 (m, 3H), 
3.27 (s, 3H), 1.63 (s, 3H).    
13C NMR (CDCl3, 400 MHz): δ 136.5, 136.3, 136.1, 133.5, 133.4, 133.2, 129.2, 129.0, 
129.0, 128.5, 128.4, 121.3, 97.7, 79.0, 77.6, 77.2, 76.9, 75.9, 74.7, 72.5, 72.1, 70.9, 70.4, 
69.0, 50.4, 21.4. 
HRMS (ESI): [M + Na]+ calcd for C30H31Cl3NaO7+ 631.1028, found 631.1035   
 
OpClBnO
pClBnO
AcOOH
pClBnO
OpClBnO
pClBnO
OO
pClBnO
OMe 32  
2-O-acetyl-3,4,6-tri-O-p-chlorobenzyl-α-D-glucopyranose (3) 
3, 4, 6-Tri-O-p-chlorobenzyl-α-D-glucopyranose 1,2-(methyl orthoacetate) (2) (2.00 g, 3.28 
mmol) was dissolved in dichloromethane (35 mL); a 2 N HCl solution (30 mL) was then 
added. The reaction mixture was stirred at ambient temperature for 2 h. The organic portion 
was separated and washed with a saturated NaHCO3 solution (2 x 30 mL). The organic layer 
was dried over Na2SO4. The solvent was removed under reduced pressure to leave the 
product as white crystals (1.95 g, 3.28 mmol, 100%). 
Rf: 0.71 (EtOAc/petroleum ether: 2/1) 
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1H NMR (CDCl3, 400 MHz): δ 7.21-7.29 (m, 10H, Harom), 7.04 (d, 2H, J = 8.4 Hz, Harom), 
6.20 (d, 1H, J = 3.6 Hz, H-1), 4.84 (d, 1H, J = 11.6 Hz), 4.79 (d, 1H, J = 11.6 Hz), 4.71 (d, 
1H, J = 11.2 Hz), 4.57 (d, 2H, J = 12.4 Hz), 4.47 (d, 1H, J = 11.2 Hz), 4.43 (d, 1H, J = 12.4 
Hz), 3.80-3.82 (m, 1H, H-2), 3.73-3.78 (t, 1H, J = 9.2, 8.8 Hz), 3.64-3.71 (m, 2H), 3.59-3.62 
(dd, 1H, J = 10.8, 2.0 Hz), 2.26 (s, 1H), 2.12 (s, 3H). 
13C NMR (CDCl3, 100 MHz): δ 170.0, 137.0, 136.4, 136.2, 133.5, 133.5, 133.4, 129.2, 
129.1, 129.0, 128.9, 128.8, 128.6, 92.1, 82.2, 77.5, 77.2, 76.9, 74.5, 74.1, 72.9, 72.7, 71.5, 
68.1, 21.1 
HRMS (ESI): [M + Na]+ calcd for C29H29Cl3NaO7+ 617.0871, found 617.0859   
 
OpClBnO
pClBnO
AcOO
pClBnO
OpClBnO
pClBnO
AcOOH
pClBnO
43
CCl3
NH  
2-O-acetyl-3,4,6-tri-O-p-chlorobenzyl-α-D-glucopyranose trichloroacetimidate (4) 
To a solution of 2-O-acetyl-3,4,6-tri-O-p-chlorobenzyl-α-D-glucopyranose (3) (0.50 g, 0.84 
mmol) in dichloromethane (29 mL) was added trichloroacetonitrile (0.72 g, 5.0 mmol) at 0 °C 
under argon atmosphere. DBU (0.05 g, 0.33 mmol) was then added and the reaction mixture 
was stirred at 0 °C under argon atmosphere for 3 h. The solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography on silica gel 
using EtOAc/petroleum ether/triethylamine (3/7/0.1) as eluent. The product was obtained as 
a yellow syrup (0.55 g, 0.74 mmol, 88%).  
Rf: 0.50 (EtOAc/petroleum ether: 3/7) 
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1H NMR (CDCl3, 400MHz): δ 8.64 (s, 1H, NH), 7.23-7.29 (m, 8H, Harom), 7.19 (d, 2H, J = 
8.0 Hz, Harom), 7.08 (d, 2H, J = 8.4 Hz, Harom), 5.76 (d, 1H, J = 8.0 Hz, H-1), 5.27 (t, 1H, J = 
8.0 Hz, H-2), 4.46-4.71 (m, 6H), 3.81 (t, 1H, J = 9.2), 3.63-3.73 (m, 4H), 1.96 (s, 3H) 
13C NMR (CDCl3, 100 MHz): δ 169.2, 161.3, 136.5, 136.3, 133.8, 133.7, 133.5, 129.3, 
129.2, 129.1, 128.7, 128.6, 96.1, 90.7, 82.6, 77.2, 75.9, 74.1, 74.0, 72.7, 71.8, 68.1, 20.9. 
HRMS (ESI): [M + Na]+ calcd for C31H29Cl6NNaO7+ 759.9967, found 759.9971 
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Table 1. Automated synthetic cycles for production of compound 5  
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
 
10 
11 
12 
13 
14 
15 
16 
17 
 
18 
19 
20 
21 
22 
23 
24 
25 
25 
 
26 
 
27 
28 
29 
30 
31 
 
32 
 
 
33 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
 TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
Transfer 
Evaporation 
Oxidation 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
Transfer 
Evaporation 
Reduction 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading         
 
Wash 
Wash 
Transfer 
Evaporation 
Glycosylation 
 
Repeat the same 
procedure as step 
2-28 
Transfer  
2.0 equivalent donor  (100 µmol) in 0.8 mL DCE, 1.0 equivalent 
F-tagged acceptor (50 µmol) in 0.8 mL DCE, 0.1 equivalent 
TMSOTf, 0 °C 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 oC 
0.4 mL NaOMe/MeOH, 25 °C 
20 µL of crude reaction mixture withdrawn 
0.5 mL AcOH/MeOH, 1 mL toluene 
40 °C 
0.4 mL DMF 
 
0.5 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeOH wash (repeated 3 × 2 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
1.5 mL DMP in DCE, 50 °C 
40 °C 
0.4 mL DMF 
 
0.5 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeOH wash (repeated 3 × 2 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
1.0 mL THF, 1.0 mL L-Selectride, -20 °C 
0.5 mL MeOH 
40 °C 
0.4 mL DMF 
 
0.5 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeOH wash (repeated 3 × 2 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
2.0 equivalent donor  (100 µmol) in 0.8 mL DCE, 0.8 mL DCE, 
0.1 equivalent TMSOTf, 0 °C 
Repeat 1 cycle (50 °C for the deacetylation step) 
 
 
6.0 mL solution transferred out of the synthesis platform 
45 min 
 
 
 
 
45 min 
1 h 
 
 
45 min 
 
 
 
 
 
 
45 min 
45 min 
45 min 
 
 
 
 
 
 
45 min 
45 min 
 
45 min 
 
 
 
 
 
 
 
45 min 
45 min 
 
9 h 15 min 
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OpClBnO
pClBnO
pClBnO
OpClBnO
pClBnO
pClBnO
O
OH
O O
C8F17
5  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (3,4,6-tri-O-p-chlorobenzyl-
2-O-(3,4,6-tri-O-p-chlorobenzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (5) 
After the 2nd cycle (33rd step) of the automated synthesis, the mixture was transferred out of 
the synthesis platform and purified by flash column chromatography on silica gel using 
EtOAc/petroleum ether (1/2) as eluent. The product was obtained as a colorless syrup (6.5 
mg, 4.0 µmol, 8% over 8 steps, 73% per step) 
Rf: 0.31 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 400MHz): δ (ppm) 7.31-7.00 (m, 24H, Harom), 5.76 (m, 2H, HC=CH), 4.90 
(s, 1H, H-1), 4.87-4.73 (m, 4H, CHHPh), 4.60-4.44 (m, 5H), 4.41 (s, 1H, H-1), 4.40-4.28 (m, 
6H), 4.23 (dd, 1H, J = 12.8, 8.0 Hz, O-CHHC=C), 4.00 (d, J = 6.4 Hz, C=CCH2-O), 3.90 (t, J 
= 9.2 Hz), 3.77-3.65 (m, 4H), 3.60 (dd, J = 10.0, 5.2 Hz), 3.52 (m, 2H), 3.46 (m, 3H), 3.38 
(m, 1H), 2.68 (s, 1H, OH), 2.22 (m, 2H, CH2CF2), 1.88 (m, 2H, O-CH2CH2) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 135.9, 136.8, 136.7, 136.5, 136.4, 133.7, 133.7, 
133.6, 130.4, 129.6, 129.4, 129.4, 129.2, 129.2, 129.1, 128.7, 128.7, 128.7, 128.6, 128.1, 99.6 
(C-1, JC1-H1 = 154.7 Hz), 99.3 (C-1, JC1-H1 = 159.0 Hz), 81.6, 80.6, 75.5, 75.0, 74.3, 74.1, 72.8, 
72.7, 70.7, 70.1, 69.8, 69.5, 69.2, 69.0, 67.7, 66.6, 64.7, 28.3 (t, JC-F = 22.1), 21.0 
HRMS (ESI): [M + Na]+ calcd for C69H63Cl6F17NaO12+ 1641.2047, found 1641.2074   
HPLC trace of the automated synthesis of 5 
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Figure 5. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/4, 15 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
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Phenyl 2-O-p-methoxybenzyl-3,4-di-O-benzyl-thio-α-D-mannopyranoside (8) 
To the phenyl 2-O-p-methoxybenzyl-3-O-benzyl-4,6-O-benzylidene-thio-α-D-
mannopyranoside (7) (1.4 mmol) was added borane terahydrofuran complex 1.0 M solution 
in tetrahydrofuran (14 mL, 14.0 mmol) under argon atmosphere at 0 °C and stirred until the 
starting material was dissolved. Then the dibutylboryl trifluoromethanesulfonate 1.0 M 
solution in DCM (1.7 mL, 1.70 mmol) was added dropwise and the reaction mixture was 
stirred under argon atmosphere at 0 °C for 3 h. Triethylamine (0.3 mL, 2.15 mmol) was 
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added dropwise to the reaction then methanol was added slowly to quench the reaction under 
0 °C. The solvent was removed under reduced pressure and the crude mixture was 
coevaporated with methanol twice. The crude product was purified by flash column 
chromatography on silica gel using EtOAc/petroleum ether (1/2) as eluent. The product was 
obtained as a light yellow syrup  (0.69 g, 1.20 mmol, 86%) 
Rf: 0.14 (EtOAc/petroleum ether: 1/3) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.40-7.25 (m, 17H, Harom), 6.85 (dd, 2H, J = 6.8, 2.0 
Hz, Harom), 5.47 (d, 1H, J = 1.6 Hz, H-1), 4.97 (d, 1H, J = 10.8 Hz), 4.67-4.57 (m, 5H), 4.13-
4.09 (m, 1H, H-5), 4.04 (d, 1H, J = 9.2Hz), 3.99 (dd, 1H, J = 3.2, 2.0 Hz, H-2), 3.89 (dd, 1H, 
J = 9.2, 2.8 Hz, H-3), 3.83-3.79 (m, 5H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 159.4, 138.4, 138.2, 134.1, 131.8, 129.8, 129.7, 
129.1, 128.4, 128.1, 127.8, 127.7, 125.6, 113.8, 86.1, 80.0, 75.8, 75.3, 74.7, 73.4, 72.1, 72.0, 
62.0, 55.2 
HRMS (ESI): [M + Na]+ calcd for C34H36NaO6S+ 595.2125, found 595.2083 
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Phenyl 2-O-p-methoxybenzyl-3,4-di-O-benzyl-thio-α-D-mannopyranosiduronic acid (9) 
To a solution of phenyl 2-O-p-methoxybenzyl-3,4-di-O-benzyl-thio-α-D-mannopyranoside 
(8) (0.50 g, 0.87 mmol) in dichloromethane/water (5.8 mL/2.9 mL) were added TEMPO 
(0.03 g, 0.19 mmol) and (diacetoxyiodo)benzene (0.70 g, 2.17 mmol) and stirred at ambient 
temperature. After 45 min, the mixture was diluted with dichloromethane (10 mL) and 
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washed with a 10% Na2S2O3 solution (10 mL) and water (10 mL). The organic layer was 
dried over Na2SO4. The solvent was removed under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel using EtOAc/petroleum ether (1/1 
→ 1/0) as eluent. The product was obtained as a light yellow syrup  (0.39 g, 0.66 mmol, 
76%). 
Rf: 0.11 (EtOAc/petroleum ether: 1/1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.50 (s, 1H, Harom), 7.48 (s, 1H, Harom), 7.35-7.21 (m, 
15 H, Harom), 6.85 (d, 2H, J = 12.0 Hz, Harom), 5.63 (d, 1H, J = 4.8 Hz, H-1), 4.74-4.46 (m, 
7H), 4.22 (t, 1H, J = 7.2 Hz), 3.91 (dd, 1H, J = 4.4, 2.8 Hz, H-2), 3.81 (d, 1H, J = 3.2 Hz), 
3.79 (s, 1H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 174.5, 159.4, 137.8, 137.7, 133.8, 131.4, 129.9, 
129.8, 129.1, 128.5, 128.5, 128,0, 128.0, 127.9, 127.9, 127.4, 113.9, 84.1, 75.7, 74.3, 73.8, 
72.5, 72.4, 72.0, 55.3, 29.8 
HRMS (ESI): [M + Na]+ calcd for C34H34NaO7S+ 609.1917, found 609.1912 
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Methyl (phenyl 2-O-p-methoxylbenzyl-3,4-di-O-benzyl-thio-α-D-mannopyranoside) 
uronate (10) 
To a solution of phenyl 2-O-p-methoxybenzyl-3,4-di-O-benzyl-thio-α-D-
mannopyranosiduronic acid (9) (0.5 g, 0.85 mmol) in anhydrous DMF (4 mL) were added 
K2CO3 (0.12 g, 0.85 mmol) and iodomethane (0.3 g, 2.13 mmol). The reaction mixture was 
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stirred at ambient temperature under argon atmosphere for 6 h. The mixture was diluted with 
EtOAc (10 mL) and washed with water (10 mL). The aqueous portion was separated and 
extracted with EtOAc (2 x 10 mL). The combined organic layer was dried over Na2SO4. The 
solvent was removed under reduced pressure and the crude product was purified by flash 
column chromatography on silica gel using EtOAc/petroleum ether (1/3) as eluent. The 
product was obtained as a light yellow syrup  (0.44 g, 0.74 mmol, 87%). 
Rf: 0.80 (EtOAc/petroleum ether: 1/1) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.54 (d, 2H, J = 6.4 Hz, Harom), 7.34-7.21 (m, 15H, 
Harom), 6.84 (d, 2H, J = 8.4 Hz, Harom), 5.65 (d, 1H, J = 5.2 Hz, H-1), 4.66-4.59 (m, 4H), 4.55 
(s, 2H), 4.48 (d, 1H, J = 11.6 Hz), 4.26 (t, 1H, J = 6.4 Hz, H-3), 3.90 (dd, 1H, J = 5.6, 3.2 Hz, 
H-2), 3.79-3.77 (m, 4H), 3.65 (s, 3H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.7, 159.4, 138.0, 137.9, 134.0, 131.4, 129.8, 
129.8, 129.0, 128.4, 128.4, 127.9, 127.8, 127.8, 127.3, 113.8, 84.1, 76.0, 74.3, 73.7, 73.0, 
72.4, 72.0, 55.5, 55.3, 55.2, 55.0, 52.2 
HRMS (ESI): [M + Na]+ calcd for C35H36NaO7S+ 623.2074, found 623.2069 
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Methyl (2-O-p-methoxylbenzyl-3,4-di-O-benzyl-α-D-mannopyranose) uronate (11) 
To a solution of methyl (phenyl 2-O-p-methoxylbenzyl-3,4-di-O-benzyl-thio-α-D-
mannopyranoside) uronate (10) (0.50 g, 0.83 mmol) in 10% water/acetone (13 mL) were 
added N-bromosuccinimide (1.33 g, 7.47 mmol) and NaHCO3 (1.37 g, 16.3 mmol). The 
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reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was dilute 
with EtOAc (30 mL) and washed with a saturated NaHCO3 solution (30 mL). The organic 
layer was dried over Na2SO4. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography on silica gel using EtOAc/petroleum 
ether (2/3) as eluent. The product was obtained as a light yellow syrup  (0.37 g, 0.72 mmol, 
87%). 
Rf: 0.52 (EtOAc/petroleum ether: 1/1) 
1H NMR (CDCl3, 400MHz): δ 7.25-7.33 (m, 12H, Harom), 6.85 (d, 2H, J = 8.4 Hz, Harom), 
5.39 (s, 1H, H-1), 4.56-4.73 (m, 6H), 4.46 (d, 1H, J = 6.4 Hz, H-5), 4.21 (t, 1H, J = 6.8 Hz, 
H-4), 3.87-3.90 (dd, 1H, J = 6.4, 2.8 Hz, H-3), 3.79 (s, 3H), 3.71-3.73 (dd, 1H, J = 4.0, 3.2 
Hz, H-2), 3.65 (s, 3H), 3.09 (s, 1H).  
13C NMR (CDCl3, 100 MHz): δ 170.3, 159.2, 138.2, 138.1, 130.3, 130.0, 129.6, 128.6, 
128.4, 128.4, 128.0, 127.9, 127.8, 127.7, 127.6, 114.0, 113.8, 92.8 (JC1-H1 = 167.4 Hz, C-1), 
77.8, 75.9, 74.8, 74.0, 72.4, 72.3, 72.1, 55.3, 52.3. 
HRMS (ESI): [M + Na]+ calcd for C29H32NaO8+ 531.1989, found 531.1988 
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Methyl (2-O-p-methoxylbenzyl-3,4-di-O-benzyl-α/β-D-mannopyranose) uronate 
trichloroacetimidate (12) 
To a solution of methyl (2-O-p-methoxylbenzyl-3,4-di-O-benzyl-α-D-mannopyranose) 
uronate (0.50 g, 0.98 mmol) in dichloromethane (35 mL) was added trichloroacetonitrile (11) 
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(0.85 g, 5.88 mmol) at 0 °C under argon atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) (0.03 g, 0.2 mmol) was then added and the reaction mixture was stirred at 0 °C under 
argon atmosphere for 3 h. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography on silica gel using EtOAc/petroleum 
ether/triethylamine (1/1/0.1) as eluent. The product was obtained as a mixture of anomers 
(α/β = 4/1) (0.57 g, 0.87 mmol, 89%).  
Rf: 0.40 (EtOAc/petroleum ether: 1/3) 
1H NMR (CDCl3, 400MHz): δ (ppm) 9.32 (s, 1H, NH), 8.62 (s, 1H, NH), 7.35-7.22 (m, 
12H), 6.87 (d, 2H, J = 2.1 Hz), 6.39 (d, 1H, J = 2.4 Hz, Ha-1), 5.96 (d, 1H, J = 8.0 Hz, Hb-
1), 4.83 (d, 1H, J = 10.8 Hz), 4.75 (d, 1H, J = 12.0 Hz), 4.66 (s, 1H), 4.63-4.48 (m, 6H), 4.39 
(d, 1H, J = 8.4 Hz, Ha-4), 4.29 (t, 1H, J = 8.8, 8.0 Hz, Ha-3), 4.18 (dd, 1H, J = 4.4, 2.0 Hz), 
3.91-3.84 (m, 2H), 3.81 (s, 3H), 3.71 (s, 3H), 3.62 (s, 3H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.4, 169.1, 160.5, 159.5, 159.0, 138.0, 138.0, 
137.4, 137.2, 130.1, 129.9, 129.8, 128.7, 128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 113.9, 
95.8, 95.2, 90.9, 77.8, 75.9, 75.7, 75.5, 75.0, 74.3, 74.1, 73.2, 73.2, 73.1, 72.9, 72.6, 55.4, 
52.7, 52.6 
HRMS (ESI): [M + Na]+ calcd for C31H32Cl3NNaO8+ 674.1086, found 674.1085  
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Table 2. Automated synthetic cycles for production of compound 13 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
 
13 
14 
 
15 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deprotection 
 TLC sample 
Sample loading        
Wash 
Wash 
Transfer 
Evaporation 
Glycosylation 
 
Repeat the same 
procedure as step 
2-15 
Transfer  
3.0 equivalent donor  (150 µmol) in 0.8 mL DCM, 1.0 
equivalent F-tagged acceptor (50 µmol) in 0.8 mL DCM, 0.1 
equivalent TMSOTf, -20 °C 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 oC 
1.0 mL CAN/MeCN/H2O, 25 °C 
20 µL of crude reaction mixture withdrawn 
1.0 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeOH wash (repeated 3 × 2 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
3.0 equivalent donor  (150 µmol) in 0.8 mL DCM, 0.8 mL 
DCM, 0.1 equivalent TMSOTf, 0 °C 
Repeat 1 cycle 
 
 
6.0 mL solution transferred out of the synthesis platform 
30 min 
 
 
 
 
45 min 
1 h 
 
 
45 min 
 
 
45 min 
30 min 
 
4 h 25 min 
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13  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 3,4-di-O-benzyl-4-
O-(methyl 3,4-di-O-benzyl-β-D-mannopyranosyl uronate)-β-D-mannopyranoside 
uronate) (13) 
After the 2nd cycle (17th step) of the automated synthesis, the mixture was transferred out of 
the synthesis platform and purified by flash column chromatography on silica gel using 
diethyl ether/benzene (1/4) as eluent. The product was obtained as a colorless syrup (24.5 
mg, 19 µmol, 38% over 4 steps, 79% per step) 
Rf: 0.19 (diethyl ether/benzene = 1/4 developed for 3 times) 
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1H NMR (CDCl3, 400MHz): δ (ppm) 7.41-7.22 (m, 20H, Harom), 5.77-5.57 (m, 2H, 
HC=CH), 4.95 (s, 1H, CHHPh), 4.92 (s, 1H, H-1), 4.88-4.82 (m, 3H, CHHPh), 4.69-4.66 (m, 
2H, CHHPh), 4.61 (d, 1H, J = 10.8 Hz, CHHPh) 4.48-4.43 (m, 2H, CHHPh, H-2), 4.46 (s, 
1H, H-1), 4.37-4.33 (m, 2H, H-2, O-CHHC=C), 4.30 (t, 1H, J = 9.2 Hz, H-4), 4.21 (dd, 1H, J 
= 12.8, 7.6 Hz, O-C-HHC=C), 4.11 (t, 1H, J = 9.6 Hz, H-4), 4.01 (d, 2H, J = 6.4 Hz, 
C=CCH2-O), 3.87 (d, J = 9.6 Hz, H-5), 3.80 (d, J = 9.6 Hz, H-5), 3.73 (s, 3H, CO2CH3), 3.61 
(s, 3H, CO2CH3), 3.58 (m, 1H, H-3), 3.54 (m, 1H, H-3), 3.49 (m, 2H, OCH2CH2), 2.76 (s, 
1H, OH), 2.25 (m, 2H, CH2CF2), 1.91 (m, 2H, OCH2CH2) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 168.8, 168.7, 138.4, 138.2, 138.0, 130.8, 128.7, 
128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.9, 127.7, 100.0 (JC1-
H1 = 156.3 Hz), 99.8 (JC1-H1 = 166.9 Hz), 80.5, 79.6, 76.9, 75.4, 75.3, 75.1, 75.1, 71.0, 70.8, 
70.8, 69.1, 67.7, 66.6, 64.9, 52.6, 52.4, 28.3 (t, JC-F = 21.8 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C57H57F17NaO14+ 1311.3369, found 1311.3357   
HPLC trace of the automated synthesis of 13 
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Figure 6. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/4, 15 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
 
Table 3. Automated synthetic cycles for production of compound 14 
Step Task Reagent/ Operation Operation 
Time 
18 
 
 
19 
20 
21 
22 
Transfer 7 to 
reactor vial 
Evaporation  
Reduction 
TLC sample 
Quenching 
Transfer  
19 µmol in 3.0 mL EtOAc 
  
40 °C 
1.0 mL THF, 0.3 mL LiTEBH, 0 °C 
20 µL of crude reaction mixture withdrawn 
0.5 mL sat. NH4Cl  
solution transferred out of the synthesis platform 
 
 
45 min 
30 min 
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O
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O O
C8F17
HO
HO
14  
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (3,4-di-O-benzyl-2-O-(3,4-
di-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (14) 
After the 3rd cycle (22nd step) of the automated synthesis, the mixture was transferred out of 
the synthesis platform, diluted with DCM (10 mL) and washed by sat NH4Cl solution (10 
mL). The organic layer was concentrated and the crude mixture was purified by FSPE. The 
product was obtained as a colorless syrup (23.4 mg, 19.0 µmol, quant.)  
Rf: 0.78 (MeOH/DCM = 1/9)  
1H NMR (CDCl3, 400MHz): δ (ppm) 7.41-7.28(m, 20H, Harom), 5.77-5.61 (m, 2H, HC=CH), 
4.92-4.80 (m, 4H, CHHPh), 4.87 (s, 1H, H-1), 4.67-4.59 (m, 4H, CHHPh), 4.47 (s, 1H, H-1), 
4.39 (dd, 1H, J = 12.8, 5.6 Hz, O-CHHC=C), 4.23-4.19 (m, 3H, O-CHHC=C, 2 × H-2), 4.00 
(m, 2H, C=CHCH2O), 3.97 (t, 1H, J = 8.4 Hz, H-4), 3.89 (t, 1H, J = 9.6 Hz, H-4), 3.85 (m, 
2H, 2 × H-6), 3.71 (m, 3H, H-3, 2 × H-6), 3.60 (dd, J = 9.2, 2.8 Hz), 3.50-3.44 (m, 3H, H-5, 
OCH2CH2), 3.31 (m, 1H, H-3), 3.16 (d, 1H, J = 2.4 Hz, OH), 2.52 (s, 1H, OH), 2.23 (m, 1H, 
CH2CF2), 1.99 (s, 1H, OH), 1.89 (m, 2H, OCH2CH2) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 138.4, 138.3, 137.7, 130.4, 128.7, 128.6, 128.5, 
128.5, 128.3, 128.2, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.9, 127.8, 101.2 (JC1-H1 = 
161.7 Hz), 99.5 (JC1-H1 = 157.2 Hz), 80.8, 80.7, 76.1, 76.0, 75.4, 74.9, 74.4, 74.2, 74.1, 71.7, 
71.3, 69.0, 67.9, 66.6, 64.8, 62.3, 62.1, 28.3 (t, JC-F = 22.6 Hz), 20.9 
HRMS (ESI): [M + Na]+ calcd for C55H57F17NaO12+ 1255.3471, found 1255.3471   
HPLC trace of the automated synthesis of 14 
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Figure 7. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/4, 15 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
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3-(perfluorooctyl)propanyloxybutanyl (2-O-(β-D-mannopyranosyl)-β-D-
mannopyranoside) (6) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (3,4,6-tri-O-p-chlorobenzyl-2-
O-(3,4,6-tri-O-p-chlorobenzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (5) (32.5 mg, 
20.0 µmol), was dissolved in MeOH (2.0 mL) and 20% Pd(OH)2/C (11 mg) was added and 
stirred at 20 °C under 500 psi H2 atmosphere. After 3 h, the mixture was filter through a 
small pad of silica gel and elute with MeOH. The collected solution was concentrated under 
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reduced pressure and the product was obtained as a colorless syrup (15.2 mg, 17.4 µmol, 
87%). 
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (3,4-di-O-benzyl-2-O-(3,4-di-
O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (14) (30.0 mg, 24.3 µmol) was  
dissolved in MeOH (2.0 mL) and 10% Pd/C (10 mg) was added and stirred 20 °C under 1000 
psi H2 atmosphere. After 20 h, the mixture was filter through a small pad of silica gel and 
elute with MeOH. The collected solution was concentrated under reduced pressure and the 
product was obtained as a colorless syrup (19.0 mg, 21.7 µmol, 89%) 
Rf: 0.45 (MeOH/DCM = 1/3) 
1H NMR (CD3OD, 400MHz): δ (ppm) 4.79 (s, 1H, H-1), 4.59 (s, 1H, H-1), 4.13 (d, 1H, J = 
3.2 Hz, H-2), 3.99 (d, 1H, J = 3.2 Hz, H-2), 3.97 (m, 1H), 3.90 (dd, 1H, J = 7.6, 2.0 Hz, H-6), 
3.88 (dd, 1H, J = 8.0, 2.4 Hz, H-6), 3.74 (t, 1H, J = 6.0 Hz, H-6), 3.69 (t, 1H, J = 6.4 Hz, H-
6), 3.58-3.46 (m, 8H), 3.41 (dd, 1H, J = 9.2, 3.2 Hz, H-3), 3.23-3.15 (m, 2H, 2 × H-5), 2.33 
(m, 2H, CH2CF2), 1.90 (m, 2H, O-CH2CH2), 1.68 (t, 4H) 
13C NMR (CD3OD, 100 MHz): δ (ppm) 102.3, 102.1, 79.1, 78.7, 78.6, 75.4, 74.6, 72.2, 
71.8, 70.3, 69.1, 68.6, 62.9, 62.8, 29.2 (t, JC-F = 22.4 Hz), 27.7, 27.6, 22.0 
HRMS (ESI): [M + Na]+ calcd for C27H35F17NaO12+ 897.1749, found 897.1756 
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CHAPTER 3 
Automated Solution-Phase Synthesis of β-1,4-Mannuronate and β-1,4-Mannan 
Oligomers 
Shu-Lun Tang and Nicola L. B. Pohl* 
 
Abstract 
The first automated solution-phase synthesis of β-1,4-mannuronate and β-1,4-mannan 
oligomers has been accomplished by using the β-directing C-5 carboxylate strategy. By using 
the fluorous-tag assisting purification after the reaction cycles, the β-1,4-mannuronate was 
synthesized up to hexamer with relatively small amount of glycosyl donor (3.5 equiv.) for 
each glycosylation cycle compared to the automated solid-phase protocol due to the 
homogeneous solution-phase condition. After a global reduction of the esters, the β-1,4-
mannan could be produced from the uronates and revealed a new method for the β-mannan 
synthesis. 
 
Introduction 
The β-mannosidic linkage is considered one of the most challenging glycosidic 
linkages to construct. Both steric hindrance from the 1,2-cis configuration and 
thermodynamic instability from the anomeric effect renders the β-anomer less favorable than 
the α-anomer (El Ashry et al. 2005). However, this linkage is crucial to a variety of natural 
oligosaccharides, including N-linked glycans (Schmaltz et al. 2011), antigenic bacterial 
glycans (Crich et al. 2001; Crich et al. 2004a), immunogenic fungal cell wall glycans (Nitz et 
al. 2000; Nitz and Bundle 2001; Wu and Bundle 2005), and antifreeze xylomannan (Walters 
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et al. 2009; Crich and Rahaman 2011; Ishiwata et al. 2011). In addition, a variety of natural 
polysaccharides, such as alginates, contain the related β-mannuronic acid. Small oligomers of 
β-1,4-mannuronic acid have been found recently to have immunostimulatory properties by 
activation of the Toll-like receptors (TLR) 2 and 4 and induction of cytokine production (Flo 
et al. 2002; Janeway et al. 2002; Iwamoto et al. 2005). Structurally well-defined synthetic 
alginate fragments can therefore be potential therapeutic agents and useful tools to study the 
mechanism of TLR-mediated cytokine production. Also, β-1,4-mannan in the tagua palm 
seed, which is also called “ivory nut mannan” forms microfibrils similar to cellulose (Robyt 
1998). Herein we report the first strategy for the automated solution-phase synthesis of this 
class of β-linked oligosaccharides and demonstrate the value of mannuronate building blocks 
as precursors for stereodefined β-mannose linkages. 
A well-known strategy for the synthesis of β-mannosidic linkages has been developed 
by Crich and co-workers by using a conformationally-constrained 4,6-O-benzylidene-
protected thiomannoside building block to provide high β-selectivity during the glycosylation 
(Crich 2010; Crich 2011). In fact, this approach was successfully implemented using 
automated solid-phase synthesis to incorporate up to two β-mannosidic linkages (Codee et al. 
2008; Seeberger 2008; Hsu et al. 2011). After formation of the β-mannosidic bond, a series 
of protecting group shuffles, including removal of the 4,6-O-benzylidene acetal under acidic 
conditions and formation of the ester protecting group at C-6, must be carried out to provide 
a free 4-OH as an acceptor for further glycosylation. β-1,4-mannan oligomers up to a 
hexasaccharide were synthesized by this glycosylation-deprotection-esterification sequence 
(Crich et al. 2004a; Kim et al. 2008). However, a strategy that avoids the acidic deprotection 
conditions that can also cleave particularly acid-sensitive glycosidic bonds and avoids the 
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extra protecting step could potentially shorten a synthetic route to β-1,4-mannan, make it 
more general, and render it more amenable to the automated synthesis of structures such as 
the β-mannans and β-1,4-mannuronate oligomers that contain more than two such 
challenging linkages. 
To this end, we were inspired by the elegant recent work by van der Marel and co-
workers in their construction of β-mannosidic linkages with excellent β-selectivity in the 
presence of a C-5 carboxylate. After the thio-mannuronate donor was activated by diphenyl 
sulfoxide and triflic anhydride, the formed anomeric α-triflate, which is stabilized by the C-5 
electron-withdrawing carboxylate gave the β-anomer via an SN2-like mechanism (van den 
Bos et al. 2006; Codee et al. 2009; Dinkelaar et al. 2009; Walvoort et al. 2009; Walvoort et 
al. 2011). Also, the group addressed that the relatively stable 3H4 half-chair oxacarbenium 
intermediate in the reaction gave high β-selectivity through an SN1-like manner by the attack 
of the nucleophile from the β-face along a pseudoaxial trajectory. The stability of the 3H4 
half-chair oxacarbenium intermediate comes from the through-space stabilization of the 
cation from the pseudoaxial C-5 carboxylate and the most favorable position of other ring 
substituents (Walvoort et al. 2009; Walvoort et al. 2011). By using this strategy, β-1,4-
mannuronate oligomers up to a pentasaccharide were successfully synthesized (Codee et al. 
2009). We reasoned that, if conditions could be found for the global reduction of the 
uronates, the use of mannuronate building blocks would be a unique retrosynthetic strategy to 
β-mannosidic linkages and one also amenable for automation. 
Demonstration of a protocol under automated conditions is of particular importance if this 
difficult linkage is to be readily incorporated in the design of carbohydrate libraries. 
Previously, in order to adapt to an automated solid-phase synthesis approach, 4,6-O-
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benzylidene-carboxybenzylmannosyl donors were used for the “non-pre-activation” protocol 
under relatively higher temperature (-30 °C) compared to the -78 °C to -60 °C needed for 
good selectivities with mannosyl sulfoxide donors. A less bulky but more expensive 
(triisopropylsiloxy)methyl (Tom) protecting group was employed at the 3-OH position in 
order to provide higher β-selectivity compared to the bulkier tert-butyldimethylsilyl (TBS) 
group. In addition, a large excess of donors (9 to 10 equivalents per coupling cycle) had to be 
used (Codee et al. 2008). Even for the recently reported automated solid-phase synthesis of 
the β-mannuronic acid alginates, up to 9 equivalents of donor was charged into the 
synthesizer. Although 20% of unreacted donor was claimed to be recovered after 
glycosylation, unfortunately, only 11 % of precious donor could be converted to the desired 
glycoside, and 71% (6.4 equiv.) of donor was wasted (Walvoort et al. 2012). In contrast, our 
automated solution-phase synthesis platform for oligosaccharide provides a more efficient 
way to synthesize oligosaccharides in which bench-top protocols can be readily adapted to 
automation. We discovered that attachment of C8F17 fluorous-tag (F-tag) to an initial sugar 
building block provided a strong enough noncovalent interaction for the reliable and 
standardized automated purification by fluorous solid phase extraction (FSPE) of a variety of 
growing sugar chains (Mamidyala, et al. 2006). All reactions with the fluorous-modified 
sugars are homogeneous in solution and can be easily monitored off-line by thin layer 
chromatography (TLC) of automatically sampled reaction aliquots. Because of the 
homogeneous reaction environment, significantly lower amounts (1.5 to 3.5 equiv.) of 
precious glycosyl donors are needed for the glycosylation compared to a heterogeneous 
solid-phase resin approach.  
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Results and discussion  
To implement an approach to β-mannosidic linkages via mannuronates, a suitably 
protected building block had to be designed. Of particular importance is the choice of 
masking group for the 4-OH as it has to be reliably removed for chain extension. The TBS 
group was chosen as the temporary protecting group on 4-OH for the automated synthesis 
due to its electron-donating nature, which provides better reactivity to the glycosylation 
compared to the electron-withdrawing Levulinate group (Zeng et al. 2008). Also, the using of 
a fluoride reagent to deprotect the TBS group does not affect the C-5 methyl ester compared 
to Zemplén deacetylation condition that could erode the yield by partial hydrolysis of the 
methyl ester. The synthesis of the desired mannuronate building block 6 started from the 
known allyl mannoside 1 (Srivastav et al. 2000) (Figure 1), which was oxidized to the 
mannuronic acid 2 by the 2,2,6,6-tetramethyl-1-piperidinyloxy free radical 
(TEMPO)/(diacetoxyiodo)benzene (BAIB) condition then followed by an esterification with 
methyl iodide/K2CO3 to give the methyl mannuronate 3 (van den Bos et al. 2006). The 
silylation of 3 with the tert-butyldimethyl silyl chloride (TBSCl)/imidazole/4-
dimethylaminopyridine (DMAP) gave the fully protected mannuronate 4. The subsequent 
combination of (1,5-cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) 
hexafluorophosphate/hydrogen and the following HgCl2/HgO condition completed the 
deallylation to afford 5 with a free anomeric OH group. The formation of the 
trichloroacetimidate on the anomeric position furnished the desired building block 6 for trials 
of the automated solution phase synthesis of both β-1,4-mannuronate and β-1,4-mannan 
oligomers (Figure 1). 
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Figure 1. Synthesis of the building block 6 and the automated solution-phase synthesis of β-
1,4-mannuronate and β-1,4-mannan hexamers 
Reagents and conditions: (a) TEMPO, BAIB, DCM/H2O, rt, 45 min, 75%; (b) MeI, K2CO3, 
DMF, rt, 6 h; (c) TBSCl, imidazole, DMAP, DMF, 50 °C, 20 h, 69% over 2 steps; (d) H2, 
{Ir(COD)[PCH3(C6H5)2]2}PF6, THF, rt, 20 h, then HgCl2, HgO, acetone/H2O, rt, 20 h, 93% 
over 2 steps; (e) Cl3CCN, DBU, DCM, 0 °C, 40 min, 97%; (f) TMSOTf, DCM, -20 °C, 30 
min; (g) TBAF/TEA·3HF (4/1), DMSO/THF, 45 °C, 12 h; (h) DIBAL-H/toluene, DCM, 0 
°C, 1 h, 82% over 2 steps. (a: purified on bench-top then reinjected to the synthesis platform; 
b: “F” cartridge: FSPE, “S” cartridge: SPE with silica gel; c: half of the material was 
remained to produce 10) 
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The synthesis of the β-1,4-mannuronate hexamer 9 and the β-1,4-mannan hexamer 10 
in the automated solution-phase synthesis platform (Figure 1) began with the attachment of 
the allyl F-tag to building block 6. After the transfer of the solution of the tag and 6 (3.5 
equiv.) from the stock solution station, the temperature control unit lowered the temperature 
to –20 °C prior to addition of the trimethylsilyl trifluoromethanesulfonate (TMSOTf) stock 
solution (0.1 equiv.). After 30 min, a small aliquot was automatically removed for TLC 
monitoring. Next, triethylamine (TEA) was added to quench the reaction and the solvent was 
removed under reduced pressure generated by the vacuum pump unit under elevated 
temperature. The desilylation was carried on without further purification. Various conditions 
were tested to cleave the TBS group without degrading the esters and the glycosidic linkage. 
Also, the reagents should not etch the precision glass reactors. Tetrabutylammonium fluoride 
(TBAF)/tetrahydrofuran (THF) was found to be too basic for the methyl ester; however, the 
buffered conditions (TBAF/AcOH) turned out to lack reactivity (Walvoort et al. 2011). The 
milder HF-pyridine/pyridine condition was eliminated because of the ability of etching 
glassware. Triethylamine trihydrofluoride (TEA·3HF) did not hurt the glassware but was 
found too acidic for the glycosidic linkages. Finally, a mixture of TBAF and TEA·3HF (mole 
ratio = 4/1) provided a mild condition with enough strength for desilylation while also being 
safe for the glass reactor. After another TLC monitoring showed the completion of the 
desilylation, the solvent was removed under reduced pressure and the mixture was loaded 
onto the FSPE cartridge. The automated synthesis platform finished the elution, collected the 
product fractions, evaporated the solvent, and let the re-dissolved product pass through 
another silica gel SPE to remove the impurities. The crude product was transferred out of the 
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synthesis platform and purified to get the monosaccharide 7 (74% over 2 steps).  After 7 (50 
µmol) was reinjected into the ASW and followed by 4 repeating glycosylaiton-desilylation 
cycles and one more glycosylation, the mixture was transferred to the bench top and purified 
to afford the fully-protected hexamannuronate 8 in 7% yield over 9 steps (75% per step). The 
hexasaccharide 8 was reinjected into the synthesis platform followed by a desilylation cycle 
to afford 9 with quantitative yield. Half portion of 9 was remained in the platform and added 
with diisobutylaluminum hydride (DIBAL-H) and stirred for 1 h at 0 °C for the global 
reduction of the esters into alcohols to afford the β-1,4-mannan hexamer 10 in 82% yield 
over 2 steps (Figure 1) 
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Figure 2. Deprotection of β-1,4-mannuronate hexamer 9 and β-1,4-mannan hexamer 10 
Reagents and conditions: (a) (1) Grubbs catalyst 2nd generation, ethylene, DCM, 20 °C, 24 h; 
(2) KOH, THF/H2O, 20 °C, 1 h; (3) H2, Pd/C, Pd black, MeOH/AcOH, 20 °C, 48 h, 61% 
over 3 steps; (b) (1) Grubbs catalyst 2nd generation, ethylene, DCM, 20 °C, 24 h; (2) H2, 
Pd/C, Pd black, MeOH, 20 °C, 48 h, 73% over 2 steps. 
 
The deprotection of the β-mannuronate hexamer 9 started from the cleavage to the F-
tag by olefin cross-metathesis, followed by hydrolysis of the esters and hydrogenolysis of the 
benzyl ethers to afford the fully-depretected β-1,4-mannuronic acid hexamer 11 in 61% yield 
over 3 steps. Also, the F-tag of 10 was cleaved by olefin cross-metathesis and followed by 
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the removal of the benzyl groups by hydrogenolysis, which provided the fully-deprotected β-
1,4-mannan hexamer 12 in 73% yield over 2 steps (Figure 2). 
 
Conclusion 
In conclusion, we report the strategy for the first automated solution-phase synthesis 
of the β-1,4-mannuronate and β-1,4-mannan oligomers. By using significantly limited 
amount of glycosyl donor per glycosylation cycle, 4-OTBS protecting group with mild 
desilylation condition, F-tag assisted purification, and real-time reaction monitor, the 
synthesis oligosaccharides up to hexamers has been successfully achieved. Also, the global 
reduction of the methyl β-mannuuronates revealed a new method to synthesize the β-
mannans within various natural glycans with critical bioactivities. We are currently exploring 
the scope of this strategy to apply to the synthesis of other β-mannan-containing natural 
products.    
 
Experimental section 
 
General materials and methods 
Dichloromethane (DCM) for glycosylation was distilled from calcium hydride and 
tetrahydrofuran (THF) was distilled to remove BHT and peroxides right before reactions. All 
other commercial solvents and reagents were reagent grade and used as received without 
further purification. The reactions were monitored by thin layer chromatography (TLC) with 
250 µm Sorbent Technologies silica gel HL TLC plates. The developed TLC plates were 
visualized by stain with p-anisaldehyde solution followed by heating on a hot plate. Flash 
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column chromatography was performed with Zeochem ZEOprep 60 silica gel, 40-63 µm 
particle size. Preparative TLC was performed with Dynamic Adsorbents Prep TLC, Silica 
Gel, HLO, 20 cm × 20 cm F-254, 1000 micron layer. Fluorous solid-phase extraction was 
performed with SPE cartridges containing 2.0 g of silica gel bounded with 
perfluorooctylethylsilyl chains (Fluorous Technologies, Inc., Pittsburgh, PA). The automated 
solution phase synthesis was performed in the Chemspeed ASW1000  (Chemspeed, Augst, 
Switzerland) synthesis platform with hood, 16 reactor vials (13-mL capacity each) and 
heating/cooling unit (200 °C to -20 °C) machined to hold the SPE cartridges at the Iowa State 
University Machine Shop. The hydrogenolysis reaction under 1000 psi hydrogen was 
operated in the Parr model 4766 general purpose vessel high pressure reactor (Parr 
Instrument Company, Moline, IL). 1H and 13C NMR spectra were obtained at 400 MHz and 
100 MHz on a Bruker DRX-400 spectrometer; 700 MHz and 175 MHz on a Bruker Avance 
II 700 spectrometer. The C-H coupling constants were measured by the coupled 13C NMR 
spectra. Chemical shifts (δ) were reported in parts per million (ppm) relative to CDCl3 and 
D2O as internal references. Mass spectra were obtained on a Finnigan TSQ700 triple 
quadrupole mass spectrometer (Finnigan MAT, San Jose, CA) fitted with a Finnigan ESI 
interface. HPLC traces were obtained from a Varian ProStar HPLC system using a Waters 
Nova-Pak 4 µm 3.9 × 150 mm silica column. 
 
General procedure for bench-top fluorous solid-phase extraction (FSPE) 
Crude product (less than 300 mg) was dissolved in 1.0 mL dimethyl sulfoxide 
(DMSO) and loaded onto the 80% MeOH preconditioned 2 g FSPE cartridge. The cartridge 
was washed with 80% MeOH (4.0 mL × 3 times). Then the product was washed out with 
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acetone (12 mL). The solvent was removed under reduce pressure to obtain the desired 
product.  
 
General procedure for automated synthetic cycles to produce β-1,4-mannuronate and 
β-1,4-mannan oligomers 
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Figure 3. Basic layout of automated solution-phase oligosaccharide synthesis platform 
1: F-tagged acceptor, 2: TEA, 3: DMSO, 4: TBAF/TEA·3HF/THF, 5: DIBAL-H (1.0 M in 
toluene), 6: water, 7-8: MeOH, 9: MeCN, 10: reservoir (toluene), 11: TMSOTf (0.55 M in 
DCM), 12: donor, 13: DCM, 14: EtOAc/petroleum ether = 2/1, 15: 80 % MeOH, 16: FSPE 
cartridge, 17: silica gel cartridge. 
 
1. Sample Preparation 
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Donor molecule (679 mg, 1.05 mmol) was dissolved in anhydrous DCM (5.6 mL) in 
the 13 mL-vial and placed at the inert reagent rack (Donor) under argon atmosphere. A 0.055 
M trimethylsilyltrifluoromethanesulfonate (TMSOTf) solution (5.0 mL) in anhydrous DCM 
was prepared in an 8 mL-vial and placed as indicated on the inert reagent rack under argon. 
Acetonitrile (MeCN,100 mL) was placed in the stock solution bottle at the stock solution 
station as indicated. Toluene (1.0 L) was placed in the stock solution bottle and placed at the 
reservoir bottle rack with tubing as reservoir solution for rinsing. Anhydrous DCM (20 mL) 
was transferred to the 50 mL-vial and placed as indicated on the inert reagent rack under 
argon. 80% methanol/water (100 mL) stock was prepared in the 100 mL-vial and placed as 
indicated on the inert reagent rack. Ethyl acetate (EtOAc)/petroleum ether (2/1, 100 mL) 
stock was prepared in the 100 mL-vial and placed as indicated on the inert reagent rack. F-
tagged acceptor molecule (50 µmol) was dissolved with anhydrous DCM (0.80 mL) in a 
Wheaton 8 mL-E-Z extraction vial (conically-bottomed) flushed with argon, capped with 
septa and placed at the reagent rack as indicated. Triethylamine (TEA, 5.0 mL) was 
transferred to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. 
Anhydrous dimethyl sulfoxide (8.0 mL) was transferred to an 8 mL-vial capped with septa 
and placed at the reagent rack as indicated. Tetrabutylammonium fluoride 
(TBAF)/triethylamine trihydrofluoride (TEA·3HF)/THF (mole/mole = 4/1) (8.0 mL) was 
prepared in an 8 mL-vial capped with septa and placed at the reagent rack as indicated. 
Diisobutylaluminum hydride (DIBAL-H) solution in toluene (1.0 M, 1.0 mL) was transferred 
to an 8 mL-vial flushed with argon, capped with septa and placed at the reagent rack as 
indicated.  Water (8.0 mL) was transferred to an 8 mL-vial capped with septa and placed at 
the reagent rack as indicated. A fluorous solid phase extraction (FSPE) cartridge (2.0 g, 10 
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cc) was preconditioned with 80% methanol/water and placed on the machined FSPE block as 
indicated. An empty Wheaton 8 mL-E-Z extraction vial was placed under the FSPE 
cartridge. A silica gel cartridge (2.0 g,) was preconditioned with EtOAc/petroleum ether (2/1) 
and placed on the machined FSPE block as indicated. An empty Wheaton 8 mL-E-Z 
extraction vial was placed under the silica gel cartridge. 
 
2. Cleaning Cycle 
Prior to introduction of reagents, the reactor vials were cleaned, dried and purged 
with argon by running the cleaning cycle. During the cleaning cycle, each of the 16 reactor 
vials (13 mL capacity each) was rinsed with toluene (8.0 mL) and methanol (8.0 mL) 3 times 
each. After the solvents were completely removed, the reactor vials were dried under vacuum 
and purged with argon for 45 minutes. Donor solution was prepared by azeotropic removal of 
water from the glycosyl donor with toluene; the resulting glycosyl donor was then dried 
under high vacuum. After the cleaning cycles were done, the reagents were transferred into 
the reagent vials respectively, which were then placed on the inert condition reagent rack and 
general atmosphere reagent rack. 
 
3. Glycosylation 
The needle transferred the acceptor molecule (F-tag) solution (50 µmol, 0.8 mL) to 
the reaction vial 1, followed by the transfer of the donor molecule solution (0.8 mL). The 
mixture was vortexed under ambient temperature at 800 rpm for 20 min. Then the reactor 
vials were cooled to -20 °C during the 60 minutes wait time by the heat transfer oil with 800 
rpm vortex rate. The TMSOTf solution (5.0 µmol, 0.1 mL) was transferred into the reactor 
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vial 1 under 200 rpm vortex rate. After each individual transfer, the needle (inside and 
outside) was rinsed by toluene (2.0 ml) before operating the next task. The reaction mixture 
was vortexed at 800 rpm for 30 minutes at -20 °C under argon atmosphere. After the reaction 
time the needle withdrew 20 µL of the solution from the reaction mixture and placed it into 
the first well of the microtiterplate for thin layer chromatography monitoring. TEA (0.05 mL) 
was added to the solution for quenching and the solvent was evaporated under reduced 
pressure.   
 
4. Desilylation 
To the residue after the glycosylation (after evaporating solvent), DMSO (0.5 mL) 
was added to the reactor vial followed by TBAF/TEA·3HF/THF (1.0 mL). The reaction 
mixture was vortexed at 800 rpm for 12 hours at 45 °C. After the specified reaction time, the 
needle withdrew 20 µL from the reaction mixture and placed it into the second well of the 
microtiterplate for thin layer chromatography monitoring. The solvent was evaporated under 
reduced pressure.   
 
5. Fluorous solid-phase extraction (FSPE) 
DMSO (0.5 mL) was added to the reactor vials to dissolve the crude mixture and the 
vials were vortexed at 800 rpm for 3 minutes. The reaction mixture (1.2 mL) was carried to 
the FSPE cartridge at the FSPE block and dispensed at a speed of 1.0 mL/s via the 10 mL 
syringe. Then 80% methanol (2.0 mL) was used to rinse the empty reactor vial. The 80% 
methanol solution was removed from the reactor vial and delivered to the FSPE cartridge. 
The 80% methanol rinsing and transferring was repeated one more time. Additional 80% 
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methanol solution (4.0 mL, repeated 2 times) was used to rinse the FSPE cartridge. During 
the 80% methanol rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to 
be disposed. MeCN (2.0 mL, repeated 3 times) was used to wash the FSPE cartridge for 
eluting the desired compound. During the task, the FSPE cartridge was positioned as ‘SPE 
collect’ to be placed right above the 8 mL vial for collection of the sample. After the task, the 
position of the SPE rack was changed into ‘SPE direct’ for the needle to withdraw the 
collected sample from the conically-bottomed vial and deliver it to the clean reactor vial for 
the next reaction. Toluene (1.0 mL) was added to the solution and solvent was evaporated 
under reduced pressure. After the evaporation cycle, The MeCN wash step and the 
evaporation were repeated one more time. Once again toluene (1.0 mL) was added and 
removed under reduced pressure to remove residual water. 
 
6. SPE with silica gel cartridge 
EtOAc/petroleum ether (2/1, 1.5 mL) was added to the dry residue from the FSPE 
step and vortexed at 800 rpm for 10 min. The solution (1.7 mL) was carried to the silica gel 
cartridge at the SPE block and dispensed at a speed of 1.0 mL/s via the 10 mL syringe. 
During the task, the silica gel cartridge cartridge was positioned as ‘SPE collect’ to be placed 
right above the 8 mL vial for collection of the sample. The dissolving with EtOAc/petroleum 
ether (2/1, 1.5 mL) and transferring to the silica gel cartridge were repeated for 3 times 
followed by another EtOAc/petroleum ether (2/1, 1.5 mL) transferred to the silica gel SPE 
cartridge. After the task, the position of the SPE rack was changed into ‘SPE direct’ for the 
needle to withdraw the collected sample from the conically-bottomed vial and deliver it to 
the same reactor vial just rinsed by EtOAc/petroleum ether (2/1). The solvent was removed 
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under reduced pressure. Another EtOAc/petroleum ether (2/1) wash (2.5 mL, repeated 2 
times) was performed and the collected sample was transferred from the conically-bottomed 
vial and deliver it to the same reactor vial followed by the addition of 1.0 mL toluene. The 
solvent was removed under reduced pressure. 
 
7. Reduction 
DCM (1.0 mL) was added to the sample and vortexed at 800 rpm, 0 °C under argon 
atmosphere for 10 min. The DIBAL-H (37 µL, 1.0 M in toluene) was added to the reaction 
solution and the mixture was vortexed for 1 h at 800 rpm, 0 °C under argon atmosphere. 
After the reaction time the needle withdrew 20 µL of the solution from the reaction mixture 
and placed it into the seventh well of the microtiterplate for thin layer chromatography 
monitoring. MeOH (0.1 mL) was added to quench the reaction followed by the addition of 
2.0 mL saturated Rochelle salt solution and vortexed for 2 h at 800 rpm. The mixture was 
transferred out of the synthesis platform. 
 
Synthetic procedures 
OHO
BnO
OBn
O
HO
O
HO2C
HO
BnO
OBn
O
1 2  
Allyl-2,3-di-O-benzyl-a-D-mannopyranosiduronic acid (2) 
To a solution of allyl-2,3-di-O-benzyl-a-D-mannopyranoside 1 (0.500 g, 1.25 mmol) in 
DCM/water (4.0 mL/2.0 mL) were added 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical 
(TEMPO) (0.04 g, 0.26 mmol) and (diacetoxyiodo)benzene (BAIB) (1.0 g, 3.1 mmol) and 
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stirred at ambient temperature. After 45 min, the mixture was diluted with dichloromethane 
(10 mL) and washed with 10% Na2S2O3 solution (10 mL) and water (10 mL). The organic 
layer was dried over Na2SO4. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography on silica gel using EtOAc/petroleum 
ether/AcOH (1/1/0.02 → 1/0/0.02) as eluent. The product was obtained as a light yellow 
syrup  (0.39 g, 0.94 mmol, 75%) (van den Bos et al. 2006). 
Rf: 0.35 (MeOH/dichloromethane: 1/9) 
1H NMR (CDCl3, 400MHz): δ (ppm) 7.36-7.30 (m, 10H, Harom), 5.87-5.79 (m, 1H, HC=C), 
5.26-5.19 (m, 2H, C=CH2), 4.98 (d, 1H, J = 1.6 Hz, H-1), 4.72-4.62 (m, 4H, 4 × CHHPh), 
4.29 (t, 1H, J = 9.6 Hz, H-4), 4.21 (dd, 1H, J = 13.2, 5.2 Hz, OHHCHC=C), 4.16 (d, 1H, J = 
10.0 Hz, H-5), 4.02 (dd, 1H, J = 13.2, 6.4 Hz, OHHCHC=C), 3.83 (dd, 1H, J = 9.2, 3.2 Hz, 
H-3), 3.78 (d, 1H, J = 2.0 Hz, H-2) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 172.8, 138.1, 137.9, 133.3, 128.6, 128.6, 128.4, 
128.2, 128.0, 118.0, 97.8 (JC1-H1 = 170.1 Hz, C-1), 78.6, 74.4, 73.2, 72.8, 71.2, 68.8, 68.4 
HRMS (ESI): [M + K]+ calcd for C23H26KO7+ 453.1310, found 453.1318  
 
O
HO2C
HO
BnO
OBn
O
O
MeO2C
HO
BnO
OBn
O
2 3  
Methyl (allyl-2,3-di-O-benzyl-a-D-mannopyranoside) uronate (3) 
To a solution of allyl-2,3-di-O-benzyl-a-D-mannopyranosiduronic acid 2 (0.500 g, 1.21 
mmol) in anhydrous DMF (6.0 mL) were added K2CO3 (0.12 g, 0.87 mmol) and iodomethane 
(0.64 g, 4.51 mmol). The reaction mixture was stirred at ambient temperature under argon 
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atmosphere for 6 h. The mixture was diluted with EtOAc (10 mL) and washed with water (10 
mL). The aqueous portion was separated and extracted with EtOAc (2 x 10 mL). The 
combined organic layer was dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude product was obtained as a yellow syrup and ready for the next step 
without further purification (van den Bos et al. 2006). 
Rf: 0.38 (EtOAc/petroleum ether: 1/2) 
 
O
MeO2C
HO
BnO
OBn
O
O
MeO2C
TBSO
BnO
OBn
O3 4  
Methyl (allyl-2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-a-D-mannopyranoside) 
uronate (4) 
To a solution of the crude mixture of methyl (allyl-2,3-di-O-benzyl-a-D-mannopyranoside) 
uronate 3 (1.21 mmol) in anhydrous DMF (7.0 mL) was added imidazole (0.330 g, 4.85 
mmol), tert-butyldimethylsilyl chloride (0.73 g, 4.84 mmol), and 4-(dimethylamino)pyridine 
(0.03 g, 0.25 mmol). The reaction mixture was stirred at 50 oC under argon atmosphere for 
20 h. The mixture was diluted with EtOAc (10 mL) and washed with sat. NaHCO3 solution 
(10 mL). The organic layer was dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography on silica gel 
using EtOAc/petroleum ether (1/6) as eluent. The product was obtained as a light yellow 
syrup (0.45 g, 0.83 mmol, 69% over 2 steps). 
Rf: 0.49 (EtOAc/petroleum ether: 1/6) 
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1H NMR (CDCl3, 400MHz): δ (ppm) 7.33-7.24 (m, 10H, 10 × Harom), 5.96 (m, 1H, HC=C), 
5.30 (d, 1H, J = 17.2 Hz, C=CHH), 5.21 (d, 1H, J = 10.4 Hz, C=CHH), 5.08 (d, 1H, J = 4.0 
Hz, H-1), 4.74 (d, 1H, J = 12.4 Hz, CHHPh), 4.66 (d, 1H, J = 12.0 Hz, CHHPh), 4.61 (d, 1H, 
J = 12.0 Hz, CHHPh), 4.55 (d, 1H, J = 12.0 Hz, CHHPh), 4.36 (t, 1H, J = 7.2 Hz, H-4), 4.29 
(dd, 1H, J = 13.2, 5.2 Hz, OHHCHC=C), 4.18 (d, 1H, J = 6.4 Hz, H-5), 4.08 (dd, 1H, J = 
12.8, 6.0 Hz, OHHCHC=C), 3.73 (t, 1H, J = 3.6 Hz, H-2), 3.69 (s, 3H, CO2CH3), 3.66 (dd, 
1H, J = 7.2, 2.8 Hz, H-3), 0.81 (s, 9H, 9 × Ht-butyl), 0.01 (s, 3H, 3 × Hdimethyl), -0.03 (s, 3H, 3 × 
Hdimethyl) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.7, 138.4, 138.1, 133.8, 128.2, 128.2, 128.0, 
127.7, 127.5, 127.5, 117.3, 97.9, 79.2, 74.8, 74.2, 72.9, 71.9, 69.4, 68.9, 52.0, 25.7, 17.9, -
4.4, -5.3 
HRMS (ESI): [M + Na]+ calcd for C30H42NaO7Si+ 565.2592, found 565.2608 
 
O
MeO2C
TBSO
BnO
OBn
O
O
MeO2C
TBSO
BnO
OBn
OH4 5  
Methyl (2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-α-D-mannopyranose) uronate (5) 
To a solution of methyl (allyl-2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-α-D-
mannopyranoside) uronate 4 (0.580 g, 1.06 mmol) in anhydrous THF (14 mL) was added 
(1,5-cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (9.0 mg, 
10.6 µmol). The solution was stirred at ambient temperature under hydrogen atmosphere 
until the red solution became light yellow. The hydrogen was replaced by argon atmosphere 
and the solution was stirred at ambient temperature for 20 h. The solvent was removed under 
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reduced pressure and the mixture was dissolved in acetone/H2O = 5/1 (13 mL). To the 
solution of the mixture was added mercury(II) chloride (0.13 g, 0.48 mmol) and mercury(II) 
oxide (0.13 g, 0.60 mmol). The reaction mixture was stirred at ambient temperature under 
argon atmosphere for 20 h. The solvent was removed under reduced pressure and the mixture 
was diluted with chloroform (50 mL) and the solid was filtered off through a celite pad. The 
solution was washed with 10% KI solution (30 mL) and the organic layer was dried over 
Na2SO4. The solvent was removed under reduced pressure and the crude product was purified 
by flash column chromatography on silica gel using EtOAc/petroleum ether (1/2) as eluent. 
The product was obtained as a light yellow syrup (0.50 g, 0.99 mmol, 93% over 2 steps). 
Rf: 0.37 (EtOAc/petroleum ether: 3/7) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.35-7.25 (m, 10H, 10 × Harom), 5.51 (s, 1H, H-1), 
4.77 (d, 1H, J = 12.0 Hz, CHHPh), 4.68-4.53 (m, 3H, 3 × CHHPh), 4.41 (t, 1H, J = 5.2, 4.4 
Hz, H-3), 4,32 (d, 1H, J = 4.0 Hz, H-4), 3.69 (t, 2H, J = 5.6, 4.8 Hz, H-2, H-5), 3.62 (s, 3H, 
CO2CH3), 0.82 (s, 9H, 9 × Ht-butyl), 0.03 (s, 3H, 3 × Hdimethyl), -0.02 (s, 3H, 3 × Hdimethyl) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 138.6, 138.2, 128.4, 128.4, 127.9, 127.8, 
127.7, 92.9 (JC1-H1 = 168.8 Hz, C-1), 78.4, 75.8, 75.4, 73.0, 72.4, 69.6, 52.2, 25.8, 18.1, -4.6, -
5.0 
HRMS (ESI): [M + K]+ calcd for C27H38KO7Si+ 541.2018, found 541.2039 
 
O
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Methyl (2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-α/β-D-mannopyranose) uronate 
trichloroacetimidate (6)       
To a solution of methyl (2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-α-D-mannopyranose) 
uronate 5 (0.49 g, 0.98 mmol) in dichloromethane (26 mL) was added trichloroacetonitrile 
(0.85 g, 5.88 mmol) at 0 oC under argon atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) (0.03 g, 0.2 mmol) was then added and the reaction mixture was stirred at 0 °C under 
argon atmosphere for 40 min. The solvent was removed under reduced pressure and the 
crude product was purified by flash column chromatography on silica gel using 
EtOAc/petroleum ether/triethylamine (1/3/0.04) as eluent. The product was obtained as a 
mixture of anomers (α/β = 1.8/1) (0.61 g, 0.95 mmol, 97%).  
Rf: 0.69 (EtOAc/petroleum ether: 1/3) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 9.47 (s, 1H, NH), 8.66 (s, 1H, NH), 7.38-7.26 (m, 
10H, 10 × Harom), 6.45 (d, 1H, J = 3.6 Hz, Hα-1), 6.03 (d, 1H, J = 8.0 Hz, Hβ-1), 4.91 (d, 1H, J 
= 12.0 Hz, CHHPh), 4.78-4.58 (m, 4H, 4 × CHHPh), 4.45 (t, 1H, J = 7.2 Hz, Hα-4), 4.40 (dd, 
1H, J = 4.0, 1.6 Hz, Hβ-4), 4.36 (s, 1H, Hβ-5), 4.31 (d, 1H, J = 7.2 Hz, Hα-5), 3.92 (dd, 1H, J 
= 8.0, 2.4 Hz, Hβ-2), 3.90 (t, 1H, J = 3.2 Hz, Hα-2), 3.72 (m, 12H, 2 × H3, 2 × CO2CH3), 0.87 
(s, 9H, 9 × Ht-butyl), 0.82 (s, 9H, 9 × Ht-butyl), 0.06 (s, 3H, 3 × Hdimethyl), 0.06 (s, 3H, 3 × Hdimethyl), 
0.03 (s, 3H, 3 × Hdimethyl), -0.05 (s, 3H, 3 × Hdimethyl) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.4, 169.1, 160.6, 159.1, 138.1, 138.0, 137.8, 
137.5, 128.5, 128.5, 128.1, 128.0, 128.0, 128.0, 127.9, 95.9, 95.4, 92.4, 91.1, 78.5, 77.9, 76.6, 
73.6, 73.5, 73.4, 73.1, 72.9, 72.6, 69.7, 69.1, 52.6, 52.4, 25.9, 25.8, 18.1, 18.0, -4.1, -5.0, -
5.0, -5.1 
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HRMS (ESI): [M + Na]+ calcd for C29H38Cl3NNaO7Si+ 668.1375, found 668.1381 
 
Table 1. Automated synthetic cycles for production of compound 7 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
 
3 
4 
5 
 
 
6 
7 
8 
 
9 
10 
11 
12 
Glycosylation (2 
parallel 
reactions) 
TLC sample 
 
Quenching 
Evaporation 
Desilylation ((2 
parallel 
reactions) 
TLC sample 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
 Transfer 
3.0 × 2 equivalent donor  (150 × 2 µmol) in 0.8 × 2 mL DCM, 
1.0 × 2 equivalent F-tagged acceptor (50 × 2 µmol) in 1 mL 
DCM; 0.11 equivalent TMSOTf, -20 °C 
20 µL of crude reaction mixture withdrawn 
0.05 × 2 mL TEA 
40 °C 
1 × 2 mL TBAF/ TEA·3HF/THF, 0.5 × 2 mL DMSO, 45 °C 
 
 
 
30 × 2 µL of crude reaction mixture withdrawn 
40 °C 
0.5 × 2 mL DMSO 
 
1.2 × 2 mL crude sample transferred to cartridges 
12 × 2 mL 80% methanol wash 
2 mL MeCN wash (repeated 3 × 2 times) 
6 × 2 mL collected sample out of the synthesis platform 
45 min 
 
 
 
 
45 min 
12 h 
 
 
 
 
45 min 
 
 
 
 
 
 
O
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7
O O
C8F17
 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,3-di-O-benzyl-β-
D-mannopyranoside) uronate (7) 
The crude product solution was transferred out of the synthesis platform after the FSPE step 
of the first cycle (12th step of the automated synthesis). The solvent was removed under 
reduced pressure and the product was purified by flash column chromatography on silica gel 
using EtOAc/petroleum ether (3/7) as eluent. The product was obtained as a colorless syrup 
(68 mg, 0.074 mmol, 74% over 2 steps). 
Rf: 0.24 (EtOAc/petroleum ether: 1/2) 
  71 
1H NMR (CDCl3, 400MHz): δ (ppm) 7.44-7.42 (d, 2H, J = 6.8 Hz, 2 × Harom), 7.32-7.26 (m, 
8H, 8 × Harom), 5.77 (m, 2H, HC=CH), 4.98 (d, 1H, J = 12.4, CHHPh), 4.80 (d, 1H, J = 12.4, 
CHHPh), 4.56 (d, 1H, J = 12.0, CHHPh), 4.5 (d, 1H, CHHPh), 4.47 (s, 1H, H-1), 4.45 (d, 
1H, J = 3.2 Hz, OHHCHC=C), 4.34 (t, 1H, J = 9.4 Hz, H-4), 4.25 (dd, 1H, J = 12.9, 5.2 Hz, 
OHHCHC=C), 4.10 (m, 2H, C=CHCH2O), 3.87 (d, 1H, J = 2.2 Hz, H-2), 3.81 (s, 3H, 
CO2CH3), 3.76 (d, 1H, J = 9.6 Hz, H-5), 3.50 (t, 2H, J = 5.9 Hz, OCH2CH2), 3.37 (dd, 1H, J 
= 9.4, 2.6 Hz, H-3), 2.97 (s, 1H, 4-OH), 2.26 (m, 2H, CH2CF2), 1.91 (m, 2H, OCH2CH2)  
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.9, 138.6, 138.1, 130.4, 128.6, 128.5, 128.3, 
128.3, 128.0, 127.8, 127.7, 101.0 (JC1-H1 = 152.3 Hz, C-1), 80.5, 75.4, 74.5, 73.9, 71.9, 69.0, 
68.4, 66.7, 65.0, 52.8, 28.4 (t, JC-F = 21.8 Hz), 21.0 
HRMS (ESI): [M + K]+ calcd for C36H35F17KO8+ 957.1692, found 957.1697 
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Table 2. Automated synthetic cycles for production of compound 8 
Step Task Reagent/ Operation Operation 
Time 
1 
 
2 
3 
 
4 
5 
6 
7 
8 
9 
10 
 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
 
21 
22 
 
23 
24 
25 
26 
 
27 
28 
29 
30 
31 
32 
 
 
33 
Transfer 7 to 
reactor vial 
Evaporation 
Glycosylation  
 
TLC sample 
Quenching 
Evaporation 
Desilylation 
TLC sample 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
 Transfer 
Evaporation 
Wash 
Evaporation 
Transfer EtOAc 
Evaporation 
Silica gel SPE 
Preparation 
Sample loading 
Repeating 20 and 
21 for 3 times  
Transfer 
Evaporation 
Transfer 
Transfer 
 
Evaporation 
Transfer 
Evaporation 
Transfer 
Evaporation 
Repeat the same 
procedure as step 
3-31 
Repeat the same 
procedure as step 
3-6 
50 µmol in 3.0 mL EtOAc 
  
40 °C 
3.5 equivalent donor  (150 × 2 µmol) in 1.6 mL DCM 
0.11 equivalent TMSOTf, -20 °C 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 °C 
1.0 mL TBAF/ TEA·3HF/THF, 0.5 mL DMSO, 45 °C 
20 µL of crude reaction mixture withdrawn 
40 °C 
0.5 mL DMSO 
 
1.2 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeCN wash (repeated 3 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
2.0 mL MeCN wash (repeated 3 times) 
40 °C 
1.0 mL 
40 °C 
1.5 mL EtOAc/petroleum ether (2/1) 
 
1.7 mL sample transfer to the cartridge 
 
 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
2.5 × 2 mL EtOAc/petroleum ether (2/1) to the cartridge  
5.0 mL collected sample and 1.0 mL toluene to the reactor vial 
for next cycle 
40 °C 
1.0 mL toluene 
40 °C 
1.0 mL toluene 
40 °C 
Repeat for 4 cycles 
 
 
Repeat one cycle 
 
 
45 min 
45 min 
 
 
 
45 min 
12 h 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
 
45 min 
 
 
 
 
 
 
45 min 
 
 
 
45 min 
 
45 min 
 
45 min 
81 h 
 
 
90 min 
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,3-di-O-benzyl-4-
O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-
O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-tert-butyldimethylsilyl-β-D-
mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranosyl 
uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-
mannopyranoside uronate) (8) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,3-di-O-benzyl-β-D-
mannopyranoside) uronate 7 (46 mg, 50 µmole) was transferred back to the synthesis 
platform for further synthesis. After the 6th cycle (33rd step of the automated synthesis) was 
finished the mixture was transferred out of the synthesis platform and purified by FSPE as 
described by the general procedure for bench-top FSPE. The crude product from the FSPE 
was purified by preparative TLC using diethyl ether/benzene (1/3). The crude product was 
collected from the preparative TLC plate and purified by another preparative TLC using 
diethyl ether/DCM (1/10). The product was collected as a white solid (9.5 mg, 3.3 μmol, 7% 
over 9 steps, 75 % per step).  
Rf: 0.23 (EtOAc/petroleum ether: 1/2), 0.59 (diethyl ether/DCM: 1/10), 0.38 (diethyl 
ether/benzene: 1/3 developed twice) 
1H NMR (CDCl3, 700 MHz): δ (ppm) 7.36-7.32 (m, 11H, 11 × Harom), 7.28-7.21 (m, 49H, 49 
× Harom) 5.75 (m, 2H, HC=CH), 4.83-4.76 (m, 6H, 6 × CHHPh), 4.74-4.66 (m, 11 H, 1 × H-1, 
10 × CHHPh ), 4.62-4.60 (m, 3 H, 2 × H-1, 1 × CHHPh), 4.58 (s, 1H, H-1), 4.56 (s, 1H, H-
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1), 4.53-4.67 (m, 7H, 1 × H-1, 6 × CHHPh), 4.45-4.41 (m, 3 H, 1 × OHHCHC=C, 1 × H-4, 1 
× CHHPh), 4.33 (m, 5 H, 5 × H-4), 4.20 (dd, 1H, J = 12.6, 6.3 Hz, OHHCHC=C), 4.07 (m, 
2H, C=CHCH2O), 3.84 (d, 1H, J = 8.4 Hz, H-5), 3.80 (d, 1H, J = 2.8 Hz, H-2), 3.79 (d, 1H, J 
= 2.8 Hz, H-2), 3.75 (d, 1H, J = 5.6 Hz, H-2), 3.74-3.67 (m, 7H, 3 × H-2, 4 × H-5), 3.64-3.52 
(m, 8H, 1 × H-3, 1 × H-5, 2 × CO2CH3), 3.49-3.37 (m, 18H, 4 × H-3, OCH2CH2, 4 × 
CO2CH3), 3.23 (dd, 1H, J = 9.8, 2.8 Hz, H-3), 2.20 (m, 2H, CH2CF2), 1.88 (m, 2H, 
OCH2CH2), 0.79 (s, 9H, 9 × Ht-butyl), -0.03 (s × 2, 6H, 6 × Hdimethyl) 
13C NMR (CDCl3, 175 MHz): δ (ppm) 168.8, 168.8, 139.4, 139.1, 139.1, 138.9, 138.6, 
138.1, 130.3, 128.4, 128.3, 128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 127.5, 127.5, 127.5, 
127.4, 127.3, 103.0 (JC1-H1 = 155.1 Hz, C-1), 102.7 (JC1-H1 = 157.7 Hz, 3 × C-1), 102.5 (JC1-H1 
= 155.8 Hz, C-1), 100.6 (JC1-H1 = 157.0 Hz, C-1), 82.0, 79.9, 79.2, 77.6, 76.4, 76.2, 74.7, 74.7, 
74.6, 74.0, 72.8, 72.7, 72.4, 71.4, 69.0, 66.8, 65.1, 52.5, 52.3, 52.3, 52.1, 28.3 (t, JC-F = 22.2 
Hz), 25.9, 21.0, 18.2, -3.8, -5.1 
HRMS (ESI): [M + Na]+ calcd for C147H159F17NaO38Si+ 2905.9899, found 2905.9840 
HPLC trace of the automated synthesis of 8 
  75 
 
Figure 4. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/4, 15 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
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Table 3. Automated synthetic cycles for production of compound 9 and 10 
Step Task Reagent/ Operation Operation 
Time 
34 
 
35 
36 
37 
38 
39 
 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
 
50 
51 
 
52 
53 
54 
55 
 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Transfer 8 to 
reactor vial 
Evaporation 
Desilylation  
TLC sample 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
 Transfer 
Evaporation 
Wash 
Evaporation 
Transfer EtOAc 
Evaporation 
Silica gel SPE 
Preparation 
Sample loading 
Repeating 49 and 
50 for 3 times  
Transfer 
Evaporation 
Transfer 
Transfer 
 
Evaporation 
Transfer 
Transfer 
Evaporation 
Transfer 
Evaporation 
Reduction 
TLC sample 
Quenching 
Transfer 
3.1 µmol in 3.0 mL EtOAc 
  
40 °C 
1.0 mL TBAF/ TEA·3HF/THF, 0.5 mL DMSO, 45 °C 
20 µL of crude reaction mixture withdrawn 
40 °C 
0.5 mL DMSO 
 
1.2 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeCN wash (repeated 3 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
2.0 mL MeCN wash (repeated 3 times) 
40 °C 
2.0 mL 
40 °C 
1.5 mL EtOAc/petroleum ether (2/1) 
 
1.7 mL sample transfer to the cartridge 
 
 
6.0 mL collected sample to the reactor vial for reduction 
40 °C 
2.5 × 2 mL EtOAc/petroleum ether (2/1) to the cartridge  
5.0 mL collected sample and 1.0 mL toluene to the reactor vial 
for next cycle 
40 °C 
2.0 mL toluene 
1.0 mL toluene solution to the reactor vial for Storage of 9 
40 °C 
1.0 mL toluene to reactor vial for reduction 
40 °C 
1.0 mL DCM, 37 µL DIBAL-H (1.0 M in toluene), 0 °C  
20 µL of crude reaction mixture withdrawn 
0.1 mL MeOH, 0 °C 
2.0 mL sat. Rochelle salt solution, vortex at 800 rpm 
 
 
45 min 
12 h 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
 
45 min 
 
 
 
 
 
 
45 min 
 
 
 
45 min 
 
 
45 min 
 
45 min 
4 h 
 
 
2 h 
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,3-di-O-benzyl-4-
O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-
O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-β-D-mannopyranosyl uronate)-
β-D-mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranosyl 
uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranoside uronate) (9) 
After the 8th cycle (the 65th step of the automated synthesis), the product fraction after FSPE 
was taken out and the solvent was removed under reduced pressure to afford the compound 9 
as a white foam (4.3 mg, 1.6 µmol, quant.). 
Rf: 0.38 (EtOAc/petroleum ether: 1/1) 
1H NMR (CDCl3, 700 MHz): δ (ppm) 7.36-7.20 (m, 60H, 60 × Harom), 5.72 (m, 2H, 
HC=CH), 4.83-4.69 (m, 15H, 15 × CHHPh), 4.68 (s, 1H, H-1), 4.63-4.59 (m, 5H, 4 × H-1, 1 
× CHHPh), 4.56-4.49 (m, 8H, 8 × CHHPh), 4.50 (s, 1H, H-1), 4.45 (dd, 1H, J = 12.6, 5.6 Hz, 
OHHCHC=C), 4.34-4.29 (m, 4H, 4 × H-4), 4.19 (dd, 1H, J = 13.3, 7.0 Hz, OHHCHC=C), 
4.17 (t, 1H, J = 7.7 Hz, H-4), 4.04 (m, 2H, C=CHCH2O), 3.83 (d, 1H, J = 8.4 Hz, H-5), 3.76-
3.69 (m, 8H, 4 × H-2, 4 × H-5), 3.58-3.57 (m, 7H, 1 × H-3, 2 × CO2CH3), 3.48-3.42 (m, 12H, 
4 × H-3, OCH2CH2, 2 × CO2CH3), 3.39 (s, 6H, 2 × CO2CH3), 3.28 (dd, 1H, J = 9.1, 2.8 Hz, 
H-3), 2.90 (s, 1H, OH), 2.17 (m, 2H, CH2CF2), 1.86 (m, 2H, OCH2CH2) 
13C NMR (CDCl3, 175 MHz): δ (ppm) 170.2, 168.8, 139.1, 138.9, 138.6, 138.2, 130.3, 
128.6, 128.4, 128.3, 128.3, 128.3, 128.2, 128.0, 128.0, 127.9, 127.9, 127.7, 127.6, 127.5, 
127.4, 127.4, 102.8 (4 × C-1), 102.5 (C-1), 100.6 (C-1), 80.5, 80.0, 80.0, 79.2, 76.3, 76.2, 
75.9, 75.3, 74.9, 74.8, 74.7, 74.6, 74.4, 74.0, 72.8, 72.7, 72.6, 72.4, 72.4, 72.0, 69.0, 68.3, 
66.8, 65.1, 52.5, 52.5, 52.3, 52.3, 28.3 (t, JC-F = 22.2 Hz), 21.0 
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HRMS (ESI): [M + Na]+ calcd for C141H145F17NaO38+ 2791.9035, found 2791.9040 
HPLC trace of the automated synthesis of 9 
 
 
Figure 4. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/1, 10 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column). 
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (2,3-di-O-benzyl-4-O-(2,3-
di-O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-
O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-
mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranoside) (10) 
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After the 8th cycle (the 65th step of the automated synthesis), the reaction mixture was taken 
out and diluted with EtOAc (15 mL), and washed with sat. Rochelle salt solution (20 mL), 
The combined organic layer was dried over Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by preparative TLC using MeOH/DCM 
(1/19). The product was collected as a colorless syrup (3.3 mg, 1.3 µmol, 82% over 2 steps) 
Rf: 0.26 (MeOH/DCM: 1/19) 
1H NMR (CDCl3, 700 MHz): δ (ppm) 7.44-7.14 (m, 60 H, 60 × Harom), 5.75 (m, 2H, 
HC=CH), 4.94-4.89 (m, 3 H, 3 × CHHPh), 4.86-4.72 (m, 15H, 15 × CHHPh), 4.65 (s, 1H, H-
1), 4.58 (d, 1H, J = 11.9 Hz, CHHPh), 4.54-4.48 (m, 10 H, 5 × H-1, 5 × CHHPh), 4.44 (dd, 
1H, J = 11.2, 4.2 Hz), 4.36 (d, 1H, J = 11.9 Hz), 4.22-4.19 (m, 2H), 4.13 (t, 1H, J = 9.1 Hz), 
4.09-4.02 (m, 5H), 3.92 (d, 1H, J = 2.1 Hz), 3.91 (d, 1H, J = 2.8 Hz), 3.89-3.83 (m, 6 H), 
3.73-3.60 (m, 7H), 3.51 (t, 2H, J = 5.6 Hz, OCH2CH2), 3.46-3.42 (m, 7H), 3.41-3.35 (m, 3H), 
3.31 (m, 1H), 3.28 (dd, 1H, J = 9.8, 2.8 Hz), 3.20-3.16 (m, 5H), 2.33-2.26 (m, 3H, 3 × OH), 
2.23 (m, 2H, CH2CF2), 1.90 (m, 2H, OCH2CH2) 
13C NMR (CDCl3, 175 MHz): δ (ppm) 139.0, 138.9, 138.8, 138.8, 138.7, 137.9, 129.9, 
128.8, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.4, 127.2, 
127.0, 101.6 (C-1), 101.4 (C-1), 101.3 (C-1), 101.3 (C-1), 101.1 (C-1), 100.7 (C-1), 82.2, 
80.4, 80.4, 80.2, 76.9, 76.6, 76.0, 75.7, 75.6, 75.4, 75.3, 75.1, 74.9, 74.9, 74.7, 74.5, 74.2, 
72.9, 72.8, 72.7, 72.4, 71.5, 69.1, 67.6, 66.8, 65.2, 63.0, 62.2, 62.1, 62.0, 32.1, 28.3 (t, JC-F = 
21.9 Hz), 22.9, 21.1, 14.3 
HRMS (ESI): [M + H]+ calcd for C135H146F17O32+ 2601.9520, found 2601.9453 
HPLC trace of the automated synthesis of 10 
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Figure 5. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, MeOH/DCM: 2.5/97.5, 10 minutes run, Waters Nova-Pak 
4 µm 3.9 × 150 mm silica column) 
 
O
MeO2C
O
BnO
OBn
H
6
9
O
HO2C
O
HO
OH
H
6
11
O O
C8F17
O
 
n-propyl (4-O-(4-O-(4-O-(4-O-(4-O-(β-D-mannopyranosyl uronate)-β-D-
mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranosyl 
uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranoside) uronic acid (11) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,3-di-O-benzyl-4-O-
(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-
(methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-β-D-mannopyranosyl uronate)-β-D-
mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-mannopyranosyl uronate)-β-D-
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mannopyranosyl uronate)-β-D-mannopyranoside uronate) 9 (18 mg, 6.5 µmol), was dissolved 
in dry DCM (2.0 mL) and Grubbs catalyst 2nd generation (1.3 mg, 1.5 µmol) was added. The 
mixture was stirred and bubbled by ethylene gas for 30 min under 20 °C, then an ethylene 
balloon was attached and the mixture was stirred for 24 h. After the TLC showed the 
completion of the reaction, the mixture was passed through a short silica column (DCM → 
EtOAc/petroleum ether = 1/1 → EtOAc/petroleum ether = 3/2). After the product fraction 
was collected and the solvent was removed under reduced pressure, the crude product was 
dissolved in freshly distilled THF (1.6 mL), and 0.45 M KOH solution (0.35 mL) and water 
(0.5 mL) was added under Ar atmosphere. After the mixture was stirred at 20 °C under Ar 
atmosphere for 1 h, the reaction was neutralized by 0.45 M AcOH in THF (0.4 mL) and 
diluted with EtOAc (5.0 mL) and washed with water. The aqueous layer was extracted with 
EtOAc (5.0 mL × 3 times). The organic layer was collected and the solvent was removed 
under reduce pressure. The crude product was dissolved in MeOH/AcOH (3.0 mL/0.15 mL), 
and 10% Pd/C (11.0 mg) was added. The mixture was stirred at 20 °C under 1000 psi H2 
atmosphere for 24 h. An additional portion of Pd black (10.0 mg) was added and the reaction 
was stirred at 20 °C under 1000 psi H2 atmosphere for another 24 h. The mixture was filtered 
through a small pad of Celite and the Celite pad was washed with MeOH (10 mL), 80% 
MeOH (10 mL), and water (10 mL). The collected filtrate was concentrated under reduced 
pressure and the residue was rinsed with DCM (1.0 mL × 3). The fully-deprotected product 
11 was obtained as a white film (4.4 mg, 3.9 µmol, 61% over 3 steps) (van den Bos et al. 
2006; Codee et al. 2009). 
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1H NMR (D2O, 700 MHz): δ (ppm) 4.79 (s, 2H, 2 × H-1), 4.74 (s, 1H, H-1), 4.71 (s, 2H, 2 × 
H-1), 4.69 (s, 1H, H-1), 4.07 (d, 5H, J = 4.9 Hz), 4.02 (s, 1H), 3.96-3.94 (m, 5H), 3.88-3.77 
(m, 13H), 3.70 (d, 1H, J = 9.1 Hz), 3.64 (dd, 1H, J = 16.8, 7.0 Hz), 1.64 (m, 2H, CH2CH3), 
0.93 (t, 3H, J = 7.7 Hz, CH3) 
13C NMR (D2O, 175 MHz): δ (ppm) 174.7, 100.4, 100.3, 100.1, 78.5, 78.2, 78.1, 75.8, 75.5, 
72.7, 72.1, 71.7, 71.5, 70.5, 70.1, 70.0, 68.4, 22.3, 9.8 
HRMS (ESI): [M + Na]+ calcd for C39H56NaO37+ 1139.2393, found 1139.2374 
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n-propyl (4-O-(4-O-(4-O-(4-O-(4-O-(β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-
mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranoside) 
(12) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (2,3-di-O-benzyl-4-O-(2,3-di-
O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-O-benzyl-4-O-(2,3-di-O-
benzyl-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-
mannopyranosyl)-β-D-mannopyranosyl)-β-D-mannopyranoside) 10 (9.7 mg, 3.7 µmol), was 
dissolved in dry DCM (2.0 mL) and Grubbs catalyst 2nd generation (1.3 mg, 1.5 µmol) was 
added. The mixture was stirred and bubbled by ethylene gas for 30 min under 20 °C, then an 
ethylene balloon was attached and the mixture was stirred for 24 h. After the TLC showed 
the completion of the reaction, the mixture was passed through a short silica column (EtOAc 
→ MeOH/DCM = 0.5/9.5). After the product fraction was collected and the solvent was 
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removed under reduced pressure, the crude product was loaded on a preparative TLC plate 
and developed by MeOH/DCM = 0.5/9.5. The desired product was collected and dissolved in 
MeOH (1.5 mL) and 10 % Pd/C (10 mg) was added. The mixture was stirred under 20 °C, 
1000 psi H2 atmosphere. After 24 h, a portion of Pd black (10 mg) was added and the mixture 
was stirred under 20 °C, 1000 psi H2 atmosphere for additional 24 h. The mixture was 
filtered through a small pad of Celite and the Celite pad was washed with MeOH (10 mL), 
and 80% MeOH (10 mL). The collected filtrate was concentrated under reduced pressure and 
the residue was rinsed with DCM (1.0 mL × 3). The fully-deprotected product 12 was 
obtained as a white film (2.8 mg, 2.7 µmol, 73% over 2 steps) (Crich et al. 2004a). 
1H NMR (D2O, 700 MHz): δ (ppm) 4.79-4.78 (m, 4H, 4 × C-1), 4.76 (s, 1H, C-1), 4.72 (s, 
1H, C-1), 4.15 (s, 3H), 4.09 (d, 2H, J = 9.1 Hz), 3.98-3.92 (m, 8H), 3.86-3.83 (m, 10H), 3.80-
3.74 (m, 8H), 3.69-3.63 (m, 3H), 3.59-3.52 (m, 6H), 3.48 (t, 1H, J = 9.1 Hz), 1.66 (m, 2H, 
CH2CH3), 0.94 (t, 3H, J = 7.0 Hz, CH3)  
13C NMR (D2O, 175 MHz): δ (ppm) 100.4, 100.0, 77.0, 76.8, 76.8, 76.6, 75.2, 75.1, 73.0, 
71.9, 71.6, 70.7, 70.2, 69.9, 68.7, 66.9, 61.2, 60.7, 23.5, 22.3, 20.2, 9.8 
HRMS (ESI): [M + Na]+ calcd for C39H68NaO31+ 1055.3637, found 1055.3620 
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CHAPTER 4 
Automated Solution-Phase Synthesis of Insect Glycans to Probe the Binding Affinity of 
Pea Enation Mosaic Virus  
Shu-Lun Tang and Nicola L. B. Pohl* 
Collaboration with Luke Linz and Bryony Bonning, Department of Entomology, Iowa State 
University  
 
Abstract 
Pea enation mosaic virus (PEMV) is an RNA plant virus that infects pea, sweet pea, 
and related plants. Pea aphids and green pea aphids are the specific vectors for PEMV; 
however, the transmission pathway within the aphids remains unclear. The endocytosis of the 
PEMV into the hemocoel happens in the aphid gut, a process that is probably mediated by 
the heavily glycosylated receptor aminopeptidase N. To investigate the role of the glycans on 
the receptor in the PEMV transmission pathway, the insect N-glycan terminal trimannosides 
have been synthesized by automated solution-phase synthesis. The insect N-glycan terminal 
trimannosides with fluorous tags (F-tags) attached were then used to form a fluorous 
microarray to analyze the binding with fluorescein isothiocyanate labeled PEMV (FITC-
PEMV). No specific binding was detected between the insect glycan and PEMV on the array. 
To confirm these microarray results, the fluorous tag was removed from the insect N-glycan 
terminal trimannosides for isothermal titration calorimetry (ITC) studies with unlabeled 
PEMV. The ITC studies confirmed the microarray results and suggested that this specific 
interaction in the transmission pathway of PEMV does not rely on the glycan-virus 
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interaction. Further investigations of the binding of the receptor protein and PEMV are 
ongoing. 
 
Introduction 
Pea enation mosaic virus (PEMV) is a plant virus that infects pea, sweet pea, and 
other related plants.  PEMV is a RNA virus that belongs to the luteovirus family, and the 
virion is assembled by 180 identical subunit proteins (molecular weight 21.8 KDa for each 
subunit) (Gray and Gildow 2003; Liu et al. 2006). PEMV has very specific transmission 
pathway and is transmitted by aphids, which cause serious agricultural losses across the 
world. However, the transmission pathway of luteovirus within its vectors remains unclear. 
The transmission of luteovirus is highly specific toward the vectors. For PEMV, only pea 
aphids and green pea aphids are responsible for the transmission. Also, PEMV is the only 
luteovirus that can enter the transmission pathway in the pea aphid hemocoel without exiting 
the aphid in the honeydew excrement. Based on earlier studies, the transmission pathway 
starts from the endocytosis of the PEMV at the epithelial tissue in the aphid gut (Gray and 
Gildow 2003; Liu et al. 2006). The most probable receptor protein for triggering the 
endocytosis of the virus is aminopeptidase N, which is the most abundant protein in the aphid 
gut and also heavily glycosylated. In order to investigate the specific interaction between the 
aminopeptidase N and PEMV, studying the binding of the aminopeptidase N glycans and 
PEMV subunit proteins is necessary since each subunit protein could be a potential glycan 
binding protein. N-linked glycans are found on glycoproteins from bacteria to mammals 
(Gamblin et al. 2009; Schmaltz et al. 2011). The most common insect N-glycan structures 
share a common terminal trimannoside structure containing a β-mannoside with two α-
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mannosides attached at the O-3 and O-6 positions. Glycan microarray and isothermal 
titration calorimetry have been used to study mammalian virus-mammalian glycan 
interaction (Neu et al. 2008, Song et al. 2011), however, the plant virus-insect glycan 
interaction has not been studied by neither of the methods. In order to probe this PEMV-
insect glycan binding affinity, the terminal trimannoside was synthesized by automated 
solution-phase synthesis and the binding affinity was tested by fluorous microarray 
(Mamidyala et al. 2006; Jaipuri et al. 2008; Ko et al. 2005) and isothermal titration 
calorimetry (ITC). 
 
Results and discussion 
To construct the insect N-glycan terminal trimannoside by automated solution-phase 
synthesis, we designed the mannuronate building block 6 with the C-5 carboxylate as the β-
directing group, a 3-O-p-methoxybenzyl (PMB) group as the temporary capping group for 
the chain extension at the 3-OH. The methyl ester is acting as a capping protecting group, 
which can be deprotected by a hydride reduction to release a free 6-OH for the further 
attachment of the α-mannoside. The synthesis of the building block started from the known 
4,6-O-benzylidene protected allyl mannoside 1 (Crich et al. 2004b), which could be 
synthesized from D-mannose in 7 steps. After a selective cleavage of the benzylidene by 
borane tetrahydrofurane complex (BH3-THF) and dibutylboron triflate (Bu2BOTf) (Jiang and 
Chan 1998), compound 2 with a free hydroxyl group at the 6-position was formed. The 
combination of 2,2,6,6-tetramethyl-1-piperidinyloxy free radical (TEMPO) and 
(diacetoxyiodo)benzene (BAIB) oxidized the primary alcohol on 2 and gave the mannuronic 
acid 3 (van den Bos et al. 2006). After esterification of the carboxylic acid, the anomeric 
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thiophenyl group of the methyl mannuronate 4 was removed with N-bromosuccinimide 
(NBS) to give 5 with a free anomeric hydroxyl group (Liew and Wei 2002). The subsequent 
formation of the trichloroacetimidate at the anomeric hydroxyl gave the desired 
trichloroacetimidate donor 6 for automated solution-phase synthesis (Figure 1).  
 
 
Figure 1. Synthesis of the trichloroacetimidate donor 6 
 
The automated solution-phase synthesis of the insect glycan started from the 
glycosylation of the allyl C8F17 fluorous tag (F-tag) (Mamidyala et al. 2006) and the donor 6 
(3.0 equiv.) catalyzed by trimethylsilyl trifluoromethanesulfonate (TMSOTf, 0.1 equiv.) at -
20 °C. After 45 min, the reaction was quenched by triethylamine (TEA) and the solvent was 
removed by the evaporation cycle. The PMB group was removed by ceric ammonium nitrate 
(CAN) and the reaction mixture was purified by fluorous solid phase extraction (FSPE); then 
the product was transferred out of the synthesis platform for further purification. The β-
mannuronate monomer 7 was obtained in 78% yield over 2 steps. The monosaccharide 7 was 
reinjected into the synthesis platform, and the methyl ester was reduced by lithium 
triethylborohydride (LiTEBH) at 0 °C. After fluorous solid phase extraction (FSPE), the diol 
was glycosylated with the known 2-O-acetyl-mannosyl-trichloroacetimidate donor 8 (6.0 
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equiv.) (Song et al. 2010) catalyzed by TMSOTf (0.1 equiv.) to provide the two "-
mannosidic linkages via neighboring group participation. The crude trisaccharide 9 was 
transferred out of the synthesis platform; however, the desired trisaccharide could not be 
readily isolated from the mixture at this stage. However, after deacetylation, the trimannoside 
10 could be isolated and obtained in 50% yield over 2 automation steps and one bench-top 
deprotection step (Figure 2).  
 
 
Figure 2. Automated solution-phase synthesis of the insect N-glycan terminal trimannoside 
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The final deprotection of the benzyl groups of 10 was completed by hydrogenolysis 
catalyzed by 10% Pd/C under 1000 psi hydrogen at 20 °C for 48 h and the fully deprotected 
trimannoside 11 with fluorous tail was obtained in 51% yield. With the reducing end fluorous 
tag, the trimannoside 11 was ready for the fluorous microarray experiment with the 
fluorescein isothiocyanate labeled PEMV (FITC-PEMV). The synthesis of the trimannoside 
12 for the ITC experiment started from the cleavage of the F-tag of 10 by olefin cross-
metathesis catalyzed by Grubbs 2nd catalyst generation under ethylene atmosphere to provide 
the allyl trimannoside. The following hydrogenolysis catalyzed by 10% Pd/C, and Pd black 
under 1000 psi hydrogen atmosphere converted the allyl trimannoside into the fully 
deprotected n-propyl trimannoside 12 in 91% over 2 steps and which was ready for the ITC 
experiments with unlabeled PEMV (Figure 3).  
 
 
Figure 3. Deprotection of the insect N-glycan terminal trimannosides 
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With the reducing end F-tag, the insect N-glycan trimannoside 11 could be 
immobilized on a C8F17-coated commercially available glass slide for the proposed 
microarray experiments with the PEMV. The virus used in the experiment was labeled by 
FITC for visualizing the possible binding, and the concentration of PEMV subunit protein is 
used for the experiment since each subunit protein is considered one potential glycan binding 
protein. The control sugars of the experiment were the known F-tag-modified α-mannoside 
and β-galactoside; the FITC labeled concanavalin A (FITC-ConA) was the positive control 
for binding. In the experiment, the F-tagged sugars were spotted on the fluorous glass slide 
by a microarray spotter and allowed to slowly dry in a humidified chamber. Then, the slide 
was incubated with solutions of FITC-PEMV or FITC-ConA for 1 h. The following rinsing 
step removed the unbound protein; then the slide was air dried for the scanning step. From 
the results of the microarray control experiment of F-tagged α-mannoside (Mamidyala et al. 
2006), β-galactoside (Mamidyala et al. 2006), and 11 incubated with FITC-ConA, the α-
mannoside and 11 showed strong binding as expected and the β-galactoside showed no 
binding as expected. However, the FITC-PEMV incubated slide also showed no binding with 
any of the saccharides even with elevated incubation concentrations (Figure 4).  
 
 
 
! 91 
 
Figure 4. Fluorous microarray of F-tag attached saccharides incubated with A. 0.2 "M of 
FITC-ConA; B. 1.6 "M of FITC-PEMV subunit protein  
 
To confirm the negative result found in the fluorous microarray experiment, ITC 
experiments were commenced. The n-propyl trimannoside 12 was used for the ITC 
experiment with the commercially available methyl "-mannoside as the control group. ConA 
was the positive control for comparison with the PEMV, and also the concentration of PEMV 
subunit protein is used for the ITC experiments since each subunit protein is considered one 
potential glycan binding protein. The ITC experiments involved titration of the ligand 
(saccharide) solution into a cell with the macromolecule solution. By comparing the 
temperature of the mixing cell and the reference cell, the machine inputs an energy pulse to 
equalize the temperature in the two cells after each injection of the ligand solution. At the 
end of each titration experiment, Kd, !H, !S, and N could be extracted from the resulting 
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data. In the ITC experiments with the two saccharides and ConA, there was obvious specific 
binding (Kd = 11.15 μM for methyl α-mannoside, and Kd = 3.27 μM for 12). However, with 
PEMV, both methyl α-mannoside and 12 did not show any noticeable binding (see Figure 9-
12 in experimental section). This result combined with the fluorous microarray data provides 
strong evidence that there is no observable specific binding with the insect N-glycan terminal 
trimannoside and the PEMV. Hence, the terminal glycans coated on the aminopeptidase N in 
the pea aphid gut do not appear to be responsible for the specific binding with the PEMV.  
 
Conclusion 
The automated solution-phase synthesis of the insect N-glycan trimannoside 11 and 
12 was the first automated synthesis of the N-glycan related structures by using the β-
directing mannuronate strategy. Results from the fluorous microarray and ITC showed no 
specific binding between the trimannosides and the PEMV and provide evidence that this 
specific interaction in the transmission pathway of PEMV does not only rely on the terminal 
glycan-virus interaction. Related studies have been initiated to see whether the 
aminopeptidase N without the sugar coating has any specific binding interaction with PEMV 
or whether both the peptide and sugar parts are responsible for this interaction. 
 
Experimental section 
 
General materials and methods 
Dichloromethane (DCM) for glycosylation was distilled from calcium hydride. 
Tetrahydrofuran (THF) was collected from PureSolv Micro solvent purification system 
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(Innovative Technology, Inc., Amesbury, MA) before reactions. All other commercial 
solvents and reagents were reagent grade and used as received without further purification. 
The reactions were monitored by thin layer chromatography (TLC) with 250 µm Sorbent 
Technologies silica gel HL TLC plates. The hydrogenation reaction under 1000 psi hydrogen 
was operated in the Parr model 4766 general purpose vessel high pressure reactor (Parr 
Instrument Company, Moline, IL). The developed TLC plates were visualized by stain with 
p-anisaldehyde solution followed by heating on a hot plate. Flash column chromatography 
was performed with Zeochem ZEOprep 60 silica gel, 40-63 µm particle size. The automated 
solution phase synthesis was performed in the Chemspeed ASW1000  (Chemspeed, Augst, 
Switzerland) synthesis platform with hood, 16 reactor vials (13-mL capacity each) and 
heating/cooling unit (200 °C to –20 °C) machined to hold the SPE cartridges at the Iowa 
State University Machine Shop. 1H and 13C NMR spectra were obtained at 400 MHz and 100 
MHz on a Bruker DRX-400 spectrometer and a Varian MR-400 spectrometer and also 600 
MHz and 150 MHz on a Bruker Avance III 600 spectrometer. The C-H coupling constants 
were measured by the coupled 13C NMR spectra. Chemical shifts (δ) were reported in parts 
per million (ppm) relative to CDCl3 and CD3OD as internal references. Mass spectra were 
obtained on a Finnigan TSQ700 triple quadrupole mass spectrometer (Finnigan MAT, San 
Jose, CA) fitted with a Finnigan ESI interface. HPLC traces were obtained from a Varian 
ProStar HPLC system using a Waters Nova-Pak 4 µm 3.9 × 150 mm silica column. 
 
General procedure for bench-top fluorous solid-phase extraction (FSPE) 
Crude product (less than 300 mg) was dissolved in 0.4 mL N,N-dimethylformamide 
(DMF) and loaded onto the 80% MeOH preconditioned 2 g FSPE cartridge. The cartridge 
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was washed with 80% MeOH (4.0 mL × 3 times). Then the product was washed out with 
acetone (12 mL). The solvent was removed under reduce pressure to obtain the desired 
product.  
 
General procedure for automated synthetic cycles to produce insect glycan 
trimannoside 
 
ASW1000
TLC Well
Reactor Block Reagent Rack SPE Rack Inert Reagent Rack
1
2
3
4
5
6
7
8 9
10
11
12
13
14
15
16
FSPE 
Cartridge
 
Figure 5. Basic layout of automated solution-phase oligosaccharide synthesizer (ASW1000) 
1: F-tagged acceptor (solution in DCM), 2: TEA, 3: DMSO, 4: LiTEBH (1.0 M in THF), 5: 
water, 6: CAN/MeCN, 7: MeOH, 8: MeCN, 9: reservoir (toluene), 10: TMSOTf (0.55 M in 
DCM), 11: donor, 12: donor, 13: DCM, 14: THF, 15: 80% MeOH, 16: FSPE cartridge. 
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1. Sample Preparation 
Mannuronate donor molecule (0.20 g, 0.30 mmol) was dissolved in anhydrous DCM 
(1.6 mL) in the 13 mL-vial and placed at the inert reagent rack (Donor) under argon 
atmosphere. Mannosyl donor molecule (0.19 g, 0.30 mmol) was dissolved in anhydrous 
DCM (1.6 mL) in the 13 mL-vial and placed at the inert reagent rack (Donor) under argon 
atmosphere A 0.055 M trimethylsilyltrifluoromethanesulfonate (TMSOTf) solution (5 mL) in 
anhydrous DCM was prepared in an 8 mL-vial and placed as indicated on the inert reagent 
rack under argon. MeOH (100 mL) was placed in the stock solution bottle at the stock 
solution station as indicated. Toluene (1 L) was placed in the stock solution bottle and placed 
at the reservoir bottle rack with tubing as reservoir solution for rinsing. Anhydrous DCM (20 
mL) was transferred to the 50 mL-vial and placed as indicated on the inert reagent rack under 
argon. Anhydrous tetrahydrofuran (THF, 10 mL) was transferred to the 50 mL-vial and 
placed as indicated on the inert reagent rack under argon.  80% methanol/water (100 mL) 
stock was prepared in the 100 mL-vial and placed as indicated on the inert reagent rack. F-
tagged acceptor molecule (50 µmol) was dissolved with anhydrous DCM (0.8 mL) in a 
Wheaton 8 mL-E-Z extraction vial (conically-bottomed) flushed with argon, capped with 
septa and placed at the reagent rack as indicated. Triethylamine (TEA, 5 mL) was transferred 
to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. 
Dimethylsufoxide (DMSO, 8 mL) was transferred to an 8 mL-vial capped with septa and 
placed at the reagent rack as indicated. A 0.45 M CAN (ceric ammonium nitrate) solution in 
acetonitrile/water (9/1) (5 mL) was prepared in an 8 mL-vial capped with septa and placed at 
the reagent rack as indicated. LiTEBH solution in THF (1.0 M, 3 mL) was transferred to an 8 
mL-vial capped with septa and placed at the reagent rack as indicated. Water (8 mL) was 
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transferred to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. A 
fluorous solid phase extraction (FSPE) cartridge (2 g, 10 cc) was preconditioned with 80% 
methanol/water and placed on the machined FSPE block as indicated. An empty Wheaton 8 
mL-E-Z extraction vial was placed under the FSPE cartridge. 
 
2. Cleaning Cycle 
Prior to introduction of reagents, the ASW1000 reactor vials were cleaned, dried and 
purged with argon by running the cleaning cycle. During the cleaning cycle, each of the 16 
reactor vials (13 mL capacity each) was rinsed with toluene (8 mL) and methanol (8 mL) 3 
times each. After the solvents were completely removed, the reactor vials were dried under 
vacuum and purged with argon for 45 minutes. Reagent solutions were prepared by 
azeotropic removal of water from each building block with toluene; the resulting building 
blocks were then dried under high vacuum. After the cleaning cycles were done, the reagents 
were transferred into the reagent vials respectively, which were then placed on the inert 
condition reagent rack and general atmosphere reagent rack. 
 
3. Glycosylation 
The needle transferred the acceptor molecule (F-tag) solution (0.8 mL) to the reaction 
vial 1, followed by the transfer of the donor molecule solution (0.8 mL). The mixture was 
vortexed under ambient temperature at 800 rpm for 20 min. Then the reactor vials were 
cooled to -20 °C during the 60 minutes wait time by the heat transfer oil with 800 rpm vortex 
rate. The TMSOTf solution (0.1 mL) was transferred into the reactor vial 1 under 200 rpm 
vortex rate. After each individual transfer, the needle (inside and outside) was rinsed by 
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toluene (2 ml) before operating the next task. The reaction mixture was vortexed at 800 rpm 
for 30 minutes at 0 °C under argon atmosphere. After the reaction time the needle withdrew 
20 µL of the solution from the reaction mixture and placed it into the first well of the 
microtiterplate for thin layer chromatography monitoring. TEA (0.05 mL) was added to the 
solution for quenching and the solvent was evaporated under reduced pressure.   
 
4. PMB deprotection 
To the dried residue after the glycosylation, The CAN solution (1.0 mL) was added to 
the reactor vial. The reaction mixture was vortexed at 800 rpm for 1 h at room temperature. 
After the reaction time the needle withdrew 20 µL of the solution from the reaction mixture 
and placed it into the second well of the microtiterplate for thin layer chromatography 
monitoring.  
 
5. Fluorous solid-phase extraction (FSPE) 
The reaction mixture (1.2 mL) was carried to the FSPE cartridge at the FSPE block 
and dispensed at a speed of 1 mL/s via the 10 mL syringe. Then 80% methanol (2.0 mL) was 
used to rinse the empty reactor vial. The 80% methanol solution was removed from the 
reactor vial and delivered to the FSPE cartridge. The 80% methanol rinsing and transferring 
was repeated one more time. Additional 80% methanol solution (4 mL, repeated 2 times) was 
used to rinse the FSPE cartridge. During the 80% methanol rinse, the cartridge was 
positioned at ‘SPE waste’ for the eluted mixture to be disposed. Acetonitrile (MeCN) (2.0 
mL, repeated 3 times) was used to wash the FSPE cartridge for eluting the desired 
compound. During the task, the FSPE cartridge was positioned as ‘SPE collect’ to be placed 
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right above the 8 mL vial for collection of the sample. After the task, the position of the SPE 
rack was changed into ‘SPE direct’ for the needle to withdraw the collected sample from the 
conically-bottomed vial and deliver it to the clean reactor vial for the next reaction. Toluene 
(1 mL) was added to the solution and solvent was evaporated under reduced pressure. After 
the evaporation cycle, The MeOH wash step and the evaporation were repeated one more 
time. Once again toluene (1 mL) was added and removed under reduced pressure to remove 
residual water. 
 
7. LiTEBH Reduction 
Anhydrous THF (1.0 mL) was added to the sample and vortexed at 800 rpm, 0 °C 
under argon atmosphere for 30 min. The LiTEBH (0.3 mL, 1.0 M in THF) was added to the 
reaction solution and the mixture was vortexed for 45 min at 800 rpm, 0 °C under argon 
atmosphere. After the reaction time the needle withdrew 20 µL of the solution from the 
reaction mixture and placed it into the fourth well of the microtiterplate for thin layer 
chromatography monitoring. MeOH (0.5 mL) was added to quench the reaction and the 
solvent was removed by evaporation cycle. 
 
Synthetic procedures 
OBnO
PMBO
OBn
SPh
HOOO
PMBO
OBnO
SPh
Ph
1 2  
Phenyl 2,4-di-O-benzyl-3-O-p-methoxybenzyl-thio-α-D-mannopyranoside (2) 
To the phenyl 2-O-benzyl-3-O-p-methoxybenzyl-4,6-O-benzylidene-thio-α-D-
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mannopyranoside (1) (0.80 g, 1.4 mmol) was added borane terahydrofuran complex 1.0 M 
solution in tetrahydrofuran (14 mL, 14 mmol) under argon atmosphere at 0 °C and stirred 
until the starting material was dissolved. Then the dibutylboryl trifluoromethanesulfonate 1.0 
M solution in DCM (1.7 mL, 1.7 mmol) was added dropwise and the reaction mixture was 
stirred under argon atmosphere at 0 °C for 3 h. Triethylamine (0.30 mL, 2.2 mmol) was 
added dropwise to the reaction then methanol was added slowly to quench the reaction under 
0 °C. The solvent was removed under reduced pressure and the crude mixture was 
coevaporated with methanol twice. The crude product was purified by flash column 
chromatography on silica gel using EtOAc/petroleum ether (1/2) as eluent. The product was 
obtained as a colorless syrup  (0.69 g, 1.2 mmol, 86%) 
Rf: 0.38 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 400MHz): δ (ppm) 7.41-7.26 (m, 17H, Harom), 6.89-6.86 (m, 2H, Harom), 
5.50 (d, 1H, J = 1.6 Hz, H-1), 4.96 (d, 1H, J = 10.8 Hz, CHHPh), 4.69-4.64 (m, 2H, 
CHHPh), 4.58 (s, 2H, CHHPh), 4.13 (m, 1H, H-5), 4.04 (t, 1H, J = 9.2 Hz, H-4), 3.98 (dd, 
1H, J = 2.8, 1.6 Hz, H-2), 3.90 (dd, 1H, J = 9.2, 3.2 Hz, H-3), 3.82 (s, 3H, CO2CH3), 3.81-
3.75 (m, 2H, 2 × H-6)  
13C NMR (CDCl3, 150 MHz): δ (ppm) 159.4, 138.5, 138.0, 134.1, 131.9, 130.6, 130.3, 
129.6, 129.4, 129.2, 128.5, 128.2, 128.0, 127.9, 127.9, 127.7, 114.0, 86.1, 79.8, 76.6, 75.3, 
74.8, 73.4, 72.4, 72.0, 62.2, 55.4 
HRMS (ESI): [M + Na]+ calcd for C34H36NaO6S+ 595.2125, found 595.2119  
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O
HO2C
BnO
PMBO
OBn
SPh
OBnO
PMBO
OBn
SPh
2 3
HO
 
Phenyl 2,4-di-O-benzyl-3-O-p-methoxybenzyl-thio-α-D-mannopyranosiduronic acid (3) 
To a solution of Phenyl 2,4-di-O-benzyl-3-O-p-methoxybenzyl-thio-α-D-mannopyranoside 2 
(0.50 g, 0.87 mmol) in dichloromethane/water (5.8 mL/2.9 mL) were added TEMPO (0.03 g, 
0.19 mmol) and (diacetoxyiodo)benzene (0.700 g, 2.17 mmol) and stirred at ambient 
temperature. After 45 min, the mixture was diluted with dichloromethane (10 mL) and 
washed with a 10% Na2S2O3 solution (10 mL) and water (10 mL). The organic layer was 
dried over Na2SO4. The solvent was removed under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel using EtOAc/petroleum ether (1/2 
→ 1/0) as eluent. The product was obtained as a light yellow syrup (0.34 g, 0.57 mmol, 
66%). 
Rf: 0.1 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 600MHz): δ (ppm) 7.52 (d, 2H, J = 6.6 Hz, Harom), 7.33-7.24 (m, 13H, 
Harom), 7.19 (d, 2H, J = 8.4 Hz, Harom), 6.83 (d, 2H, J = 9.0 Hz, Harom), 5.67 (d, 1H, J = 4.8 Hz, 
H-1), 4.69-4.65 (m, 3H, CHHPh), 4.64 (d, 1H, J = 6.6 Hz, H-5), 4.52 (m, 3H, CHHPh), 4.21 
(t, 1H, J = 6.6 Hz, H-4), 3.88 (dd, 1H, J = 4.8, 2.4 Hz, H-2), 3.82 (m, 1H, H-3), 3.78 (s, 3H, 
CO2CH3) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 174.8, 159.3, 137.8, 137.7, 133.8, 131.4, 129.7, 
129.6, 129.0, 128.4, 128.4, 128.4, 128.1, 127.9, 127.9, 127.8, 127.3, 113.8, 75.7, 72.6, 72.6, 
72.3, 72.0, 55.2 
HRMS (ESI): [M + Na]+ calcd for C34H34NaO7S+ 609.1917, found 609.1904 
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O
MeO2C
BnO
PMBO
OBn
SPh
O
HO2C
BnO
PMBO
OBn
SPh
3 4  
Methyl (phenyl 3-O-p-methoxylbenzyl-2,4-di-O-benzyl-thio-α-D-mannopyranoside) 
uronate (4) 
To a solution of phenyl 3-O-p-methoxybenzyl-2,4-di-O-benzyl-thio-α-D -
mannopyranosiduronic acid (3) (0.50 g, 0.85 mmol) in anhydrous DMF (4.0 mL) were added 
K2CO3 (0.12 g, 0.85 mmol) and iodomethane (0.30 g, 2.1 mmol). The reaction mixture was 
stirred at ambient temperature under argon atmosphere for 6 h. The mixture was diluted with 
EtOAc (10 mL) and washed with water (10 mL). The aqueous portion was separated and 
extracted with EtOAc (2 x 10 mL). The combined organic layer was dried over Na2SO4. The 
solvent was removed under reduced pressure and the crude product was purified by flash 
column chromatography on silica gel using EtOAc/petroleum ether (1/3) as eluent. The 
product was obtained as a light yellow syrup  (0.47 g, 0.78 mmol, 92%). 
1H NMR (CD3OD, 600MHz): δ (ppm) 7.53 (d, 2H, J = 7.2 Hz, Harom), 7.35-7.25 (m, 13H, 
Harom), 7.25 (d, 2H, J = 8.4 Hz, Harom), 6.85 (d, 2H, J = 8.4 Hz, Harom), 5.66 (d, 1H, J = 4.8 Hz, 
H-1), 4.66-4.63 (m, 3H, CHHPh), 4.62 (d, 1H, J = 6.0 Hz, H-5), 4.52-4.49 (m, 3H, CHHPh), 
4.25 (t, 1H, J = 6.6 Hz, H-4), 3.87 (d, 1H, J = 5.4 Hz, H-2), 3.81 (s, 3H, CO2CH3), 3.79 (d, 
1H, J = 3.0 Hz, H-3), 3.65 (s, 3H, OCH3) 
13C NMR (CD3OD, 150 MHz): δ (ppm) 169.7, 159.4, 138.1, 137.9, 134.0, 131.5, 130.8, 
130.0, 129.6, 129.4, 129.1, 129.0, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 128.1, 
128.1, 128.1, 128.1, 127.9, 127.9, 127.8, 127.4, 127.3, 114.0, 113.8, 76.0, 73.1, 72.4, 72.2, 
55.3, 52.3 
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HRMS (ESI): [M + Na]+ calcd for C35H36NaO7S+ 623.2074, found 623.2071 
 
O
MeO2C
BnO
PMBO
OBn
OH
O
MeO2C
BnO
PMBO
OBn
SPh
4 5  
Methyl (2,4-di-O-benzyl-3-O-p-methoxylbenzyl-α-D-mannopyranose) uronate (5) 
To a solution of methyl (phenyl 2,4-di-O-benzyl-3-O-p-methoxylbenzyl-thio-α-D-
mannopyranoside) uronate 4 (0.50 g, 0.83 mmol) in 10% water/acetone (10 mL) were added 
N-bromosuccinimide (0.44 g, 2.5 mmol). The reaction mixture was stirred at ambient 
temperature for 1 h. The reaction mixture was dilute with EtOAc (30 mL) and washed with a 
saturated NaHCO3 solution (30 mL). The organic layer was dried over Na2SO4. The solvent 
was removed under reduced pressure and the crude product was purified by flash column 
chromatography on silica gel using EtOAc/petroleum ether (2/3) as eluent. The product was 
obtained as a light yellow syrup  (0.38 g, 0.75 mmol, 90%). 
Rf: 0.24 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 400MHz): δ (ppm) 7.36-7.20 (m, 12H, Harom), 6.85 (d, 2H, J = 8.4 Hz, 
Harom), 5.43 (t, 1H, J = 4.8 Hz, H-1), 4.75 (d, 1H, J = 12.0 Hz), 4.69-4.64 (m, 3H), 4.51 (s. 
2H), 4.47 (d, 2H, J = 6.0 Hz), 4.22 (t, 1H, J = 6.8 Hz), 3.91 (dd, 1H, J = 7.2, 2.8 Hz), 3.80 (s, 
3H), 3.71 (m, 1H), 3.65 (s, 3H), 3.18 (d, 1H, J = 4.8 Hz), 2.82 (s, 1H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 170.3, 159.3, 138.4, 138.2, 130.3, 129.5, 128.5, 
128.5, 128.4, 128.0, 127.9, 127.7, 113.8, 93.0 (JC1-H1 = 168.2 Hz, C-1), 77.3, 75.9, 75.5, 74.0, 
72.9, 72.4, 72.2, 55.4, 52.4 
HRMS (ESI): [M + Na]+ calcd for C29H32NaO8+ 531.1989, found 531.1985 
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NH  
Methyl (2,4-di-O-benzyl-3-O-p-methoxylbenzyl -α/β-D-mannopyranose) uronate 
trichloroacetimidate (6) 
To a solution of methyl (2,4-di-O-benzyl-3-O-p-methoxylbenzyl-α-D-mannopyranose) 
uronate (5) (0.50 g, 0.98 mmol) in dichloromethane (35 mL) was added trichloroacetonitrile 
(0.85 g, 5.88 mmol) at 0 °C under argon atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) (0.03 g, 0.2 mmol) was then added and the reaction mixture was stirred at 0 °C under 
argon atmosphere for 3 h. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography on silica gel using EtOAc/petroleum 
ether/triethylamine (1/2/0.1) as eluent. The product was obtained as a colorless syrup and a 
mixture of anomers (α/β = 4/1) (0.59 g, 0.93 mmol, 95%).  
Rf: 0.56 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 400MHz): δ (ppm) 9.32 (s, 1H, HN), 8.62 (s, 1H, HN), 7.41-7.26 (m, 
10H, Harom), 7.21 (d, 2H, J = 8.8 Hz, Harom), 7.16 (d, 2H, J = 8.4 Hz, Harom), 6.83 (d, 2 H, J = 
8.4 Hz, Harom), 6.40 (d, 1H, J = 2.8 Hz, H-1), 5.96 (d, 1H, J = 7.6 Hz, H-1), 4.85-4.74 (m, 
13H), 4.65-4.45 (m, 18H), 4.39 (d, 1H, J = 8.4), 4.28 (t, 1H, J = 8.4 Hz), 4.17 (dd, 1H, J = 
4.4, 2.4 Hz), 3.90-3.87 (m, 2H), 3.83-3.80 (m, 4H), 3.71 (s, 3H), 3.64 (s, 3H) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.4, 169.1, 160.4, 159.5, 159.5, 160.0, 138.0, 
137.9, 137.2, 130.0, 129.8, 129.4, 128.7, 128.6, 128.5, 128.3, 128.1, 128.0, 128.0, 113.9, 
113.9, 95.8, 95.2, 90.9, 77.3, 75.6, 75.4, 75.2, 75.0, 74.3, 74.1, 73.7, 73.6, 73.0, 72.7, 72.6, 
72.3, 55.4, 52.7, 52.6 
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HRMS (ESI): [M + Na]+ calcd for C31H32Cl3NNaO8+ 674.1086, found 674.107   
 
Table 1. Automated synthetic cycles for production of compound 7 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
 
 
 
6 
7 
8 
9 
10 
Glycosylation (2 
parallel 
reactions) 
TLC sample 
Quenching 
Evaporation 
PMB 
deprotection (2 
parallel 
reactions) 
TLC sample 
Sample loading        
Wash 
Wash 
 Transfer 
3.0 × 2 equivalent donor  (150 × 2 µmol) in 0.8 × 2 mL DCM, 
1.0 × 2 equivalent F-tagged acceptor (50 × 2 µmol) in 0.8 × 2 
mL DCM; 0.11 equivalent TMSOTf, -20 °C 
20 × 2 µL of crude reaction mixture withdrawn 
0.05 × 2 mL TEA 
40 oC 
1.0 × 2 mL CAN/MeCN/H2O, 25 °C 
 
 
 
20 × 2 µL of crude reaction mixture withdrawn 
1.2 × 2 mL crude sample transferred to cartridges 
12 × 2 mL 80% methanol wash 
2 mL MeCN wash (repeated 3 × 2 times) 
6 × 2 mL collected sample out of the ASW1000 
45 min 
 
 
 
 
45 min 
1 h 
 
 
 
 
 
 
 
 
O
MeO2C
BnO
HO
OBn
O O
C8F17
7  
Methyl (cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl -2,4-di-O-benzyl-β-
D-mannopyranoside) uronate (7) 
The crude product solution was transferred out of the ASW1000 after the FSPE step (10th 
step) of the 1st cycle. The solvent was removed under reduced pressure and the product was 
purified by flash column chromatography on silica gel using EtOAc/petroleum ether (1/3.5) 
as eluent. The product was obtained as a colorless syrup (72 mg, 0.078 mmol, 78% over 2 
steps). 
Rf: 0.57 (EtOAc/petroleum ether: 1/2) 
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1H NMR (CDCl3, 400MHz): δ (ppm) 7.35-7.23 (m, 10H, Harom), 5.74 (m, 2H, HC=CH), 4.96 
(d, 1H, J = 12.0 Hz, CHHPh), 4.77 (d, 1H, J = 11.2 Hz, CHHPh), 4.63 (s, 1H, H-1), 4.61 (d, 
J = 12.0 Hz, CHHPh), 4.60 (d, J = 11.2 Hz, CHHPh), 4.47 (dd, J = 12.8, 4.8 Hz, O-
CHHC=C), 4.24 (dd, J = 12.8, 6.4 Hz, O-CHHC=C), 4.04 (m, 2H, C=CCH2-O), 3.99 (t, J = 
7.6, H-4), 3.90 (d, J = 8.0, H-5), 3.81 (d, J = 2.4, H-2), 3.78 (m, 1H, H-3), 3.71 (s, 3H, 
CO2CH3), 3.49 (m, 2H, O-CH2CH2), 2.69 (d, 1H, J = 9.6, 4-OH), 2.22 (m, 2H, CH2CF2), 1.88 
(m, 2H, O-CH2CH2) 
13C NMR (CDCl3, 100 MHz): δ (ppm) 169.4, 138.2, 138.2, 130.6, 128.7, 128.6, 128.4, 
128.1, 128.1, 128.0, 100.3 (JC1-H1 = 154.8 Hz, C-1), 78.0, 76.0, 74.5, 74.3, 72.3, 69.0, 66.7, 
65.1, 52.5, 28.4 (t, JC-F = 21.7 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C36H35F17NaO8+ 941.1953, found 941.1959 
 
 
 
 
 
 
 
 
 
 
 
 
  106 
Table 2. Automated synthetic cycles for production of compound 9 
Step Task Reagent/ Operation Operation 
Time 
11 
 
 
12 
13 
14 
15 
16 
 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
 
29 
30 
31 
32 
 
Transfer 7 to 
reactor vial 
Evaporation  
Reduction 
TLC sample 
Quenching 
Evaporation  
FSPE 
preparation 
Sample loading        
Wash 
Wash 
 Transfer 
Evaporation 
Wash 
Evaporation 
Transfer 
Evaporation 
Transfer 
Evaporation 
Glycosylation  
 
TLC sample 
Quenching 
Evaporation 
Repeat the same 
procedure as step 
16-23 
50 µmol in 3.0 mL EtOAc 
  
40 °C 
1.0 mL THF, 0.3 mL LiTEBH, 0 °C 
20 µL of crude reaction mixture withdrawn 
0.5 mL MeOH  
40 °C 
0.5 mL DMSO 
 
1.2 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeCN wash (repeated 3 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
2.0 mL MeCN wash (repeated 3 times) 
40 °C 
1.0 mL toluene 
40 °C 
1.0 mL toluene 
40 °C 
6.0 equivalent donor 8  (300 µmol) in 1.6 mL DCM 
0.11 equivalent TMSOTf, 20 °C 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 °C 
 
 
 
 
45 min 
30 min 
 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
 
45 min 
 
45 min 
45 min 
 
 
 
45 min 
90 min 
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9  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl -2,4-di-O-benzyl-3,6-di-O-
(2-O-acetyl-3,4,6-tri-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (9) 
The crude mixture was transferred out of the synthesis platform after the 3rd cycle (32nd step 
of automated synthesis), diluted with DCM (20mL), and washed with Sat. NH4Cl(aq). The 
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organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure. 
Then, the crude product was purified by flash chromatography on silica gel EtOAc/petroleum 
ether (1/3). The disaccharide by-product could not be separated at this stage and the crude 
mixture was carried to the next step without further purification. 
Rf: 0.47 (EtOAc/petroleum ether: 1/2)  
HRMS (ESI): [M + Na]+ calcd for C93H95F17NaO19+ 1861.6088, found 1861.6118  
HPLC trace of the automated synthesis of 9 
 
 
Figure 6. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/2, 10 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column). 
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-3,6-di-O-
(3,4,6-tri-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside (10) 
The crude 9 (58 mg) from the automated synthesis was dissolved in MeOH (2.0 mL) and Na 
(0.50 mg, 0.22 mmol) was added. The mixture was stirred at ambient temperature for 1 h. 
The reaction was added by Dowex 50WX8 200 acidic resin until the pH paper showed 
neutral. The solvent was removed under reduced pressure and the crude product was purified 
by flash column chromatography on silica gel using EtOAc/petroleum ether (4/5 → 1/0) as 
eluent. The product was obtained as a colorless syrup (44 mg, 0.025 mmol, 50% over 2 
automated synthesis steps and 1 bench-top step).  
Rf: 0.34 (EtOAc/petroleum ether: 1/1)  
1H NMR (CDCl3, 600 MHz): δ (ppm) 7.41-7.14 (m, 40 H, Harom), 5.67 (m 2H, HC=CH), 
5.23 (d, 1H, J = 1.2 Hz, Hα-1), 5.08 (d, 1H, J = 1.2 Hz, Hα-1), 4.99 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.83 (2 × d, 2H, J = 10.8 Hz, CHHPh), 4.72 (d, 1H, J = 12.6 Hz), 4.66-4.59 (m, 
5H, CHHPh), 4.55-4.46 (m, 7H, CHHPh), 4.39 (s, 1H, Hβ-1), 4.35 (dd, 1H, J = 12.6, 4.8 Hz, 
O-CHHC=C), 4.11 (d, 1H, J = 1.8 Hz, Hα-2), 4.09 (dd, 1H, J = 13.2, 6.6 Hz, O-CHHC=C), 
4.02-3.99 (m, 3H, Hα-2, C=CCH2-O), 3.93 (d, 1H, J = 3.0 Hz), 3.88-3.84 (m, 5H), 3.83 (dd, 
1H, J = 9.6, 3.6 Hz, Hα-3), 3.79-3.74 (m, 4H), 3.71 (dd, 1H, J = 10.8, 4.2 Hz), 3.65-3.60 (m, 
3H), 3.40 (m, 2H, OCH2CH2), 3.33 (m, 1H), 2.33 (d, 1H, J = 1.8 Hz, 2-OH), 2.30 (d, 1H, J = 
2.4 Hz, 2-OH), 2.18 (m, 2H, CH2CF2), 1.83 (m, 2H, O-CH2CH2) 
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13C NMR (CDCl3, 150 MHz): δ (ppm) 139.2, 138.7, 138.7, 138.5, 138.4, 138.1, 138.0, 
130.0, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 128.1, 128.1, 128.0, 128.0, 128.0, 
127.9, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.5, 101.8 (JC1-H1 = 162.8 Hz, C-1), 100.8 
(JC1-H1 = 154.8 Hz, C-1), 100.2 (JC1-H1 = 171.2 Hz, C-1), 81.2, 80.2, 79.8, 78.1, 75.3, 75.2, 
75.0, 74.4, 73.6, 73.5, 72.4, 72.1, 71.6, 69.5, 69.1, 68.9, 68.9, 68.1, 66.8, 66.4, 64.9, 28.4 (t, 
JC-F = 22.4 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C89H91F17NaO17+ 1777.5877, found 1777.5875   
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3-(perfluorooctyl)propanyloxybutanyl 3,6-di-O-(β-D-mannopyranosyl)-β-D-
mannopyranoside (11) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-3,6-di-O-
(3,4,6-tri-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside 10 (44 mg, 0.025 mmol) 
was dissolved in MeOH (3.0 mL) and 10% Pd/C (10 mg) was added. The mixture was stirred 
under 1000 psi H2 atmosphere at 20 °C. After 48 h, the mixture was filtered through a short 
pad of Celite and the solvent was removed under reduced pressure. The desired product was 
collected as a white foam (13.2 mg, 0.0130 mmol, 51%). 
1H NMR (CDCl3, 600MHz): δ (ppm) 4.98 (d, 1H, J = 1.2 Hz, H-1), 4.73 (d, 1H, J = 1.2 Hz, 
H-1), 4.40 (s, 1H, H-1), 4.00 (d, 1H, J = 3.0 Hz, H-2), 3.88 (dd, 1H, J = 3.0, 1.2 Hz, H-2), 
3.85-3.81 (m, 2H), 3.78-3.74 (m, 3H), 3.73-3.69 (m, 3H), 3.67 (d, 1H, J = 9.6 Hz), 3.64-3.62 
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(m, 2H), 3.61-3.57 (m, 2H), 3.55-3.52 (m, 2H), 3.49-3.45 (m, 3H), 3.42 (t, 2H, J = 18.0 Hz, -
OCH2CH2CH2CF2), 3.38 (m, 2H, CH2CH2O-), 3.27 (m, 1H), 2.18 (m, 2H, CH2CF2), 1.77 (m, 
2H, OCH2CH2CH2CF2), 1.57 (s, 4H, -OCH2CH2CH2CH2O-) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 104.1, 101.8, 101.6, 83.0, 77.0, 75.1, 74.5, 72.8, 
72.6, 72.2, 72.2, 72.1, 71.9, 70.6, 70.2, 69.1, 68.8, 67.7, 67.4, 63.2, 63.1, 29.2 (t, JC-F = 21.8 
Hz), 27.6, 27.5, 22.1 
HRMS (ESI): [M + Na]+ calcd for C33H45F17NaO17+ 1059.2278, found 1059.2269   
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n-propyl 3,6-di-O-(β-D-mannopyranosyl)-β-D-mannopyranoside (12) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-3,6-di-O-
(3,4,6-tri-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranoside 10 (55 mg, 0.031 mmol) 
was dissolved in dry DCM (4.0 mL) and Grubbs catalyst 2nd generation (5.4 mg, 6.4 µmol) 
was added. The solution was stirred at 20 °C and ethylene gas was bubbled through for 30 
min, then an ethylene balloon was attached, and the mixture was stirred for 24 h. The solvent 
was evaporated and the mixture was loaded onto a short silica gel column for purification 
(DCM → EtOAc/petroleum ether = 1/1). The product fraction was collected, the solvent was 
evaporated, and the crude product was purified by FSPE following the general procedure for 
bench-top fluorous solid-phase extraction. After the fluorophobic fraction was collected and 
  111 
the solvent was removed under reduced pressure, the product was dissolved in MeOH (3.0 
mL) and 10% Pd/C (25 mg) was added. The mixture was stirred at 20 °C under 1000 psi H2 
atmosphere. After 24 h, another portion of Pd black (20 mg) and AcOH (0.3 mL) was added 
and the mixture was stirred at 20 °C under 1000 psi H2 atmosphere for additional 24 h. The 
mixture was filtered through a small pad of Celite and the Celite pad was washed with 
MeOH (3 × 10 mL).  After the solvent was removed under reduced pressure, the residue was 
washed with DCM (3 × 1.0 mL) and the fully deprotected product was obtained as a white 
foam (15.6 mg, 0.0280 mmol, 91% over 2 steps) 
1H NMR (CD3OD, 600MHz): δ (ppm) 4.98 (s, 1H, H-1), 4.74 (d, 1H, J = 1.2 Hz, H-1), 4.40 
(s, 1H, H-1), 4.00 (d, 1H, J = 3.0 Hz, H-2), 3.88 (dd, 1H, J = 3.0, 1.8 Hz, H-2), 3.85 (dd, J = 
10.8, 5.4 Hz), 3.78-3.70 (m, 6H), 3.67-3.61 (m, 7H), 3.49-3.46 (m, 3H), 3.41 (m, 1H), 3.27 
(m, 1H), 1.55 (m, 2H, CH2CH3), 0.86 (t, 3H, J = 7.2 Hz, CH3) 
13C NMR (CD3OD, 150 MHz): δ (ppm) 104.1, 101.8, 101.5, 83.0, 76.9, 75.1, 74.5, 72.7, 
72.6, 72.5, 72.2, 72.2, 72.1, 69.0, 68.7, 67.6, 67.3, 63.2, 63.0, 24.0, 11.0 
HRMS (ESI): [M + Na]+ calcd for C21H38NaO16+ 569.2052, found 569.2040 
 
General materials and methods for fluorous microarray 
Microarrays were printed by the MicroarrayerXactII™ (LabNEXT Inc., Glenview, IL 
60025) with robotic pin (Xtend MP Microarray Pins 0.35 mm). The F-tag attached sugar 
solution with concentration 222 μM in MeOH/DMSO/H2O (v:v:v = 1: 3.5: 1.15) was printed 
on to the fluorous glass slides (Fluorous Technologies, Inc.; Pittsburgh, PA). The printed 
slide was dried in a humid chamber for 20 h and ready for incubation with protein solution. 
The protein solution was prepared in various concentrations in 1X PBS buffer with 1% 
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bovine serum albumin (BSA, Sigma). For FITC-ConA (Sigma), the solution was with 1.0 
mg/mL CaCl2 and 1.0 mg/mL MnCl2. The incubation was carried out in a PC500 CoverWell 
incubation chamber (Grace Biolabs, Bend, OR) for 1 h, and then washed twice with 1X PBS 
buffer and once with DI water. Then the slide was dried in the air and scanned at the Iowa 
State University DNA facility by using a General Scanning ProScanArray 5000 set at 488 
nm. 
 
 
Figure 7. Printing pattern of F-tag attached saccharides on the fluorous glass slide 
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Figure 8. Microarray scanned image with FITC-PEMV subunit protein: A: 0.2 μM, B: 0.27 
μM, C: 0.4 μM, D: 0.8 μM, E: 1.6 μM, F: 0.2 μM; with FITC-ConA: G: 0.2 μM 
 
General materials and methods for isothermal titration calorimetry 
The ITC experiment was conducted in the VP-ITC MicroCalorimeter (MicroCal, 
Northampton, MA). The 10 μM protein solution and the 300 μM ligand (sugar) solution were 
both prepared in pH 7.0 NaOAc buffer. For titration experiments with ConA (Sigma), CaCl2 
and MnCl2 (1.0 mg/mL) was added to the buffer for both ConA and ligand solutions. The 
solutions were degassed prior to the experiment, and the titration was carried out at 26 °C 
with 310 rpm stirring rate.  
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Figure 9. ITC experiment: ConA with methyl α-mannoside 
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Figure 10. ITC experiment: ConA with 12 
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Figure 11. ITC experiment: PEMV with methyl α-mannoside 
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Figure 12. ITC experiment: PEMV with 12 
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CHAPTER 5 
Automated Solution-Phase Synthesis of β-1,6-Mannan and β-1,3-Mannan Oligomers 
Shu-Lun Tang and Nicola L. B. Pohl* 
 
Abstract 
β-Mannan is considered one of the most difficult glycans to chemically synthesize 
due to its kinetically and thermodynamically disfavored formation. It is also an interesting 
synthetic target due to the existence in various important natural products. Previously we 
have reported the automated solution-phase synthesis of different related structures including 
β-1,2-mannan, β-1,4-mannan, β-1,4-mannuronic acid, and the insect N-glycan terminal 
trimannoside oligomers. Herein we report explorations of the scope of the automated 
solution-phase synthesis of β-mannans by using the β-directing mannuronate/global 
reduction strategy to synthesize β-1,6-mannan and β-1,3-mannan oligomers. Interestingly, 
our automated solution-phase synthesis strategy successfully produced both of these β-
mannan oligomers up to the trisaccharide stage; however, attempts at chain extension to the 
tetrasaccharides failed, possibly due to the decrease of the acceptor nucleophilicity with the 
growing chain. A possible future direction to solve this steric hindrance is to use a less bulky 
protecting group at the 2 or 4 position such as a propargyl group.  
 
Introduction 
β-mannan is considered one of the most difficult glycans to chemically synthesize 
due to its kinetically and thermodynamically disfavored formation (El Ashry et al. 2005). 
However, because of its existence in many biologically crucial natural products, 
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methodologies for synthesizing this challenging linkage are an ongoing challenge. Previously 
we have demonstrated the automated solution-phase synthesis of different β-mannan 
structures including β-1,2-mannan, β-1,4-mannan, β-1,4-mannuronic acid, and the insect N-
glycan terminal trimannoside oligomers by incorporating different β-mannoside formation 
strategies including an oxidation-reduction sequence and a β-directing mannuronate (van den 
Bos et al. 2006; Codee et al. 2009; Dinkelaar et al. 2009; Walvoort et al. 2009)/global 
reduction strategy. After comparing the two strategies for the automated solution-phase 
synthesis, the β-directing mannuronate/final reduction strategy turned out to be the more 
efficient and flexible approach due to its straightforward β-mannosidic linkage formation and 
variable protecting group capability compared to the classic Crich 4,6-O-benzylidene 
strategy (Crich and Jayalath 2007). In order to explore the scope of this new automated 
solution-phase approach to β-mannans utilizing the β-directing mannuronate strategy, and 
test the robustness of the protocol used for previous β-mannan syntehsis, herein we report the 
first automated solution-phase synthesis of the unnatural analog oligomers of β-1,6-mannan 
and β-1,3-mannan. 
 
Results and discussion 
In order to construct the β-1,6-mannan oligomer from a mannuronate building block, 
the fully benzylated mannuronate trichloroacetimidate donor 2 was synthesized from the 
previously reported lactol 1 (Codee et al. 2009). The automated solution-phase synthesis of 
the β-1,6-mannan oligomer started with the glycosylation of the trichloroacetimidate donor 2 
(3.5 equiv.) and the allyl fluorous tag (F-tag) (Mamidyala et al. 2006) catalyzed by 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.1 equiv.) at -20 °C. The following 
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deprotection of the 6-position was furnished by a hydride reduction of the methyl ester by 
lithium triethylborohydride (LiTEBH) and afforded the monosaccharide 3 followed by a 
FSPE to afford a (α/β = 1/3) mixture of F-tag-modified anomers, which were transferred out 
of the automation platform and manually purified—a particular advantage of this solution-
phase approach over a traditional solid-phase approach. The pure 3 was reinjected into the 
automated synthesis platform for the next three repeating cycles of glycosylation and 
deprotection. The TLC of 2nd and 3rd glycosylation and deprotection showed complete 
reaction. However, after the 4th cycle the TLC showed that the only product has the same Rf 
value as the starting material trisaccharide. The mixture was transferred out of the synthesis 
platform and purified manually, and the isolated product was the trimannoside 4 instead of 
the expected tetramannoside. The production of this truncated sequence is likely due to the 
lack of reactivity of the growing glycosyl acceptor because of the possible steric hindrance 
from the more freely rotated β-1,6-mannan chain. The isolated trisaccharide 4 was 
deprotected by a 10% Pd/C, Pd black catalyzed hydrogenolysis to afford the fully-
deprotected β-1,6-mannan trisaccharide 5 (Figure 1). 
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Figure 1. Synthesis of the trichloroacetimidate donor 2 and automated solution-phase 
synthesis of !-1,6-mannan trisaccharide 5 
 
The automated solution-phase synthesis of the !-1,3-mannan oligomer began with the 
glycosylation of the previously reported 3-O-p-methoxylbenzyl trichloroacetimidate donor 6 
(3.5 equiv.) (Chapter 4) and the F-tag catalyzed by TMSOTf (0.1 equiv.) at -20 °C for 45 
min. After the glycosylation, the cycle was completed by the removal of the p-
methoxylbenzyl (PMB) group by ceric ammonium nitrate (CAN) and a fluorous solid phase 
extraction (FSPE) to give a mixture of anomers (("/! = 1/3.6)  that were separated manually 
to afford the monosaccharide 7. The pure 7 was reinjected into the automated synthesis 
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platform followed by 3 additional cycles of glycosylation/deprotection. The 2nd cycle gave a 
complete conversion of monosaccharide 7 to the disaccharide from TLC monitor. However, 
after the 3rd cycle, the TLC showed the product as a mixture of disaccharide and 
trisaccharide. After the 4th cycle, the mixture was transferred out of the synthesis platform 
and manually purified. However, instead of having the desired tetrasaccharide, the major 
product was the trisaccharide 8. This is probably due to the steric hindrance from the 2,3-cis 
conformation of the built-up β-1,3-mannan chain, which gives a lower nucleophilicity to the 
3-OH. The β-1,3-mannuronate trimer 8 was reinjected into the synthesis platform for the 
hydride reduction of the methyl esters by LiTEBH, and the β-1,3-mannan trisaccharide 9 was 
formed. The hydrogenolysis of 9 was catalyzed by Pd/C, Pd black and gave the fully 
deprotected trisaccharide 10. 
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Figure 2. Automated solution-phase synthesis of !-1,3-mannan trisaccharide 10 
 
Conclusion 
The first automated solution-phase synthesis of !-1,6-mannan and !-1,3-mannan 
oligomers has shown the scope and potential of the automated solution-phase synthesis of 
different !-mannans, and also the power of the !-directing mannuronate strategy for !-
mannan synthesis. In addition, the unfavorable formation of the !-1,6-mannan and !-1,3-
mannan tetrasaccharides was from the acceptors larger than the trisaccharide stage, which 
has insufficient nucleophilicity due to the increasing steric hindrance. Therefore, a donor 
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which has a less bulky protecting group such as a propargyl group at 4 or 2 position (Crich 
and Jayalath 2005) could possibly overcome this difficulty and improve the yield of β-
mannan structure synthesis.  
 
Experimental section 
 
General materials and methods 
Dichloromethane (DCM) for glycosylation reactions was distilled from calcium 
hydride. Tetrahydrofuran (THF) was collected from PureSolv Micro solvent purification 
system (Innovative Technology, Inc., Amesbury, MA) before reactions. All other 
commercial solvents and reagents were reagent grade and used as received without further 
purification. The reactions were monitored by thin layer chromatography (TLC) with 250 µm 
Sorbent Technologies silica gel HL TLC plates. The hydrogenation reaction under 1000 psi 
hydrogen was operated in the Parr model 4766 general purpose vessel high pressure reactor 
(Parr Instrument Company, Moline, IL). The developed TLC plates were visualized by stain 
with p-anisaldehyde solution followed by heating on a hot plate. Flash column 
chromatography was performed with Zeochem ZEOprep 60 silica gel, 40-63 µm particle 
size. Preparative TLC was performed with Dynamic Adsorbents Prep TLC, Silica Gel, HLO, 
20 cm × 20 cm F-254, 1000 micron layer. Fluorous solid-phase extraction was performed 
with SPE cartridges containing 2.0 g of silica gel bonded with perfluorooctylethylsilyl chains 
(Fluorous Technologies, Inc., Pittsburgh, PA). The automated solution phase synthesis was 
performed in a modified Chemspeed ASW1000  (Chemspeed, Augst, Switzerland) synthesis 
platform with hood, 16 reactor vials (13-mL capacity each) and heating/cooling unit (200 °C 
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to -20 °C) machined to hold the SPE cartridges at the Iowa State University Machine Shop. 
1H and 13C NMR spectra were obtained at 600 MHz and 150 MHz on a Bruker Avance III 
600 spectrometer, and 700 MHz on a Bruker Avance II 700 spectrometer. The C-H coupling 
constants were measured by the coupled 13C NMR spectra. Chemical shifts (δ) were reported 
in parts per million (ppm) relative to CDCl3 and CD3OD as internal references. Mass spectra 
were obtained on a Finnigan TSQ700 triple quadrupole mass spectrometer (Finnigan MAT, 
San Jose, CA) fitted with a Finnigan ESI interface.  
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General procedure for automated synthetic cycles to produce !-1,6-mannan and !-1,3-
mannan oligomers  
 
 
Figure 3. Basic layout of automated solution-phase oligosaccharide synthesizer (ASW1000) 
1: F-tagged acceptor (solution in DCM), 2: TEA, 3: DMF, 4: LiTEBH (1.0 M in THF), 5: 
water, 6: CAN/MeCN, 7: MeOH, 8: reservoir (toluene), 9: TMSOTf (0.55 M in 
DCM/DCM), 10: donor, 11: DCM, 12: THF, 13: 80 % MeOH, 14: FSPE cartridge. 
 
1. Sample Preparation 
Donor molecule (0.20 g, 0.30 mmol) was dissolved in anhydrous DCM (1.6 mL) in 
the 13 mL-vial and placed at the inert reagent rack location (Donor) under argon atmosphere. 
A 0.055 M trimethylsilyltrifluoromethanesulfonate (TMSOTf) solution (5.0 mL) in 
anhydrous DCM was prepared in an 8 mL-vial and placed as indicated on the inert reagent 
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rack under argon. MeOH (100 mL) was placed in the stock solution bottle at the stock 
solution station as indicated. Toluene (1.0 L) was placed in the stock solution bottle and 
placed at the reservoir bottle rack with tubing as reservoir solution for rinsing. Anhydrous 
DCM (20 mL) was transferred to the 50 mL-vial and placed as indicated on the inert reagent 
rack under argon. Anhydrous tetrahydrofuran (THF, 10 mL) was transferred to the 50 mL-
vial and placed as indicated on the inert reagent rack under argon.  80% methanol/water (100 
mL) stock was prepared in the 100 mL-vial and placed as indicated on the inert reagent rack. 
F-tagged acceptor molecule (50 µmol) was dissolved with anhydrous DCM (0.8 mL) in a 
Wheaton 8 mL-E-Z extraction vial (conically-bottomed) flushed with argon, capped with 
septa and placed at the reagent rack as indicated. Triethylamine (TEA, 5.0 mL) was 
transferred to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. 
N,N-dimethylformamide (DMF, 8.0 mL) was transferred to an 8 mL-vial capped with septa 
and placed at the reagent rack as indicated. A 0.45 M CAN (ceric ammonium nitrate) 
solution in acetonitrile/water (9/1) (5 mL) was prepared in an 8 mL-vial capped with septa 
and placed at the reagent rack as indicated. LiTEBH solution in THF (1.0 M, 3.0 mL) was 
transferred to an 8 mL-vial capped with septa and placed at the reagent rack as indicated. 
Water (8.0 mL) was transferred to an 8 mL-vial capped with septa and placed at the reagent 
rack as indicated. A fluorous solid phase extraction (FSPE) cartridge (2 g, 10 cc) was 
preconditioned with 80% methanol/water and placed on the machined FSPE block as 
indicated. An empty Wheaton 8 mL-E-Z extraction vial was placed under the FSPE 
cartridge. 
 
2. Cleaning Cycle 
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Prior to the introduction of reagents, the ASW1000 reactor vials were cleaned, dried 
and purged with argon by running the cleaning cycle. During the cleaning cycle, each of the 
16 reactor vials (13 mL capacity each) was rinsed with toluene (8.0 mL) and methanol (8.0 
mL) 3 times each. After the solvents were completely removed, the reactor vials were dried 
under vacuum and purged with argon for 45 minutes. Reagent solutions were prepared by 
azeotropic removal of water from each building block with toluene; the resulting building 
blocks were then dried under high vacuum. After the cleaning cycles were done, the reagents 
were transferred into the reagent vials respectively, which were then placed on the inert 
condition reagent rack and general atmosphere reagent rack. 
 
3. Glycosylation 
The needle transferred the acceptor molecule (F-tag) solution (0.8 mL) to the reaction 
vial 1, followed by the transfer of the donor molecule solution (0.8 mL). The mixture was 
vortexed under ambient temperature at 800 rpm for 20 min. Then the reactor vials were 
cooled to 0 °C by the heat transfer oil with 800 rpm vortex rate. The TMSOTf solution (0.1 
mL) was transferred into the reactor vial 1 under 200 rpm vortex rate. After each individual 
transfer, the needle (inside and outside) was rinsed with toluene (2 ml) before operating the 
next task. The reaction mixture was vortexed at 800 rpm for 45 minutes at 0 °C under argon 
atmosphere. After the reaction time the needle withdrew 20 µL of the solution from the 
reaction mixture and placed it into the first well of the microtiterplate for thin layer 
chromatography monitoring. TEA (0.05 mL) was added to the solution for quenching and the 
solvent was evaporated under reduced pressure.   
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4. PMB deprotection 
To the dried residue after the glycosylation, the CAN solution (1.0 mL) was added to the 
reactor vial. The reaction mixture was vortexed at 800 rpm for 1 h at room temperature. After 
the reaction time the needle withdrew 20 µL of the solution from the reaction mixture and 
placed it into the second well of the microtiterplate for thin layer chromatography 
monitoring.  
 
5. Fluorous solid-phase extraction (FSPE) 
DMF (0.4 mL) was added to the reactor vials to dissolve the crude mixture and the 
vials were vortexed at 800 rpm for 3 min. The reaction mixture (1.2 mL) was carried to the 
FSPE cartridge at the FSPE block and dispensed at a speed of 1.0 mL/s via the 10 mL 
syringe. Then 80% methanol (2 mL) was used to rinse the empty reactor vial. The 80% 
methanol solution was removed from the reactor vial and delivered to the FSPE cartridge. 
The 80% methanol rinsing and transferring was repeated one more time. Additional 80% 
methanol solution (4.0 mL, repeated 2 times) was used to rinse the FSPE cartridge. During 
the 80% methanol rinse, the cartridge was positioned at ‘SPE waste’ for the eluted mixture to 
be disposed. MeOH (2.0 mL, repeated 3 times) was used to wash the FSPE cartridge for 
eluting the desired compound. During the task, the FSPE cartridge was positioned as ‘SPE 
collect’ to be placed right above the 8 mL vial for collection of the sample. After the task, the 
position of the SPE rack was changed into ‘SPE direct’ for the needle to withdraw the 
collected sample from the conically-bottomed vial and deliver it to the clean reactor vial for 
the next reaction. Toluene (1.0 mL) was added to the solution and solvent was evaporated 
under reduced pressure. After the evaporation cycle, the MeOH wash step and the 
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evaporation were repeated one more time. Once again toluene (1.0 mL) was added and 
removed under reduced pressure to remove residual water. 
 
7. LiTEBH Reduction 
Anhydrous THF (1.0 mL) was added to the sample and vortexed at 800 rpm, 0 °C 
under argon atmosphere for 30 min. The LiTEBH (0.3 mL, 1.0 M in THF) was added to the 
reaction solution and the mixture was vortexed for 30 min at 800 rpm, 0 °C under argon 
atmosphere. After the reaction time the needle withdrew 20 µL of the solution from the 
reaction mixture and placed it into the fourth well of the microtiterplate for thin layer 
chromatography monitoring. Methanol (0.5 mL) was added to quench the reaction and the 
solvent was removed under reduced pressure. 
 
Synthetic procedures 
O
MeO2C
BnO
BnO
OBn
OH
O
MeO2C
BnO
BnO
OBn
O CCl3
NH1 2  
Methyl (2,3,4-tri-O-benzyl-α/β-D-mannopyranose) uronate trichloroacetimidate (2) 
To a solution of methyl (2,3,4-tri-O-benzyl-α/β-D-mannopyranose) uronate (1) (0.50 g, 1.0 
mmol) in dichloromethane (35 mL) was added trichloroacetonitrile (0.85 g, 5.9 mmol) at 0 
°C under argon atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (0.03 g, 0.2 mmol) 
was then added and the reaction mixture was stirred at 0 °C under argon atmosphere for 3 h. 
The solvent was removed under reduced pressure and the crude product was purified by flash 
column chromatography on silica gel using EtOAc/petroleum ether/triethylamine (1/2/0.1) as 
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eluent. The product was obtained as a colorless syrup and a mixture of anomers (α/β = 4/1) 
(0.59 g, 0.93 mmol, 95%).  
Rf: 0.66 (EtOAc/petroleum ether: 1/2) 
1H NMR (CDCl3, 600MHz): δ (ppm) 9.34 (s, 1H, NHβ), 8.62 (s, 1H, NHα), 7.4 (d, 2H, J = 
7.2 Hz, Harom), 7.35-7.21 (m, 13H, Harom), 6.41 (d, 1H, J = 2.4 Hz, Hα-1), 5.98 (d, 1H, J = 7.8 
Hz, Hβ-1), 4.86-4.79 (m, 2H, CHHPh), 4.74 (m, 1H, CHHPh), 4.66-4.56 (m, 3H, CHHPh), 
4.54 (d, 1H, J = 11.4 Hz, Hβ-4), 4.52 (d, 1H, J = 12.0 Hz CHHPh), 4.40 (d, 1H, J = 9.0 Hz, 
Hα-3), 4.30 (t, 1H, J = 8.4 Hz, Hα-3), 4.20 (dd, 1H, J = 4.2, 1.8 Hz, Hβ-3), 3.92-3.88 (m, 3H, 
Hα-5, Hβ-3, Hβ-2), 3.87 (t, 1H, J = 3.0 Hz, Hα-2), 3.71 (s, 3H, CO2CHα3), 3.63 (s, 3H, 
CO2CHβ3) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 169.3, 169.0, 160.4, 158.9, 138.0, 137.9, 137.9, 
137.8, 137.4, 137.1, 128.7, 128.5, 128.5, 128.5, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 
128.0, 128.0, 128.0, 127.9, 95.7, 95.1, 92.3, 90.9, 77.8, 75.8, 75.6, 75.5, 75.0, 74.3, 74.0, 
73.6, 73.5, 73.2, 73.0, 72.6, 72.5, 52.6, 52.5 
HRMS (ESI): [M + H]+ calcd for C30H31Cl3NO7+ 622.1161, found 622.1145 
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Table 1. Automated synthetic cycles for production of compound 3 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
6 
7 
8 
9 
 
10 
11 
12 
13 
Glycosylation (2 
parallel 
reactions) 
TLC sample 
Quenching 
Evaporation 
Reduction 
TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
Transfer 
3.5 × 2 equivalent donor  (175 × 2 µmol) in 0.8 × 2 mL DCM, 
1.0 × 2 equivalent F-tagged acceptor (50 × 2 µmol) in 0.8 × 2 
mL DCM; 0.11 equivalent TMSOTf, -20 °C 
20 × 2 µL of crude reaction mixture withdrawn 
0.05 × 2 mL TEA 
40 °C 
10 × 2 mL THF, 0.3 × 2 mL LiTEBH, 0 °C 
20 × 2 µL of crude reaction mixture withdrawn 
0.5 × 2 mL MeOH 
40 °C 
0.5 × 2 mL DMF 
 
1.2 × 2 mL crude sample transferred to cartridges 
12 × 2 mL 80% methanol wash 
2 mL MeCN wash (repeated 3 × 2 times) 
6 × 2 mL collected sample out of the ASW1000 
45 min 
 
 
 
 
45 min 
1 h 
 
 
 
 
 
 
 
 
OBnO
BnO
OBn
O O
C8F17HO
3  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,3,4-tri-O-benzyl-β-D-
mannopyranoside (3) 
The product solution was transferred out of the synthesis platform after the FSPE step of the 
first cycle (13th step of the automated synthesis). The solvent was removed under reduced 
pressure and the product was purified by preparative TLC by using diethyl ether/DCM 
(0.75/9). The product was obtained as a colorless syrup (66 mg, 0.067 mmol, 67% over 2 
steps). 
Rf: 0.35 (diethyl ether/DCM: 0.75/9) 
1H NMR (CDCl3, 600MHz): δ (ppm) 7.45 (d, 2H, J = 7.2 Hz, Harom), 7.34-7.26 (m, 10H, 
Harom), 5.75 (m, 2H, HC=CH), 4.96 (d, 2H, J = 12.0 Hz, CHHPh), 4.85 (d, 1H, J = 12.6 Hz, 
CHHPh), 4.65 (d, 1H, J = 10.8 Hz, CHHPh), 4.54 (d, 1H, J = 12.0 Hz, CHHPh), 4.49 (d, 1H, 
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J = 12.0 Hz, CHHPh), 4.45 (s, 1H, H-1), 4.44 (dd, 1H, J = 12.6, 3.6 Hz, OHHCHC=C), 4.21 
(dd, 1H, J = 12.6, 4.2 Hz, OHHCHC=C), 4.07 (m, 2H, C=CHCH2O), 3.94-3.89 (m, 3H, H-2, 
H-4, H-6), 3.79 (m, 1H, H-6’), 3.53 (dd, 1H, J = 9.6, 3.0 Hz, H-3), 3.48 (t, 2H, J = 5.4 Hz, 
OCH2CH2), 3.33 (m, 1H, H-5), 2.22 (m, 2H, CH2CF2), 2.09 (t, 1H, J = 6.6 Hz, 6-OH), 1.89 
(m, 2H, OCH2CH2) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 138.8, 138.4, 138.3, 130.0, 128.6, 128.6, 128.5, 
128.3, 128.0, 127.8, 127.7, 127.7, 100.8 (JC1-H1 = 152.0 Hz, C-1), 82.5, 76.2, 75.5, 75.0, 74.4, 
74.3, 71.8, 69.0, 66.7, 65.1, 62.7, 28.3 (t, JC-F = 22.2 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C42H41F17NaO7+ 1003.2473, found 1003.2476 
 
Table 2. Automated synthetic cycles for production of compound 4 
Step Task Reagent/ Operation Operation 
Time 
14 
 
 
15 
16 
17 
18 
19 
20 
21 
22 
 
23 
24 
25 
26 
27 
Glycosylation  
 
 
TLC sample 
Quenching 
Evaporation 
Reduction 
TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading        
Wash 
Wash 
Evaporation 
Repeat the same 
procedure as step 
14-26 
3.5 equivalent donor  (175 µmol) in 0.8 mL DCM, 1.0 equiv. 3 
(50 µmol) in 0.8 mL DCM; 0.11 equivalent TMSOTf, -20 °C 
 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 oC 
1.0 mL THF, 0.3 mL LiTEBH, 0 °C 
20 µL of crude reaction mixture withdrawn 
0.5 × 2 mL MeOH 
40 °C 
0.5 × 2 mL DMF 
 
1.2 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeCN wash (repeated 3 × 2 times) 
40 °C 
Repeat for 3 cycles 
45 min 
 
 
 
 
45 min 
1 h 
 
 
 
 
 
 
 
 
45 min 
3 h 15 min 
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OBnO
BnO
OBn
O O
C8F17OH
3
4  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,3,4-tri-O-benzyl-6-O-
(2,3,4-tri-O-benzyl-6-O-(2,3,4-tri-O-benzyl-β-D-mannopyranosyl) -β-D-mannopyranosyl) 
-β-D-mannopyranoside (4) 
The product solution was transferred out of the synthesis platform after the FSPE step of the 
first cycle (27th step of the automated synthesis). The solvent was removed under reduced 
pressure and the product was purified by flash chromatography by using EtOAc/petroleum 
ether (1/1). Then the crude product was purified by a preparative TLC by using diethyl 
ether/DCM (1/10 developed for 3 times). The product was collected from the preparative 
TLC plate and obtained as a colorless syrup (11 mg, 5.7 μmol, 11% over 6 steps). 
Rf: 0.48 (diethyl ether/DCM: 1.5/8, TLC developed with the solvent twice)  
1H NMR (CDCl3, 600MHz): δ (ppm) 7.43 (m, 6H, Harom), 7.31-7.19 (m, 39H, Harom), 5.74 
(m, 2H, HC=CH), 4.92-4.87 (m, 5H, CHHPh), 4.83-4.78 (m, 4H, CHHPh), 4.61 (d, 1H, J = 
10.8 Hz, CHHPh), 4.55 (d, 1H, J = 11.4 Hz, CHHPh), 4.50-4.46 (m, 2H, CHHPh), 4.43-4.34 
(m, 7H, 5 × CHHPh, H-1, OHHCHC=C), 4.30 (s, 1H, H-1), 4.26 (s, 1H, H-1), 4.22 (d, 1H, J 
= 10.2 Hz, H-4), 4.10 (m, 2H, H-2, OHHCHC=C), 4.00 (m, 2H, C=CHCH2O), 3.88-3.83 (m, 
3H, H-2, 2 × H-6), 3.81-3.71 (m, 5H, 2 × H-2, 4 × H-6), 3.67 (m, 2H, 2 × H-3), 3.53 (dd, 1H, 
J = 9.0, 2.4 Hz, H-5), 3.49-3.43 (m, 3H, H-3, 2 × H-4), 3.39 (dd, 1H, J = 9.6, 3.0 Hz, H-5), 
3.35 (m, 2H, OCH2CH2), 3.26 (m, 1H, H-5), 2.34 (t, 1H, J = 6.6 Hz, 6-OH), 2.13 (m, 2H, 
CH2CF2), 1.79 (m, 2H, OCH2CH2) 
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13C NMR (CDCl3, 150 MHz): δ (ppm) 138.9, 138.8, 138.6, 138.5, 138.5, 138.3, 130.0, 
128.8, 128.7, 128.6, 128.6, 128.5, 128.5, 128.3, 128.3, 128.3, 128.0, 127.8, 127.7, 127.7, 
127.6, 127.5, 102.6 (JC1-H1 = 151.7 Hz), 102.5 (JC1-H1 = 155.3 Hz), 101.0 (JC1-H1 = 151.5 Hz), 
82.5, 82.5, 82.3, 76.1, 75.7, 75.6, 75.4, 75.1, 75.1, 75.0, 74.8, 74.1, 74.1, 74.0, 73.9, 73.7, 
73.4, 71.6, 71.5, 71.5, 69.7, 69.6, 68.9, 66.8, 65.1, 62.6, 28.3 (t, JC-F = 22.5 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C96H97F17NaO17+ 1867.6347, found 1867.6322 
HPLC trace of the automated synthesis of 4 
 
 
Figure 4. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 2/3, 15 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column)  
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OBnO
BnO
OBn
O O
C8F17OH
3
4
OHO
HO
OH
O
OH
3
5
O
C8F17
 
3-(perfluorooctyl)propanyloxybutanyl 6-O-(6-O-(β-D-mannopyranosyl)-β-D-
mannopyranosyl)-β-D-mannopyranoside (5) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,3,4-tri-O-benzyl-6-O-(2,3,4-
tri-O-benzyl-6-O-(2,3,4-tri-O-benzyl-β-D-mannopyranosyl) -β-D-mannopyranosyl) -β-D-
mannopyranoside 4 (11 mg, 5.7 μmol) was dissolved in MeOH/AcOH = 10/1 (2.5 mL) and 
10% Pd/C (5.0 mg) and Pd black (5.0 mg) were added. The mixture was stirred under 1000 
psi H2 atmosphere at 20 °C. After 48 h, the mixture was filtered through a short pad of Celite 
and the solvent was removed under reduced pressure. The desired product was collected as a 
white foam (4.4 mg, 4.2 μmol, 74%). 
1H NMR (CDCl3, 700 MHz): δ (ppm) 4.64 (s, 1H, H-1), 4.62 (s, 1H, H-1), 4.50 (s, 1H, H-
1), 4.21 (dd, 1H, J = 11.2, 2.1 Hz, H-6), 4.17 (dd, 1H, J = 11.2, 1.4 Hz, H-6), 3.93 (d, 1H, J = 
3.5 Hz, H-2), 3.92 (d, 1H, J = 2.8 Hz, H-2), 3.89-3.86 (m, 3H, -OCH2CH2CH2CH2O-, H-2, 
H-6), 3.83 (dd, 1H, J = 11.9, 6.3 Hz, H-6), 3.79 (dd, 1H, J = 11.2, 5.6 Hz, H-6), 3.74 (dd, 1H, 
J = 11.2, 5.6 Hz, H-6), 3.62-3.55 (m, 4H, 3 × H-4, -OCH2CH2CH2CH2O-, 3.53 (t, 2H, J = 6.3 
Hz, -OCH2CH2CH2CF2), 3.45 (m, 2H, CH2CH2O-), 3.45 (m, 3H, 3 × H-3), 3.38 (m, 2H, 2 × 
H-5), 3.23 (m, 1H, H-5), 2.29 (m, 2H, CH2CF2), 1.87 (m, 2H, OCH2CH2CH2CF2), 1.68 (m, 
4H, -OCH2CH2CH2CH2O-) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 102.6, 102.3, 102.0, 78.4, 77.3, 77.3, 75.3, 75.2, 
75.2, 72.5, 72.5, 72.4, 71.9, 70.7, 70.2, 70.0, 69.4, 68.6, 68.5, 68.4, 62.8, 29.1 (t, JC-F = 22.4 
Hz), 27.6, 27.6, 22.0 
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HRMS (ESI): [M + Na]+ calcd for C33H45F17NaO17+ 1059.2278, found 1059.2291 
 
Table 2. Automated synthetic cycles for production of compound 7 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
 
 
 
6 
7 
8 
9 
10 
Glycosylation (2 
parallel 
reactions) 
TLC sample 
Quenching 
Evaporation 
PMB 
deprotection (2 
parallel 
reactions) 
TLC sample 
Sample loading        
Wash 
Wash 
 Transfer 
3.0 × 2 equivalent donor  (150 × 2 µmol) in 0.8 × 2 mL DCM, 
1.0 × 2 equivalent F-tagged acceptor (50 × 2 µmol) in 0.8 × 2 
mL DCM; 0.11 equivalent TMSOTf, -20 °C 
20 × 2 µL of crude reaction mixture withdrawn 
0.05 × 2 mL TEA 
40 oC 
1.0 × 2 mL CAN/MeCN/H2O, 25 °C 
 
 
 
20 × 2 µL of crude reaction mixture withdrawn 
1.2 × 2 mL crude sample transferred to cartridges 
12 × 2 mL 80% methanol wash 
2 mL MeCN wash (repeated 3 × 2 times) 
6 × 2 mL collected sample out of the ASW1000 
45 min 
 
 
 
 
45 min 
1 h 
 
 
 
 
 
 
 
 
O
MeO2C
BnO
HO
OBn
O O
C8F17
7  
Methyl (cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-β-
D-mannopyranoside) uronate (7) 
For the synthetic procedure, and spectral data see compound 7 in chapter 4.  
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Table 3. Automated synthetic cycles for production of compound 8 
Step Task Reagent/ Operation Operation 
Time 
11 
 
 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
 
23 
24 
 
25 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
Deprotection 
 TLC sample 
Sample loading        
Wash 
Wash 
Transfer 
Evaporation 
Glycosylation 
 
Repeat the same 
procedure as step 
2-15 
Transfer  
3.0 equivalent donor  (150 µmol) in 0.8 mL DCM, 1.0 
equivalent 7 (50 µmol) in 0.8 mL DCM, 0.1 equivalent 
TMSOTf, -20 °C 
20 µL of crude reaction mixture withdrawn 
0.05 mL TEA 
40 oC 
1.0 mL CAN/MeCN/H2O, 25 °C 
20 µL of crude reaction mixture withdrawn 
1.0 mL crude sample transferred to cartridges 
12 mL 80% methanol wash 
2.0 mL MeOH wash (repeated 3 × 2 times) 
6.0 mL collected sample to the reactor vial for next cycle 
40 °C 
3.0 equivalent donor  (150 µmol) in 0.8 mL DCM, 0.8 mL 
DCM, 0.1 equivalent TMSOTf, 0 °C 
Repeat 2 cycle 
 
 
6.0 mL solution transferred out of the synthesis platform 
30 min 
 
 
 
 
45 min 
1 h 
 
 
45 min 
 
 
45 min 
30 min 
 
8 h 50 min 
 
 
 
 
O
MeO2C
BnO
O
OBn
O O
C8F17
H 3
8  
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl (methyl 2,4-di-O-benzyl-4-
O-(methyl 2,4-di-O-benzyl-4-O-(methyl 2,4-di-O-benzyl-β-D-mannopyranosyl uronate)-
β-D-mannopyranoside uronate)-β-D-mannopyranoside uronate) (8) 
The product solution was transferred out of the synthesis platform after the FSPE step of the 
first cycle (25th step of the automated synthesis). The solvent was removed under reduced 
pressure and the product was purified by flash chromatography by using EtOAc/petroleum 
ether (1/2). Then the crude product was purified by a preparative TLC by using diethyl 
ether/benzene (1/5). The product was collected from the preparative TLC plate and obtained 
as a colorless syrup (14 mg, 11 μmol, 22% over 6 steps). 
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Rf: 0.35 (diethyl ether/benzene: 1/5) 
1H NMR (CDCl3, 600MHz): δ (ppm) 7.43-7.41 (m, 2H, Harom), 7.34-7.18 (m, 28H, Harom), 
5.76 (m, 2H, HC=CH), 4.98-4.96 (m, 3H, CHHPh), 4.93 (d, 1H, J = 10.8 Hz, CHHPh), 4.90 
(d, 1H, J = 12.0 Hz, CHHPh), 4.86 (d, 1H, J = 10.8 Hz, CHHPh), 4.75 (d, 1H, J = 12.6 Hz, 
CHHPh), 4.72 (d, 1H, J = 12.0 Hz, CHHPh), 4.61 (s, 1H, H-1), 4.59 (d, 1H, J = 4.2 Hz, 
CHHPh), 4.51-4.47 (m, 3H, OHHCHC=C, 2 × CHHPh), 4.44 (d, 1H, J = 10.2 Hz, CHHPh), 
4.28-4.24 (m, 2H, H-5, OHHCHC=C), 4.19 (s, 1H, H-1), 4.14 (s, 1H, H-1), 4.12 (d, 1H, J = 
9.6 Hz, H-4), 4.07 (d, 2H, J = 3.6 Hz, C=CHCH2O), 3.99 (dd, 1H, J = 8.4, 3.0 Hz, H-3), 
3.92-3.87 (m, 3H, H-2, 2 × H-4), 3.74-3.67 (m, 10H, H-5, 9 × OCH3), 3.63-3.61 (m, 2H, H-2, 
H-5), 3.50-3.45 (m, 3H, H-3, OCH2CH2), 3.37 (d, 1H, J = 3.6 Hz, H-2), 2.34 (d, 1H, J = 10.2 
Hz, 3-OH), 2.21 (m, 2H, CH2CF2), 1.90 (m, 2H, OCH2CH2) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 168.9, 168.8, 168.6, 138.6, 138.4, 138.4, 138.3, 
138.1, 130.7, 128.8, 128.8, 128.7, 128.7, 128.6, 128.6, 128.6, 128.6, 128.6, 128.5, 128.5, 
128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.0, 128.0, 127.8, 
100.4 (JC1-H1 = 154.4 Hz), 98.6 (JC1-H1 = 155.3 Hz), 98.2 (JC1-H1 = 152.7 Hz), 78.4, 77.8, 77.4, 
75.3, 75.3, 75.2, 75.2, 75.2, 75.1, 74.9, 74.9, 74.6, 73.9, 73.6, 73.0, 72.4, 69.0, 66.7, 65.0, 
52.6, 52.6, 52.5, 28.3 (t, JC-F = 21.8 Hz), 21.0 
HRMS (ESI): [M + Na]+ calcd for C78H79F17NaO20+ 1681.4785, found 1681.4762 
HPLC trace of the automated synthesis of 8 
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Figure 5. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 1/2, 10 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
 
Table 4. Automated synthetic cycles for production of compound 9 
Step Task Reagent/ Operation Operation 
Time 
26 
27 
28 
29 
30 
Reduction 
TLC sample 
Quenching 
Evaporation 
Transfer 
2.0 mL THF, 0.3 mL LiTEBH, 8 (11 μmol), 0 °C 
20 µL of crude reaction mixture withdrawn 
0.5 mL MeOH 
40 °C 
Transfer out of the synthesis platform 
1 h 
 
 
45 min 
 
 
OBnO
O
OBn
O O
C8F17
H 3
9
HO
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cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-3-O-(2,4-di-
O-benzyl-3-O-(2,4-di-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-
mannopyranoside (9) 
The product solution was transferred out of the synthesis platform after the FSPE step of the 
first cycle (30th step of the automated synthesis). The solvent was removed under reduced 
pressure and the product was purified by flash chromatography by using EtOAc/petroleum 
ether (3/1 to 1/0). The product was obtained as a colorless syrup (10 mg, 6.3 μmol, 57%). 
Rf: 0.23 (EtOAc/benzene: 4/1) 
1H NMR (CDCl3, 700 MHz): δ (ppm) 7.44 (d, 2H, J = 7.7 Hz, Harom), 7.35-7.21 (m, 28H, 
Harom), 5.77 (m, 2H, HC=CH), 5.05-4.99 (m, 4H, CHHPh), 4.95 (d, 1H, J = 11.9 Hz, 
CHHPh), 4.91 (d, 1H, J = 11.2 Hz, CHHPh), 4.77 (d, 2H, J = 11.2 Hz, CHHPh), 4.63 (d, 1H, 
J = 11.2 Hz, CHHPh), 4.56-4.48 (m, 4H, H-1, 3 × CHHPh), 4.47 (dd, 1H, J = 12.6, 3.5 Hz, 
OHHCHC=C), 4.34 (s, 1H, H-1), 4.26 (dd, 1H, J = 12.6, 4.9 Hz, OHHCHC=C), 4.22 (s, 1H, 
H-1), 4.07 (m, 2H, C=CHCH2O), 3.97-3.89 (m, 5H, H-6), 3.86-3.76 (m, 6H, 3 × H-3), 3.70 
(dd, 1H, J = 9.8, 2.8 Hz), 3.65-3.60 (m, 3H), 3.59-3.56 (m, 3H, H-6), 3.53 (s, 1H), 3.50 (m, 
2H, OCH2CH2), 3.38 (m, 1H, H-5), 3.21 (s, 1H, H-5), 3.16 (m, 1H, H-5), 2.31 (d, 1H, J = 8.4 
Hz, OH), 2.21 (m, 2H, CH2CF2), 2.13 (s, 1H, OH), 1.90 (m, 2H, OCH2CH2), 1.82 (s, 1H, 
OH) 
13C NMR (CDCl3, 150 MHz): δ (ppm) 138.8, 138.5, 138.5, 138.3, 138.2, 130.2, 128.8, 
128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 
128.0, 127.9, 127.9, 127.9, 100.5, 98.4, 97.8, 79.8, 79.1, 78.3, 76.7, 75.9, 75.6, 75.6, 75.4, 
75.2, 75.0, 75.0, 75.0, 74.8, 74.6, 74.5, 74.3, 74.0, 73.8, 73.7, 69.1, 66.7, 65.1, 62.7, 62.4, 
62.3, 28.3 (t, JC-F = 22.4 Hz), 21.0 
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HRMS (ESI): [M + Na]+ calcd for C75H79F17NaO17+ 1597.4938, found 1597.4925 
HPLC trace of the automated synthesis of 9 
 
 
Figure 6. Analytical HPLC chromatogram of the crude product from the synthesis platform 
after FSPE (1.0 mL/min flowrate, EtOAc/hexanes: 9/1, 10 minutes run, Waters Nova-Pak 4 
µm 3.9 × 150 mm silica column) 
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3-(perfluorooctyl)propanyloxybutanyl 3-O-(3-O-(β-D-mannopyranosyl)-β-D-
mannopyranosyl)-β-D-mannopyranoside (10) 
cis-4-(1H,1H,2H,2H,3H,3H-perfluoroundecyloxy)-2-butenyl 2,4-di-O-benzyl-3-O-(2,4-di-O-
benzyl-3-O-(2,4-di-O-benzyl-β-D-mannopyranosyl)-β-D-mannopyranosyl)-β-D-
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mannopyranoside 9 (10 mg, 6.3 μmol) was dissolved in MeOH/AcOH = 10/1 (2.5 mL) and 
10% Pd/C (5.0 mg) and Pd black (5.0 mg) were added. The mixture was stirred under 1000 
psi H2 atmosphere at 20 °C. After 48 h, the mixture was filtered through a short pad of Celite 
and the solvent was removed under reduced pressure. The desired product was collected as a 
white foam (6.2 mg, 6.0 μmol, 95%). 
1H NMR (CDCl3, 700 MHz): δ (ppm) 4.74 (s, 1H, H-1), 4.73 (s, 1H, H-1), 4.52 (s, 1H, H-
1), 4.15 (d, 1H, J = 2.8 Hz, H-2), 4.06 (s, 1H, J = 2.8 Hz, H-2), 3.98 (s, 1H, J = 2.8 Hz, H-2), 
3.96 (dd, 1H, J = 6.3, 2.8 Hz, -OCH2CH2CH2CH2O-), 3.93-3.89 (m, 3H, 3 × H-6), 3.84-3.81 
(m, 2H, 2 × H-3), 3.75-3.72 (m, 2H, 2 × H-6), 3.71-3.66 (m, 3H, 2 × H-4, H-6), 3.59 (dd, 1H, 
J = 5.6, 3.5 Hz, -OCH2CH2CH2CH2O-), 3.56 (t, 1H, J = 9.8 Hz, H-4), 3.52 (t, 2H, J = 6.3 Hz, 
-OCH2CH2CH2CF2), 3.49 (m, 3H, H-3, CH2CH2O-), 3.28-3.24 (m, 2H, 2 × H-5), 2.29 (m, 
2H, CH2CF2), 1.87 (m, 2H, OCH2CH2CH2CF2), 1.69 (m, 4H, -OCH2CH2CH2CH2O-)  
13C NMR (CDCl3, 150 MHz): δ (ppm) 101.7, 98.5, 98.1, 81.2, 81.2, 78.7, 78.3, 78.1, 75.3, 
72.7, 71.9, 70.6, 70.2, 69.5, 69.3, 68.8, 67.0, 66.9, 63.1, 62.9, 29.1 (t, JC-F = 21.5 Hz), 27.6, 
27.5, 22.0. 
HRMS (ESI): [M + Na]+ calcd for C33H45F17NaO17+ 1059.2278, found 1059.2292 
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CHAPTER 6 
Conclusions and Future Directions 
 
This dissertation reports the first automated solution-phase synthesis of the 
challenging β-mannans including β-1,2-mannan, β-1,4-mannan, the structurally related β-
1,4-mannuronates, the insect N-glycan terminal trimannoside, β-1,6-mannan, and β-1,3-
mannan oligosaccharides by using two different synthetic strategies including an oxidation-
reduction sequence and the β-directing mannuronate strategy. The β-directing mannuronate 
strategy turned out to be a more efficient methodology providing better yields and a shorter 
synthetic route with high β-selectivities. Also, the solution-phase synthesis is more 
economical with only 2.0 to 3.5 equivalent of glycosyl donor needed for each glycosylation 
reaction compared to 9.0 to 10 equivalents for a comparable automated solid-phase protocol. 
In addition, a simple TLC could monitor the reaction with the homogeneous solution-phase 
mixture. Plus, the chapters include examples in which the fluorous tag-modified sugars have 
been transferred out of the synthesis platform, purified on bench top, and reinjected into the 
synthesis platform for further reactions; such flexibility was not provided by the solid-phase 
protocol. Besides the successful synthesis of the challenging β-mannans by the automated 
solution-phase synthesis, the β-mannan-containing insect N-glycan trimannoside was also 
synthesized and used for probing the possible binding of this carbohydrate motif with pea 
enation mosaic virus (PEMV). Both a fluorous microarray and subsequent isothermal 
titration calorimetry (ITC) studies did not show any specific interactions between the virus 
and sugar.  Therefore, the results clarified that the specific interaction between PEMV and 
the receptor protein aminopeptidase N does not rely on the insect N-glycan. 
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With the new protocols developed for automated solution-phase synthesis using the 
β-directing mannuronate strategy, more β-mannan-containing potentially biologically 
significant natural products can be synthesized with high efficiency in the future; those 
molecules can then be used for microarray binding studies, ITC experiments, drug delivery 
applications, and other biological experiments.  
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APPENDIX A. CHAPTER 2 1H NMR, 13C NMR, COSY, AND HMQC SPECTRA 
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APPENDIX B. CHAPTER 3 1H NMR, 13C NMR, COSY, AND HSQC SPECTRA 
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APPENDIX C. CHAPTER 4 1H NMR, 13C NMR, COSY, AND HSQC SPECTRA 
 
 
  224 
 
  225 
 
  226 
 
  227 
 
  228 
 
  229 
 
  230 
  231 
  232 
  233 
  234 
  235 
  236 
  237 
  238 
  239 
  240 
  241 
 
 
  242 
 
 
  243 
 
  244 
 
 
  245 
 
  246 
 
 
 
  247 
 
 
  248 
 
 
  249 
 
 
 
 
 
 
 
 
 
 
 
 
  250 
APPENDIX D. CHAPTER 5 1H NMR, 13C NMR, COSY, AND HSQC SPECTRA 
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